Page last updated: 2024-12-05

amiloride

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Amiloride is a potassium-sparing diuretic that blocks sodium channels in the distal convoluted tubule and collecting duct of the nephron, thus reducing sodium reabsorption and increasing potassium retention. It was first synthesized in 1965 and is used to treat hypertension, edema associated with heart failure, and hypokalemia. Amiloride is also studied for its potential therapeutic effects in a variety of other conditions, including cystic fibrosis, diabetic nephropathy, and cancer. It is a relatively safe and effective medication, but it can cause side effects such as hyperkalemia, dizziness, and gastrointestinal upset.'

Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16231
CHEMBL ID945
CHEBI ID2639
SCHEMBL ID27562
MeSH IDM0000906

Synonyms (162)

Synonym
AC-13631
BIDD:GT0466
LS-13128
AB00053415-24
AB00053415-25
BRD-K97181089-310-03-0
BRD-K97181089-003-02-3
gtpl2421
KBIO1_000182
DIVK1C_000182
SPECTRUM_000034
BPBIO1_000015
BSPBIO_001572
lopac-a-7410
tocris-0890
BIO2_000772
BIO1_001337
BIO1_000359
NCGC00015089-01
NCGC00024443-02
BIO2_000292
BIO1_000848
LOPAC0_000111
BSPBIO_001826
PRESTWICK3_000007
amiloride (inn)
amiclaran (tn)
D07447
IDI1_000182
BCBCMAP01_000101
PRESTWICK2_000007
BSPBIO_000013
IDI1_034042
AB00053415
amiloride [inn:ban]
amipramizid
pyrazinecarboxamide, 3,5-diamino-n-(aminoiminomethyl)-6-chloro-
n-amidino-3,5-diamino-6-chlorpyrazincarboxamid
ccris 6545
guanamprazin
amilorida [inn-spanish]
einecs 220-024-7
amiloridum [inn-latin]
2609-46-3
amiloride
C06821
guanamprazine
3,5-diamino-n-carbamimidoyl-6-chloro-pyrazine-2-carboxamide
3,5-diamino-n-(aminoiminomethyl)-6-chloropyrazinecarboxamide
amikal (hydrochloride dihydrate)
amipramidin
midamor (hydrochloride dihydrate)
mk-870 (hydrochloride dihydrate)
amipramizide
3,5-diamino-n-carbamimidoyl-6-chloropyrazine-2-carboxamide
amyloride
1F5L
DB00594
n-amidino-3,5-diamino-6-chloropyrazinecarboxamide
amipramidine
NCGC00024443-06
NCGC00024443-07
midamor
KBIO2_005428
KBIOSS_000292
KBIO2_000394
KBIOGR_000292
KBIO2_005530
KBIO3_000583
KBIO3_001326
KBIO2_000292
KBIO2_002860
KBIO2_002962
KBIOGR_000544
KBIO3_000584
KBIOSS_000394
SPECTRUM2_000118
PRESTWICK0_000007
SPECTRUM3_000293
NINDS_000182
SPBIO_001934
SPBIO_000136
PRESTWICK1_000007
SPECTRUM4_000132
SPECTRUM5_000776
NCGC00015089-02
NCGC00024443-09
NCGC00024443-05
amiloridum
3,5-diamino-n-[amino(imino)methyl]-6-chloropyrazine-2-carboxamide
amilorida
CHEBI:2639 ,
bdbm16173
3,5-diamino-6-chloro-n-(diaminomethylene)pyrazinamide;hydrochloride
chembl945 ,
smr000486264
MLS001060798
HMS2089H05
HMS1989O14
NCGC00015089-12
amiclaran
3,5-diamino-6-chloro-n-(diaminomethylidene)pyrazine-2-carboxamide
HMS1791O14
NCGC00015089-08
unii-7dzo8eb0z3
7dzo8eb0z3 ,
cas-2609-46-3
tox21_110080
dtxsid9043853 ,
dtxcid7023853
HMS2213E05
CCG-204206
AKOS015961348
NCGC00015089-05
NCGC00015089-13
NCGC00015089-14
NCGC00015089-16
NCGC00015089-07
NCGC00015089-06
NCGC00015089-04
NCGC00015089-09
NCGC00015089-03
NCGC00015089-11
NCGC00015089-15
mk-870
STL373007
amiloride [mi]
amiloride [inn]
amiloride [who-dd]
amiloride [vandf]
HMS3355K04
HY-B0285
BBL028157
SCHEMBL27562
NCGC00015089-17
tox21_110080_1
n-amidino-3,5-diamino-6-chloropyrazinamide
n-amidino 3,5-diamino-6-chloro-2-pyrazinecarboxamide
n-amidino-3,5-diamino-6-chloro-2-pyrazinecarboxamide
137053-86-2
(3,5-diamino-6-chloropyrazinoyl)guanidine
AB00053415_26
AB00053415_28
AB00053415_27
J-016249
SBI-0050099.P004
FT-0703177
F2173-0531
amiloridehcl
BCP16815
Q419995
EN300-149459
SDCCGSBI-0050099.P005
NCGC00015089-24
SB74937
n-(3,5-diamino-6-chloro-pyrazine-2-carbonyl)-guanidine
amipramidin, midamor
3,5-diamino-n-(amino(imino)methyl)-6-chloropyrazine-2-carboxamide
amiloridum (inn-latin)
c03db01
amilorida (inn-spanish)
amilorid

Research Excerpts

Overview

Amiloride is a potassium-sparing diuretic that has been used as an anti-kaliuretic for the chronic management of hypertension and heart failure. It could be effective in the management of mineralocorticoid excess syndrome (MCES)

ExcerptReferenceRelevance
"Amiloride is an inhibitor of the ASICs in the brain and was shown to reduce panic symptoms in preclinical animal models."( Pharmacokinetics of intranasal amiloride in healthy volunteers.
Alt, J; Anderson, DJ; Ashby, S; Battaglia, M; Davies, SJC; Mim, SR; Reilly, C; Rower, JE; Shipman, P; Voight, M; Yellepeddi, VK, 2023
)
1.92
"Amiloride is an antagonist of the renal tubular epithelial sodium channel (ENaC). "( Registration of amiloride in South Africa: Cutting the Gordian knot.
Bryer, A; Mpe, MT; Rayner, BL; Spence, JD, 2019
)
2.3
"Amiloride is a potassium retaining diuretic and natriuretic which acts by reversibly blocking luminal epithelial sodium channels (ENaCs) in the late distal tubule and collecting duct. "( Amiloride: A review.
Sever, P; Sun, Q,
)
3.02
"Amiloride is a competitive blocker of the epithelial sodium (Na) channel in the renal collecting duct. "( Acute decrease of urine calcium by amiloride in healthy volunteers under high-sodium diet.
Azizi, M; Blanchard, A; Bonny, O; Harmacek, D; Jeunemaitre, X; Maillard, M; Wuerzner, G, 2022
)
2.44
"Amiloride is a drug that selectively reduces the aldosterone-sensitive Na+/K+ exchange and could be effective in the management of mineralocorticoid excess syndrome (MCES)."( Amiloride Is Effective in the Management of Abiraterone-Induced Mineralocorticoid Excess Syndrome without Interfering with Its Antineoplastic Activity.
Bedussi, F; Berruti, A; Dalla Volta, A; Ferrari, V; Fragni, M; Galli, D; Lazzari, B; Memo, M; Roca, E; Rossini, E; Sigala, S; Valcamonico, F; Vezzoli, S, 2017
)
2.62
"Amiloride is a potassium-sparing diuretic that has been used as an anti-kaliuretic for the chronic management of hypertension and heart failure. "( A cell-permeant amiloride derivative induces caspase-independent, AIF-mediated programmed necrotic death of breast cancer cells.
Carraway, KL; Gorin, F; Leon, LJ; Pasupuleti, N, 2013
)
2.18
"Amiloride derivatives are a class of new promising chemotherapeutic agents. "( Multiple effects of the Na(+)/H (+) antiporter inhibitor HMA on cancer cells.
Aredia, F; Forlino, A; Giansanti, V; Jaadane, I; Mazzini, G; Ortiz, LM; Savio, M; Scovassi, AI; Torriglia, A; Zaffaroni, N, 2013
)
1.83
"Amiloride is a widely used diuretic that blocks epithelial sodium channels (ENaCs). "( Controlling epithelial sodium channels with light using photoswitchable amilorides.
Althaus, M; Clauss, W; Fronius, M; Schönberger, M; Trauner, D, 2014
)
2.08
"Amiloride is a small molecule diuretic, which has been used to dissect sodium transport pathways in many different systems. "( Amiloride docking to acid-sensing ion channel-1.
Benos, DJ; Fuller, CM; Qadri, YJ; Song, Y, 2010
)
3.25
"Amiloride is a drug approved by the United States Food and Drug Administration, which has shown neuroprotective effects in different neuropathological conditions, including brain injury or brain ischemia, but has not been tested in spinal cord injury (SCI). "( Amiloride improves locomotor recovery after spinal cord injury.
Durham-Lee, JC; Johnson, KM; Mokkapati, VU; Nesic, O, 2011
)
3.25
"Amiloride is an effective plasminogen activator inhibitor, while celecoxib is a cylcooxygenase-2 inhibitor."( Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.
Evans, DM; Sloan Stakleff, KD, 2004
)
1.04
"Amiloride is a low-affinity blocker of most DEG/ENa channels, but has an unusual enhancing effect on responses of some of them."( Domain near TM1 influences agonist and antagonist responses of peptide-gated Na+ channels.
Cottrell, GA, 2005
)
1.05
"Amiloride is a nonspecific blocker of acid-sensing ion channels (ASICs) that have been recently implicated in the mediation of mechanical and chemical/inflammatory nociception. "( Sex differences in the effects of amiloride on formalin test nociception in mice.
Chanda, ML; Mogil, JS, 2006
)
2.06
"Amiloride hydrochloride is a potassium-sparing diuretic since it favors sodium excretion and potassium reabsorption. "( Adduction of amiloride hydrochloride in urea through a modified technique for the dissolution enhancement.
Madan, AK; Thakral, S, 2008
)
2.16
"Amiloride is a potassium-sparing diuretic which has been advocated for the treatment of hypokalemic disorders. "( The effect of amiloride on the renin-aldosterone system in primary hyperaldosteronism and Bartter's syndrome.
Aurecchia, SA; Griffing, GT; Melby, JC; Sindler, BH,
)
1.93
"Amiloride hydrochloride is a new, orally administered, potassium-sparing diuretic with mild natriuretic and diuretic properties. "( Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Vidt, DG,
)
1.8
"Amiloride is a potassium-sparing diuretic used in spontaneous and diuretic-induced hypokalemia. "( Amiloride in primary hyperaldosteronism.
Aurecchia, SA; Cole, AG; Griffing, GT; Komanicky, P; Melby, JC; Sindler, BH, 1982
)
3.15
"Amiloride is a new potassium-sparing diuretic that blocks sodium channels in distal renal tubular cells, independent of aldosterone."( Amiloride in Bartter's syndrome.
Aurecchia, SA; Griffing, GT; Komanicky, P; Melby, JC; Sindler, BH, 1982
)
2.43
"Amiloride is a potassium-sparing diuretic that is pharmacologically similar to triamterene. "( New drug evaluations amiloride (Midamor, Merck, Sharp and Dohme).
Anderson, PO; Colvin, CL; Macfie, HL, 1981
)
2.02
"Amiloride is a "potassium-sparing" diuretic agent of moderate natriuretic potency with site of action in postmacula densa segments of the distal nephron. "( Pathophysiology of chronic renal tubular acidosis induced by administration of amiloride.
Glynn, RD; Hulter, HN; Ilnicki, LP; Licht, JH; Sebastian, A, 1980
)
1.93
"Amiloride is a nonspecific agent that may reduce reperfusion injury, but its effect on reversible dysfunction or stunned myocardium is unclear."( Intracoronary amiloride prevents contractile dysfunction of postischemic "stunned" myocardium: role of hemodynamic alterations and inhibition of Na+/H+ exchange and L-type Ca2+ channels.
el Schultz, J; LoCurto, A; Sagar, KB; Smart, SC; Warltier, DC, 1995
)
2.09
"Amiloride is an example of such a new drug, exerting a dose-dependent action to inhibit Na+ transport."( Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways.
Brouwer, KL; Edwards, L; Knowles, MR; Liu, X; Noone, PG; Regnis, JA; Robinson, M, 1997
)
1.26
"Amiloride is a K+-sparing diuretic that effectively inhibits the Na+/H+ transporter in the plasma membrane of most mammalian cells. "( Attenuation of apoptotic DNA fragmentation by amiloride.
Barrasso, AM; Cobo, JM; Crissman, HA; Garcia-Cañero, R; Sailer, BL; Valdez, JG, 1998
)
2
"Amiloride sensitivity is a common characteristic of structurally related cationic channels that are associated with a wide range of physiological functions. "( A new member of the amiloride-sensitive sodium channel family in Drosophila melanogaster peripheral nervous system.
Barbry, P; Darboux, I; Lazdunski, M; Lingueglia, E; Pauron, D, 1998
)
2.07
"Amiloride is an inhibitor of urokinase plasminogen activator (uPA), an essential component of the plasminogen/plasmin enzyme system. "( Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.
Arvan, M; Evans, DM; Guyton, DP; Sloan-Stakleff, K, 1998
)
1.96
"Amiloride is a prototypic inhibitor of epithelial sodium channels. "( Mechanism of action of amiloride: a molecular prospective.
Kieber-Emmons, T; Kleyman, TR; Kosari, F; Sheng, S, 1999
)
2.06
"Amiloride is a competitive inhibitor for pig enzyme, but upon prolonged incubation with this drug the enzyme gradually loses its activity in an irreversible manner."( Interaction of pig kidney and lentil seedling copper-containing amine oxidases with guanidinium compounds.
Agrò, AF; Floris, G; Lorrai, A; Medda, R; Murgia, B; Padiglia, A; Pedersen, JZ, 2000
)
1.03
"Amiloride is a specific inhibitor of uPA but does not inhibit tPA."( Binding site of amiloride to urokinase plasminogen activator depends on species.
Jankun, J; Skrzypczak-Jankun, E, 2001
)
1.38
"Amiloride is an inhibitor of urokinase-type plasminogen activator, and might therefore have an inhibitory effect on neovascularization. "( Systemic amiloride inhibits experimentally induced neovascularization.
Avery, RL; Connor, TB; Farazdaghi, M, 1990
)
2.14
"Amiloride is an inhibitor of passive sodium transport. "( The effect of amiloride on taste-evoked activity in the nucleus tractus solitarius of the rat.
Giza, BK; Scott, TR, 1991
)
2.08
"Amiloride (AM) is a well known potassium sparing diuretic. "( Differential antagonism by amiloride and pirenzepine of the muscarinic receptors of rat tracheal smooth muscle.
Santacana, GE; Silva, WI, 1990
)
2.02
"Amiloride is a compound that interacts with many sodium-binding macromolecules."( Regulation of dopamine D2 receptors by sodium and pH.
Neve, KA, 1991
)
1
"Amiloride is a weak inhibitor of Na+/Ca2+ exchange in isolated plasma membrane vesicles prepared from GH3 rat anterior pituitary cells. "( Inhibition of Na+/Ca2+ exchange in pituitary plasma membrane vesicles by analogues of amiloride.
Barros, F; Cragoe, EJ; Dethmers, JK; Kaczorowski, GJ; Trumble, MJ, 1985
)
1.94
"Amiloride is a reversible inhibitor of the Na+/H+ antiporter which acts at the external aspect of the transport system. "( Interactions of chloride and amiloride with the renal Na+/H/ antiporter.
Cragoe, EJ; Huang, ZQ; Warnock, DG; Yang, WC, 1988
)
2.01
"Amiloride is a potent inhibitor of the Na+/H+ antiport. "( Asymmetry of the Na+/H+ antiport of dog red cell ghosts. Sidedness of inhibition by amiloride.
Grinstein, S; Smith, JD, 1987
)
1.94
"Amiloride is a potassium-sparing diuretic that will inhibit stimulus-induced Na+-H+ exchange and prevent an increase in cell pH."( Dissociation of human neutrophil activation events by prolonged treatment with amiloride.
Berkow, RL; Dodson, RW; Kraft, AS, 1987
)
1.22
"Amiloride is a new diuretic that reduces lithium-induced polyuria in animals without affecting lithium or potassium levels."( Treatment of severe lithium-induced polyuria with amiloride.
Forrest, JN; Kosten, TR, 1986
)
1.25

Effects

Amiloride has a significant role in the reduction of podocyte cell motility in vitro and proteinuria in mice. 5-10 mg daily has a mild to moderate BP lowering effect in patients with essential hypertension.

Amiloride has an acute hypotensive action not dependent on ENaC and eNOS and likely related to the heart. It has been shown to inhibit acid-sensing ion channels (ASICs), which contribute to ischemia-related muscle pain during exercise. Amil oride has not demonstrated any neuroprotective benefit within this trial paradigm.

ExcerptReferenceRelevance
"Amiloride has an acute hypotensive action not dependent on ENaC and eNOS and likely related to the heart."( The acute blood pressure-lowering effect of amiloride is independent of endothelial ENaC and eNOS in humans and mice.
Andersen, H; Hansen, PBL; Jacobsen, IA; Jensen, BL; Jürgensen, JF; Oxlund, CS; Peluso, AA; Staehr, M; Svenningsen, P; Vanhoutte, PM; Ydegaard, R, 2019
)
2.22
"Amiloride has a significant role in the reduction of podocyte cell motility in vitro and proteinuria in mice."( Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Shi, W; Xie, S; Yang, Y; Zhang, B, 2012
)
2.54
"Amiloride 5-10 mg daily has a mild to moderate BP lowering effect in patients with essential hypertension."( Amiloride compared with nitrendipine in treatment of essential hypertension.
Henningsen, NC; Hulthén, UL; Katzman, PL, 1988
)
2.44
"Amiloride has been shown to inhibit acid-sensing ion channels (ASICs), which contribute to ischemia-related muscle pain during exercise. "( A 10-mg dose of amiloride increases time to failure during blood-flow-restricted plantar flexion in healthy adults without influencing blood pressure.
Blaha, C; Carr, ZJ; Cauffman, A; Cui, J; Dalton, PC; Hamaoka, T; Herr, MD; Janicki, P; Luck, JC; Ruiz-Velasco, V; Stavres, J, 2022
)
2.51
"Amiloride has not demonstrated any neuroprotective benefit within this trial paradigm, but future neuroprotective trials in ON should target the window of opportunity to maximise potential neuroprotective benefit."( Amiloride does not protect retinal nerve fibre layer thickness in optic neuritis in a phase 2 randomised controlled trial.
Cottriall, CL; Craner, M; Elston, J; Epps, S; Evangelou, N; Gerry, S; Kennard, C; Koelewyn, A; Kong, Y; Kueker, W; Leite, MI; McKee, JB; Palace, J, 2019
)
3.4
"Amiloride has an acute hypotensive action not dependent on ENaC and eNOS and likely related to the heart."( The acute blood pressure-lowering effect of amiloride is independent of endothelial ENaC and eNOS in humans and mice.
Andersen, H; Hansen, PBL; Jacobsen, IA; Jensen, BL; Jürgensen, JF; Oxlund, CS; Peluso, AA; Staehr, M; Svenningsen, P; Vanhoutte, PM; Ydegaard, R, 2019
)
2.22
"Amiloride has been reported to produce a wide variety of actions, thereby affecting several ionic channels and a multitude of receptors and enzymes. "( Spinal antinociceptive action of amiloride and its interaction with tizanidine in the rat formalin test.
Huang, W; Li, Q; Nie, B; Ouyang, H; Wang, P; Zeng, W,
)
1.86
"Amiloride has been reported to selectively kill human malignant glioma cell lines but not primary astrocytes (Hegde et al., 2004)."( Dual inhibition of sodium-mediated proton and calcium efflux triggers non-apoptotic cell death in malignant gliomas.
Carraway, KL; Chen, TY; Dunn, T; Floyd, C; Gorin, FA; Harley, W; Hegde, M; Leon, L; Lyeth, B; Nantz, MH; Palandoken, H; Zhang, XD, 2010
)
1.08
"Amiloride has a significant role in the reduction of podocyte cell motility in vitro and proteinuria in mice."( Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria.
Shi, W; Xie, S; Yang, Y; Zhang, B, 2012
)
2.54
"Amiloride has antibacterial properties that may be synergistic with aminoglycosides against other species belonging to the Burkholderia cepacia complex (Bcc)."( Inhaled amiloride and tobramycin solutions fail to eradicate Burkholderia dolosa in patients with cystic fibrosis.
Adams, S; Ericson, DA; Gerard, C; Kalish, LA; Uluer, AZ; Waltz, DA, 2013
)
1.55
"Amiloride (1 mM) has no effect on the pancreatic fluid secretion either in a normal incubation medium (143 mM Na+), or in a medium containing only 25 mM Na+."( Amiloride is a cholinergic antagonist in the rabbit pancreas.
Bonting, SL; De Pont, JJ; Fleuren-Jakobs, AM; Kuijpers, GA; Rodrigues de Miranda, JF; Van Nooy, IG, 1984
)
2.43
"Amiloride which has been shown to be a reversible inhibitor of cell proliferation in rapidly dividing mammalian cell populations has similar properties on the oocyte maturation division cycle of Xenopus."( Amiloride and other blockers of electrolyte flux as inhibitors of progesterone-stimulated meiotic maturation in Xenopus oocytes.
Cameron, IL; Cragoe, EJ; Lum, JB, 1984
)
2.43
"Amiloride (10(-3) M) has no effect on pancreatic fluid secretion."( The mechanism of fluid secretion in the rabbit pancreas studied by means of various inhibitors.
Bonting, SL; De Pont, JJ; Kuijpers, GA; Van Nooy, IG, 1984
)
0.99
"Amiloride has been reported to reduce membrane permeability to sodium in a wide variety of ion-transporting epithelia."( Functional importance of sodium and potassium in the guinea pig cochlea studied with amiloride and tetraethylammonium.
Konishi, T; Salt, AN, 1982
)
1.21
"Amiloride has been suggested to inhibit responses to a variety of taste stimuli, including salty, sweet, and sour (acid). "( Proton currents through amiloride-sensitive Na+ channels in isolated hamster taste cells: enhancement by vasopressin and cAMP.
Gilbertson, TA; Kinnamon, SC; Roper, SD, 1993
)
2.04
"Amiloride has been shown to reduce the sourness, but not the saltiness, of NaCl and Na gluconate and to have no effect on the taste of KCl."( Amiloride suppresses the sourness of NaCl and LiCl.
Ossebaard, CA; Smith, DV, 1996
)
2.46
"Amiloride has been reported to promote magnesium conservation."( Mechanisms of amiloride stimulation of Mg2+ uptake in immortalized mouse distal convoluted tubule cells.
Dai, LJ; Friedman, PA; Quamme, GA; Raymond, L, 1997
)
1.38
"Amiloride has previously been shown to block a pH-induced Na+ current involved in sensory transduction in hamster taste cells; however, it has been shown to act differently in cutaneous nociceptors."( The pH response of rat cutaneous nociceptors correlates with extracellular [Na+] and is increased under amiloride.
Reeh, PW; Steen, KH; Wegner, H, 1999
)
1.24
"Amiloride has been shown to be an effective inhibitor of the cation cellular entry pathway in "tight" epithelia."( On the cross-reactivity of amiloride and 2,4,6 triaminopyrimidine (TAP) for the cellular entry and tight junctional cation permeation pathways in epithelia.
Balaban, RS; Benos, DJ; Mandel, LJ, 1979
)
1.28
"Amiloride has previously been shown to facilitate receptor binding of atrial natriuretic factor (ANF) to membranes of adrenal cortex and to enhance ANF induced inhibition of steroid secretion in vitro. "( Potentiation of the effects of atrial natriuretic factor on the cardiovascular system by amiloride.
Albus, U; Breipohl, G; Knolle, J; Linz, W; Schölkens, BA; Wiemer, G, 1989
)
1.94
"Amiloride has been shown to inhibit a number of protein kinases including the calcium phospholipid-dependent protein kinase."( Dissociation of human neutrophil activation events by prolonged treatment with amiloride.
Berkow, RL; Dodson, RW; Kraft, AS, 1987
)
1.22
"Amiloride has antiarrhythmic activity in the suppression of sustained ventricular tachyarrhythmias in this postinfarction model."( Amiloride. Antiarrhythmic and electrophysiological activity in the dog.
Duff, HJ; Lester, WM; Rahmberg, M, 1988
)
2.44
"Amiloride has been shown to impair cell volume regulatory decrease in amphiuma red cells. "( Effect of amiloride on cell volume regulation in renal straight proximal tubules.
Lang, F; Völkl, H, 1988
)
2.12
"Amiloride 5-10 mg daily has a mild to moderate BP lowering effect in patients with essential hypertension."( Amiloride compared with nitrendipine in treatment of essential hypertension.
Henningsen, NC; Hulthén, UL; Katzman, PL, 1988
)
2.44
"Amiloride has been reported to inhibit Friend murine erythroleukemic (MEL) cell commitment to differentiate by inhibiting the MEL cell plasma membrane Na+-Ca2+ antiporter (R. "( Phenamil, an amiloride analogue, inhibits differentiation of Friend murine erythroleukemic cells.
Bennington, JB; Cragoe, EJ; Knauf, PA; Lannigan, DA, 1988
)
2.09
"Amiloride hydrochloride has now been recognized as a safe and effective potassium-sparing diuretic alternative to triamterene with a similar mechanism of pharmacologic activity. "( Antihypertensive therapy with triamterene-hydrochlorothiazide vs amiloride-hydrochlorothiazide. Comparison of effects on urinary prostaglandin E2 excretion.
Zawada, ET, 1986
)
1.95
"Amiloride has not previously been tested in the hamster nor has its effect on iontophoretic stimuli (so-called 'electric taste'), which is thought to behave similarly to bulk flow stimuli, been examined."( Effect of amiloride on bulk flow and iontophoretic taste stimuli in the hamster.
Herness, MS, 1987
)
1.4
"Amiloride has been reported to reduce the positive inotropic and toxic actions of cardiac glycosides in patients as well as in experimental animals. "( Effects of amiloride and ouabain on contractile state, Ca and Na fluxes, and Na content in cultured chick heart cells.
Kim, D; Smith, TW, 1986
)
2.1
"Amiloride has no effect on the extent of this inhibition.6."( The effect of amiloride on sodium and potassium fluxes in red cells.
Aceves, J; Cereijido, M, 1973
)
1.33

Actions

Amiloride is known to inhibit membrane sodium transport and has been shown in vitro to inhibit cell activation and proliferation in several model systems. It can inhibit adrenal steroidogenesis with a pharmacological profile suggestive of a Na-H+ antiport system.

ExcerptReferenceRelevance
"Amiloride was used to inhibit urokinase plasminogen activator (uPA) in Plat KO mice, and outflow facility was measured."( Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.
Barron, AO; Chintala, S; Danias, J; Gindina, S; Hu, Y; Kumar, S; Nayyar, A, 2019
)
1.24
"Amiloride was shown to inhibit viral RNA replication and VPgpUpU synthesis."( Amiloride inhibits the initiation of Coxsackievirus and poliovirus RNA replication by inhibiting VPg uridylylation.
Boone, CD; Flanegan, JB; McKenna, R; Ogram, SA, 2014
)
2.57
"Amiloride was unable to increase R(TM) in all cases."( Pleural electrophysiology alterations in spontaneous pneumothorax patients.
Foroulis, CN; Gourgoulianis, KI; Hatzoglou, C; Ioannou, M; Kalafati, G; Kouritas, VK; Molyvdas, PA; Tsilimingas, N, 2010
)
1.08
"Amiloride reduced this increase in [Ca(2+)]i, and inhibited acid-induced articular chondrocyte injury."( Inhibition of acid-sensing ion channels in articular chondrocytes by amiloride attenuates articular cartilage destruction in rats with adjuvant arthritis.
Chen, FH; Hu, W; Li, CW; Li, JP; Li, X; Lu, WG; Wu, FR; Xu, RS; Yuan, FL; Zhang, TY, 2010
)
1.32
"Amiloride is known to inhibit Na(+)/H(+) exchangers on activated hepatic stellate cells."( Amiloride reduces portal hypertension in rat liver cirrhosis.
Beitinger, F; Bystron, M; De Toni, EN; Gerbes, AL; Hartmann, AC; Hennenberg, M; Steib, CJ, 2010
)
2.52
"Amiloride was added to inhibit the Na(+) channel ENaC, and forskolin and ATP were added successively to stimulate cAMP- and Ca(2+)-dependent Cl(-) secretions, respectively."( Effect of nitric oxide on epithelial ion transports in noncystic fibrosis and cystic fibrosis human proximal and distal airways.
Blouquit-Laye, S; Braun, C; Chinet, T; Dannhoffer, L; Dinh-Xuan, AT; Sage, E, 2012
)
1.1
"The amiloride induced increase in serum potassium (0.4 mmol/l) did not significantly change endothelial dysfunction, vascular ACE, collagen markers, or heart rate variability. "( Increasing plasma potassium with amiloride shortens the QT interval and reduces ventricular extrasystoles but does not change endothelial function or heart rate variability in chronic heart failure.
Farquharson, CA; Struthers, AD, 2002
)
1.15
"When amiloride was added to inhibit Na(+)/H(+) exchange, the increase in pH(i) during TGF was blocked (N= 5)."( Increased intracellular pH at the macula densa activates nNOS during tubuloglomerular feedback.
Carretero, OA; Garvin, JL; Liu, R; Ren, Y, 2005
)
0.78
"Amiloride is known to inhibit both influx of sodium ions and activation of quiescent cells by growth factors. "( Amiloride, protein synthesis, and activation of quiescent cells.
Cahn, F; Coutermarsh, BA; Lubin, M, 1982
)
3.15
"Amiloride was able to inhibit the stimulatory effect of the hormone, blocking the increase of both the intranuclear Na+:K+ ratio and of the DNA synthesis rate of hepatocytes."( Amiloride inhibition of triiodothyronine stimulated hepatocyte proliferation in vivo, and involvement of the intracellular Na+ content in mitotic regulation: an X-ray microanalytic study.
Bertoni-Freddari, C; Giuli, C; Lustyik, G; Pieri, C, 1984
)
2.43
"Amiloride is known to inhibit both the influx of Na+ and the activation of mitogenesis in many cultured cell lines. "( Amiloride fluxes across erythrocyte membranes.
Benos, DJ; Reyes, J; Shoemaker, DG, 1983
)
3.15
"Both amiloride and diltiazem produce 50% inhibition of Na+ uptake in kidney microsomes at the same concentrations."( Amiloride and diltiazem inhibition of microsomal and mitochondrial Na+ and Ca2+ transport.
LaBelle, EF; Rex, KA; Sordahl, LA, 1984
)
2.17
"The amiloride-induced increase in KK, from 66 +/- 6 to 205 +/- 35 nm/s, was significantly larger than could be accounted for by the changes in transepithelial voltage or membrane voltages alone."( Pathways of K+ permeation across the rabbit cortical collecting tubule: effect of amiloride.
Stokes, JB, 1984
)
0.97
"Amiloride did not increase blood levels of glucose, uric acid, lipids, calcium, or urea nitrogen."( Effects of amiloride on arterial pressure and renal function.
Chrysant, SG; Luu, TM,
)
1.24
"Amiloride prevented the increase in liquid clearance from the airspaces, indicating that this effect depended on increased uptake of sodium across the lung epithelium."( Stimulation of lung epithelial liquid clearance by endogenous release of catecholamines in septic shock in anesthetized rats.
Folkesson, HG; Matthay, MA; McElroy, MC; Pittet, JF; Wiener-Kronish, JP, 1994
)
1.01
"Amiloride is found to inhibit chloride exchange diffusion in toad skin and passive chloride transport in frog skin. "( Effect of amiloride on chloride transport across amphibian epithelia.
Kristensen, P, 1978
)
2.1
"Amiloride did not inhibit currents through Ca-activated K+ channels."( Inhibition of Ca-activated K+ channels from renal microvillus membrane vesicles by amiloride analogs.
Aronson, PS; Desir, GV; Giebisch, G; Zweifach, A, 1992
)
1.23
"Amiloride-induced increase in acNa was not affected by serosal [Na+] reduction but was blocked by preexposure to reduced luminal [Na+]."( Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium.
Boucher, RC; Willumsen, NJ, 1991
)
1
"Amiloride did not increase the further natriuretic response to ANP."( Effects of atrial natriuretic peptide on distal tubule function in humans.
Bijlsma, JA; Dorhout Mees, EJ; Koomans, HA; Rabelink, TJ; van de Stolpe, A, 1990
)
1
"Amiloride may produce its inotropic effects in guinea-pig atrial muscle by several mechanisms including sodium pump inhibition, Na+/Ca2+ exchange inhibition, prolongation of the action potential duration, and/or actions such as Na+/H+ exchange inhibition which were not directly addressed in this study."( Amiloride: effects on myocardial force of contraction, sodium pump and Na+/Ca2+ exchange.
Akera, T; Berlin, JR; Brody, TM; Kennedy, RH; Ng, YC, 1986
)
2.44
"Amiloride and verapamil inhibit pectin-induced differentiation and also reduce the onset of the Na+ and Ca2+ flux."( Accelerated ion fluxes during differentiation in zoospores of Phytophthora palmivora.
Balson, A; Grant, BR; Griffith, JM; Iser, JR, 1989
)
1
"amiloride, can inhibit adrenal steroidogenesis with a pharmacological profile suggestive of a Na+/H+ antiport system."( Regulation of aldosterone biosynthesis by Na+/H+ antiport: relationships between intracellular pH and angiotensin II.
Cragoe, EJ; De Léan, A; Horiuchi, T; Nguyen, TT, 1989
)
1
"Amiloride is known to inhibit the transcellular fluid transport without inducing any changes in the paracellular fluid transport."( Effects of amiloride on the endolymphatic sac.
Bagger-Sjöbäck, D; Takumida, M, 1989
)
1.39
"Amiloride did not enhance the maximum degree of recovery, although, when present during ischemia, it markedly shortened the time required for peak recovery."( Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange.
Karmazyn, M, 1988
)
2.44
"Amiloride analogs inhibit a number of transmembrane Na+ transport systems: 1) the epithelium Na+ channel, 2) the Na+/H+ exchange system and 3) the Na+/Ca2+ exchange system. "( Amiloride and its analogs as tools to inhibit Na+ transport via the Na+ channel, the Na+/H+ antiport and the Na+/Ca2+ exchanger.
Barbry, P; Chassande, O; Cragoe, EJ; Frelin, C; Lazdunski, M; Vigne, P, 1988
)
3.16
"Amiloride is known to inhibit membrane sodium transport and has been shown in vitro to inhibit cell activation and proliferation in several model systems. "( Inhibition of allergic contact dermatitis and ultraviolet radiation-induced tissue swelling in the mouse by topical amiloride.
Gallo, RL; Granstein, RD, 1989
)
1.93
"Amiloride is known to inhibit this exchange and to cause a cytoplasmic acidification, with inhibition of protein and DNA synthesis, in cells induced to grow."( Amiloride inhibits protein synthesis and lowers the intracellular pH in exponential growing Yoshida rat ascites hepatoma (AH 130) cells: evidence for a role of the Na+/H+ exchanger.
Comolli, R; Leonardi, MG; Mauri, C; Zanoni, L, 1985
)
2.43
"Amiloride was found to suppress p21-induced mitosis, also."( Microinjection of ras p21 induces a rapid rise in intracellular pH.
Aaronson, S; Graber, M; Hagag, N; Lacal, JC; Viola, MV, 1987
)
0.99
"Amiloride did not inhibit the stimulation of leucine uptake by concanavalin A."( Stimulation of leucine transport by a mitogen through intracellular Ca2+ increase in human peripheral lymphocytes.
Mitsumoto, Y; Mohri, T; Sato, K, 1988
)
1
"Amiloride, because it hyperpolarizes the apical membrane, increases KK; ouabain, because it depolarizes the cell, decreases KK."( Patterns of K+ permeation following inhibition of Na+ transport in rabbit cortical collecting tubule.
Stokes, JB, 1986
)
0.99
"Amiloride is known to inhibit the Na+/H+ exchanger in the plasma membrane, the main pH regulating mechanism in mammalian cells."( Effects of amiloride on hyperthermic cell killing of normal and thermotolerant mouse fibroblast LM cells.
Konings, AW; Ruifrok, AC, 1987
)
1.38
"Amiloride was found to lower the overflow of 3,4-dihydroxyphenylethylene glycol from isolated rat tail artery. "( Inhibition of monoamine oxidase by amiloride.
Palatý, V, 1985
)
1.99
"Amiloride does not inhibit the active or the passive (ouabain insensitive) extrusion of (24)Na.3."( The effect of amiloride on sodium and potassium fluxes in red cells.
Aceves, J; Cereijido, M, 1973
)
1.33

Treatment

Amiloride inhalation as treatment for cystic fibrosis (CF) lung disease has been shown in independent studies to increase mucus clearance by ciliary and/or cough action.

ExcerptReferenceRelevance
"Amiloride treatment in podocin-deficient mice resulted in weight loss, increased sodium excretion, normalization of sodium balance and prevention of the activation of plasminogen to plasmin in urine in a reversible way."( Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
Antignac, C; Birn, H; Bistrup, C; Friis, UG; Hinrichs, GR; Jensen, BL; Lund, IK; Mollet, G; Nielsen, R; Svenningsen, P; Weyer, K, 2019
)
1.49
"The amiloride treatment in tumor-bearing mice distinctly alleviated muscle atrophy and relieved cachexia-related features without affecting tumor growth."( Amiloride ameliorates muscle wasting in cancer cachexia through inhibiting tumor-derived exosome release.
Huang, C; Jiang, B; Li, Q; Li, S; Lin, D; Liu, H; Lu, R; Shao, W; Wang, L; Wang, S; Zhang, T; Zhou, L; Zhuo, H, 2021
)
2.54
"Amiloride pretreatment remarkably reduced the cellular uptake of CNPs, suggesting that lung fibroblasts mainly utilize the macropinocytosis-dependent mechanism when interacted with collagen."( The effects of collagen-rich extracellular matrix on the intracellular delivery of glycol chitosan nanoparticles in human lung fibroblasts.
Hergert, P; Im, J; Jeon, S; Kim, H; Kim, K; Nho, RS; Panyam, J; Yhee, JY; Yoon, HY, 2017
)
1.18
"Amiloride-treated cells further exhibited metabolic switching with reductions in glycolytic capacity and maximal respiration."( Effects of the potassium-sparing diuretic amiloride on chemotherapy response in canine osteosarcoma cells.
Inkol, JM; Luu, AK; Mutsaers, AJ; Poon, AC, 2019
)
1.5
"Amiloride pretreated rats received an intravenous injection of 10 mg/kg amiloride 30 min before the administration of LPS."( Amelioration of Lipopolysaccharide-Induced Acute Lung Injury in Rats by Na-H Exchanger-1 Inhibitor Amiloride Is Associated with Reversal of ERK Mitogen-Activated Protein Kinase.
Chen, Q; Gui, P; He, H; Yao, S; Zhang, B; Zhang, Y, 2018
)
1.42
"Amiloride treatment equally enhanced sodium excretion and diminished potassium secretion in knockout mice on an alkaline diet and wild-type mice on an acid diet."( Relation between BK-α/β4-mediated potassium secretion and ENaC-mediated sodium reabsorption.
Cornelius, RJ; Li, H; Rivero-Hernandez, D; Sansom, SC; Weinstein, AM; Wen, D; Yuan, Y, 2014
)
1.12
"Amiloride treatment caused a 2-fold greater increase in Na(+) excretion in knockout, compared with WT."( Increased Epithelial Sodium Channel Activity Contributes to Hypertension Caused by Na+-HCO3- Cotransporter Electrogenic 2 Deficiency.
Boettger, T; Cornelius, RJ; Li, H; Sansom, SC; Wang, B; Wang-France, J; Warner, PC; Wen, D; Yuan, Y, 2015
)
1.14
"Amiloride treatment caused an increase in α-ENaC mRNA abundance in renal cortical tissue but not in intrarenal arteries."( Amiloride lowers arterial pressure in cyp1a1ren-2 transgenic rats without affecting renal vascular function.
Grisk, O; Peters, J; Rettig, R; Rohsius, R; Schlüter, T; Schmid, C; Siepelmeyer, A; Wanka, H, 2010
)
2.52
"Amiloride treatment also reduced high blood pressure caused by the high-salt diet in these mice."( Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice.
Chen, S; Cui, Y; Jiang, J; Peng, J; Shen, J; Wang, W; Wu, Q, 2012
)
1.1
"Amiloride treatment in either sepsis or sepsis complicated by a previous burn injury prevented myocardial Na and Ca accumulation, attenuated sepsis-related lactic acidosis, and improved left ventricular function."( Sodium/hydrogen exchange activity in sepsis and in sepsis complicated by previous injury: 31P and 23Na NMR study.
Horton, JW; Maass, DL; Sikes, PJ; White, J; Zhao, P, 2005
)
1.05
"Amiloride treatment reduced the increase in epithelial ion content but had no effect on shrinkage or SNP-induced relaxation."( Effects of hyperosmolarity and airway epithelial ion transport inhibitors on sodium nitroprusside-induced relaxation of guinea pig trachea.
Hedenstierna, G; Hjoberg, J; Högman, M; Ljung, L; Roomans, GM, 2005
)
1.05
"Amiloride treatment did not lower the BP of 6 T594M heterozygotes significantly more than in 22 control subjects (P=0.8)."( Epithelial sodium channel allele T594M is not associated with blood pressure or blood pressure response to amiloride.
Auchus, RJ; Bell, DM; Chirachanchai, MG; Cooper, RS; Hollier, JM; Leonard, D; Li, JL; Martin, DF; McKenzie, C; Menon, DV; Victor, RG; Wu, X, 2006
)
1.27
"Amiloride (10(-5) M) pretreatment improved AO recoveries from 41.6 +/- 2.7% (n = 6) to 55.8 +/- 4.0% (n = 6) (p < 0.05)."( Role for the Na+/H+ exchanger in reperfusion stunning in isolated perfused rat heart.
du Toit, EF; Opie, LH, 1993
)
1.01
"In amiloride-treated rabbits, Jnet was 0.01 +/- 0.1 ml.kg-1.h-1, C decreased by 34.4% and Q by 33.1%, and Jl averaged 0.39 +/- 0.02 ml.kg-1.h-1."( Contribution of lymphatic myogenic activity and respiratory movements to pleural lymph flow.
Ballard, ST; Benoit, JN; Negrini, D, 1994
)
0.8
"Amiloride inhalation as treatment for cystic fibrosis (CF) lung disease has been shown in independent studies to increase mucus clearance by ciliary and/or cough action and to retard the decline in lung function. "( Amiloride inhalation therapy in cystic fibrosis. Influence on ion content, hydration, and rheology of sputum.
App, EM; Boucher, RC; Church, N; King, M; Knowles, MR; Ramirez, O; Tomkiewicz, RP; Zayas, JG, 1993
)
3.17
"3. Amiloride treatment did not affect the responses to electrical stimulation, indicating that the response to nerve stimulation is not due to current flowing through sodium channels."( Calcium channel blockers apparently decrease noradrenaline release from nerve-skin terminals in Caudiverbera caudiverbera.
Concha, J; Contreras, E; Contreras, G; Norris, B, 1993
)
0.8
"Both amiloride treatment and NaCl adaptation reduced responses to the Na+ stimuli."( Responses of gustatory cells in the nucleus of the solitary tract of the hamster after NaCl or amiloride adaptation.
Liu, H; Smith, DV; Vogt, MB, 1996
)
0.97
"Amiloride pretreatment also decreased creatine phosphokinase activity in the coronary effluent and completely abolished occurrence of ventricular arrhythmias during reperfusion."( Effect of amiloride on ischaemia and reperfusion injury in isolated, perfused rat hearts.
Horike, K; Katoh, I; Kitagawa, T; Masuda, Y; Ogawa, Y; Suzuki, Y; Tamaki, T; Yoshizumi, M, 1998
)
1.42
"Amiloride-pretreated group contained significantly higher glutathione levels than Group 1."( Prevention of selenite-induced opacification and biochemical changes in the rat pup lens through amiloride pretreatment.
Celebi, N; Demirel Yilmaz, E; Turan, B; Yilmaz, G; Yilmaz, N, 2000
)
1.25
"Amiloride-treated ovarian carcinoma cells showed morphological characteristics of apoptosis. "( [Apoptosis of ovarian carcinoma cell line induced by amiloride].
Peng, Z; Wei, Y; Zhao, X, 1999
)
2
"In amiloride-treated tissues an increase in mucosal K+ concentration (5 mmol/l to 25 mmol/l) depolarized Va by 5 +/- 1 mV (n = 8), while the same step on the serosal side depolarized Va by 20 +/- 2 mV (n = 8)."( Chloride and potassium conductances of cultured human sweat ducts.
Larsen, EH; Novak, I; Pedersen, PS, 1992
)
0.8
"In amiloride-treated HNE, the electrical pattern of the BK-induced response was identical, but the magnitude of the Ieq was reduced by 54% and the change in Ieq could be abolished by removal of bath Cl-."( Effects of bradykinin on Na+ and Cl- transport in human nasal epithelium.
Boucher, RC; Clarke, LL; Mason, SJ; Paradiso, AM, 1992
)
0.8
"In amiloride (150 microM)-treated, CMV-infected cells, late, yet not immediate-early or early, protein synthesis was markedly decreased relative to untreated, CMV-infected cells."( Amiloride inhibition of human cytomegalovirus replication.
Albrecht, T; Cerruti-Sola, S; Fons, M; Nokta, M, 1991
)
2.24
"In amiloride-treated ducks, hyperkalemia in response to K+ loading was exaggerated relative to the modest reduction in K+ excretion and may be attributed to moderate metabolic acidosis and/or general effects of amiloride on K+ metabolism."( Control of renal handling of potassium loads in ducks with active salt glands.
Gray, DA; Simon, E, 1991
)
0.8
"Amiloride or EIPA pretreatment also inhibited the incidence of VF and increases in LVEDP and CK release significantly during reperfusion after 30 min of ischemia."( Effects of amiloride and an analogue on ventricular arrhythmias, contracture and cellular injury during reperfusion in isolated and perfused guinea pig heart.
Cragoe, EJ; Fukunaka, M; Imamura, H; Kagawa, K; Kato, Y; Ko, T; Otani, H; Sakurai, Y; Tanaka, K, 1991
)
1.39
"Amiloride-treated 'activated' microgametocytes synthesized DNA to levels consistent with the expected 8C, but failed to develop further."( Plasmodium berghei: ionic regulation and the induction of gametogenesis.
Alejo-Blanco, R; Fleck, SL; Kawamoto, F; Sinden, RE, 1991
)
1
"Amiloride treatment significantly retarded the normal increase of Na,K-ATPase in NP rats but had no effect on ouabain-insensitive ATPase."( High protein intake accelerates the maturation of Na,K-ATPase in rat renal tubules.
Aperia, A; Jakobsson, B, 1990
)
1
"Only amiloride-treated subjects displayed significant increases in salt taste sensitivity."( Effects of hydrochlorothiazide and amiloride on salt taste and excretion (intake).
Christensen, CM; Engelman, K; Mattes, RD, 1990
)
1.01
"Amiloride treatment enhanced the stimulatory and abolished the inhibitory phase of GTP gamma S action."( Amiloride interacts with guanine nucleotide regulatory proteins and attenuates the hormonal inhibition of adenylate cyclase.
Anand-Srivastava, MB, 1989
)
2.44
"Amiloride pretreatment abolished the ANP-induced kaliuresis, whereas ANP-induced increases in urinary sodium and fractional sodium excretion were additive after amiloride pretreatment."( Interaction between ANP and amiloride in renal tubular sodium handling in anesthetized rabbits.
Abe, K; Nushiro, N; Seino, M; Yoshinaga, K, 1988
)
1.29
"In amiloride-treated tubules, neither vasopressin nor PGE2 altered KK."( Patterns of K+ permeation following inhibition of Na+ transport in rabbit cortical collecting tubule.
Stokes, JB, 1986
)
0.78
"Amiloride treatment (4 min of 0.0001 M) of the hamster's tongue effectively inhibited chorda tympani responses to NaCl and LiCl solutions."( Effect of amiloride on bulk flow and iontophoretic taste stimuli in the hamster.
Herness, MS, 1987
)
1.4
"Amiloride treated rats (0.1 mg/hr) had significant diuresis and natriuresis, as well as antikaliuresis, compared to untreated controls."( Effects of amiloride in the medullary collecting duct of rat kidney.
Honrath, U; Sonnenberg, H; Wilson, DR, 1987
)
1.38
"Treatment with amiloride of proband and his sister did not normalize the blood pressure, but normalized level of plasma renin activity."( Liddle syndrome due to a novel mutation in the γ subunit of the epithelial sodium channel (ENaC) in family from Russia: a case report.
Baryshnikova, NV; Ilinsky, VV; Klimchuk, OI; Kozina, AA; Krasnenko, AY; Obuhova, VA; Okuneva, EG; Shatalov, PA; Surkova, EI; Trofimova, TA; Tsukanov, KY, 2019
)
0.85
"Treatment with amiloride for two days increased plasma and urine NO-products, while plasma cGMP decreased and urinary cGMP was unchanged in patient samples. "( The acute blood pressure-lowering effect of amiloride is independent of endothelial ENaC and eNOS in humans and mice.
Andersen, H; Hansen, PBL; Jacobsen, IA; Jensen, BL; Jürgensen, JF; Oxlund, CS; Peluso, AA; Staehr, M; Svenningsen, P; Vanhoutte, PM; Ydegaard, R, 2019
)
1.13
"Pretreatment with amiloride significantly reduced the increase in W/D, ALI score, lung tissue MPO activity, concentrations of TP, TNF-"( Amelioration of Lipopolysaccharide-Induced Acute Lung Injury in Rats by Na-H Exchanger-1 Inhibitor Amiloride Is Associated with Reversal of ERK Mitogen-Activated Protein Kinase.
Chen, Q; Gui, P; He, H; Yao, S; Zhang, B; Zhang, Y, 2018
)
1.03
"Treatment with amiloride (an inhibitor of PM Na(+)/H(+) antiporter) and vanadate (an inhibitor of PM H(+)-ATPase) also inhibited the activity of H2S on Na(+)/K(+) ratio."( Hydrogen sulfide is involved in maintaining ion homeostasis via regulating plasma membrane Na+/H+ antiporter system in the hydrogen peroxide-dependent manner in salt-stress Arabidopsis thaliana root.
Cao, Q; Jia, H; Li, J; Wang, J; Wen, Z, 2014
)
0.74
"Co-treatment with amiloride and 9-phenanthrol showed a similar inhibitory effect on myogenic contraction compared to single treatment with amiloride or 9-phenanthrol."( Role of endogenous ENaC and TRP channels in the myogenic response of rat posterior cerebral arteries.
Choi, SK; Kim, EC; Lee, YH; Lim, M; Yeon, SI, 2013
)
0.71
"Pretreatment with amiloride significantly delayed the onset of the first episode of limbic seizures, whereas posttreatment with amiloride decreased escape latency in the Morris water maze test compared to post-FS treatment with saline."( The Effects of Amiloride on Seizure Activity, Cognitive Deficits and Seizure-Induced Neurogenesis in a Novel Rat Model of Febrile Seizures.
Ding, YX; Jiang, W; Ou-Yang, TP; Sun, XL; Yang, F; Zhu, GM, 2016
)
1.11
"Treatment with amiloride led to intracellular acidification and lower net H(+) flux in WT plants and to a decrease in intracellular Ca(2+) in WT and sos1 plants."( Na(+)/H(+) antiporter activity of the SOS1 gene: lifetime imaging analysis and electrophysiological studies on Arabidopsis seedlings.
Babourina, O; Guo, KM; Rengel, Z, 2009
)
0.69
"Pretreatment with amiloride increased mucociliary clearance rates (approximately twofold) after inhalation of 0.12 and 0.9% saline (p < 0.05), but not 7% saline."( Increasing concentration of inhaled saline with or without amiloride: effect on mucociliary clearance in normal subjects.
Bennett, WD; Boucher, RC; Brown, J; Foy, C; Knowles, MR; Sood, N; Zeman, K, 2003
)
0.89
"When treated with amiloride to block the Na(+)/H(+) exchanger, intracellular pH in hTE acidified at significantly higher rates than in Calu-3, and treatment with AEBSF blocked acidification."( NADPH oxidase-dependent acid production in airway epithelial cells.
Fischer, H; Illek, B; Machen, TE; Schwarzer, C, 2004
)
0.65
"Pretreatment with amiloride inverted the stimulatory effect of externally applied Cd(2+), suggesting competitive action on the apical Na(+) channel."( Effects of cadmium on Na+ transport in the isolated skin of the toad Pleurodema thaul.
Cárdenas, H; Norris, B; Suwalsky, M, 2005
)
0.65
"Pretreatment with amiloride abolished this relationship (rs = 0.307, p = NS)."( Amiloride-induced changes in digoxin dynamics and kinetics: abolition of digoxin-induced inotropism with amiloride.
Buch, J; Egeblad, H; Hansen, PB; Kjaergård, H; Steiness, E; Waldorff, S, 1981
)
2.03
"4. Treatment with amiloride did not affect segmental lithium handling up to the late distal tubule."( A micropuncture study of renal tubular lithium reabsorption in sodium-depleted rats.
Sampson, B; Shirley, DG; Walter, SJ, 1995
)
0.61
"Pretreatment with Amiloride, an inhibitor of the Na+/H+ exchange, partially blocked this pH recovery after acidification."( Mechanism of cadmium-induced cytotoxicity in rat hepatocytes: cadmium-induced active oxygen-related permeability changes of the plasma membrane.
Koizumi, T; Kumagai, H; Shirakura, H; Suzuki, KT; Tatsumoto, H, 1996
)
0.62
"Treatment with amiloride resulted in a 1.5-fold rise of microsomal corticosterone 11 beta-oxidation rates in kidney (using NAD and NADP as cofactors) and in liver (for NADP only), but had no effect on microsomal 11-dehydrocorticosterone reduction."( The effect of amiloride and sodium chloride on rat renal and hepatic 11 beta-hydroxysteroid dehydrogenase activities.
Hermans, JJ; Maser, E; Niepel, T, 1997
)
1
"Treatment with amiloride was effective."( [Mineralocorticoid-like hypertension. "Apparent mineralocorticoid excess". A hereditary type of hypertension?].
Christensen, TH; Ibsen, H; Kaae, HH, 1999
)
0.64
"Pretreatment with amiloride resulted in a small but significant increase in the intensity of the sensation elicited by the 15 s carbonated water stimulus, suggesting an amiloride-sensitive transduction mechanism."( The oral sensation of carbonated water: cross-desensitization by capsaicin and potentiation by amiloride.
Carstens, E; Dessirier, JM; O'Mahony, M; Simons, CT, 2001
)
0.85
"Treatment with amiloride caused a significant decrease in cellular Na concentration in adult animals and in in utero treated mice 2 days after birth."( Effect of chronic treatment with diuretics on mouse liver: a morphological and microanalytical investigation.
Mörk, AC; Roomans, GM; von Euler, A, 1992
)
0.62
"Pretreatment with amiloride (0.3 mM) mostly blocked dbcAMP- and Sp-cAMPS-induced decrease in pHi but did not affect calcium ionophore-induced decrease in pHi."( Second messenger signaling in the regulation of cytosolic pH and DNA synthesis by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: role of Na+/H+ exchange.
Fujita, T; Fukase, M; Kano, J; Sugimoto, T, 1992
)
0.61
"Treatment with amiloride or furosemide in utero caused a decrease in cellular sodium and chloride levels, indicative of inhibition of transepithelial ion and fluid transport."( Effects of chronic and in utero treatment with diuretics on mouse exocrine cells studied by X-ray microanalysis.
Mörk, AC; Roomans, GM; Von Euler, A, 1992
)
0.62
"Treatment with amiloride or EIPA for 15 min before ischemia, and during reperfusion after 15 min of ischemia, under electrical pacing at 240 rpm to eliminate a negative chronotropic effect abolished ventricular tachycardia (VT) and ventricular fibrillation (VF) during reperfusion associated with highly significant inhibition of increases in left ventricular end-diastolic pressure (LVEDP) and CK release."( Effects of amiloride and an analogue on ventricular arrhythmias, contracture and cellular injury during reperfusion in isolated and perfused guinea pig heart.
Cragoe, EJ; Fukunaka, M; Imamura, H; Kagawa, K; Kato, Y; Ko, T; Otani, H; Sakurai, Y; Tanaka, K, 1991
)
1.01
"Pretreatment with amiloride prevented surface EGF receptor depletion induced by cycloheximide and puromycin, but it did not significantly inhibit surface receptor depletion caused by monensin."( Amiloride inhibits constitutive internalization and increases the surface number of epidermal growth factor receptors in intact rat hepatocytes.
Christoffersen, T; Gladhaug, IP, 1990
)
2.05
"Treatment with amiloride reversibly reduced the compensatory increase in kidney weight and protein content (dose required to achieve 50% inhibition, 11.4 and 2.4 mg/kg/day, respectively)."( Effect of amiloride on the compensatory renal growth that follows uninephrectomy in mice.
Cragoe, EJ; Donoso, VS; Grantham, JA; Grantham, JJ, 1989
)
1.02
"Pretreatment with amiloride protected against this loss of staining."( Immunochemical localization of amiloride-sensitive sodium channels in sodium-transporting epithelia.
Alley, CD; Benos, DJ; Brinkley, BR; Sorscher, EJ; Tousson, A, 1989
)
0.89
"Treatment with amiloride + HCTZ led to elevations in serum levels of cholesterol, uric acid and urea, which were maintained at one year, whilst no abnormalities in blood biochemistry were seen in patients treated with nicardipine."( A randomised comparative trial of nicardipine versus amiloride and hydrochlorothiazide in mild to moderate hypertension. A report from the General Practitioner Hypertension Study Group.
Bradley, I; Davis, A; Ganvir, P; Gostick, NK; Hopwood, AM; MacKay, D; Mayhew, SR; Mukerji, D; Shepherd, F, 1989
)
0.87

Toxicity

100 microM amiloride and intracellular loading of BAPTA failed to counteract the nontoxic effect of 1 microM ouabain. Neither UTP alone nor in combination with amil oride caused any clinically significant adverse effects on airway mechanics, lung volumes, or gas exchange.

ExcerptReferenceRelevance
"To see whether the Na/H antiporter plays a role in digitalis cardiotoxicity, we investigated the influence of modulators of Na/H exchange on the toxic effects of ouabain in isolated, paced (0."( Opposite modulation of ouabain cardiotoxicity by hexamethyleneamiloride and phenylephrine.
Anagnostopoulos, T; Terzic, A; Vogel, SM, 1991
)
0.52
"This paper describes the case of a 74 year old patient who became lithium toxic after 15 years of lithium therapy."( Saline infusion and amiloride in the management of lithium toxicity.
Czerniewski, IW; McConnell, AA; Short, JA, 1990
)
0.6
"Effects of amiloride on the inotropic and toxic actions of cardiac glycosides were examined using left atrial muscle isolated from guinea pig heart."( Suppression of positive inotropic and toxic effects of cardiac glycosides by amiloride.
Akera, T; Brody, TM; Kennedy, RH, 1985
)
0.89
" Contrary to their action in the toxic effect, both 100 microM amiloride and the intracellular loading of BAPTA failed to counteract the nontoxic effect of 1 microM ouabain."( Toxic and nontoxic effects of ouabain on the transmitter release from frog motor nerve terminals.
Enomoto, K; Hara, N; Ichinose, M; Maeno, T; Sawada, M, 1995
)
0.53
" It is postulated that one important toxic effect of ammonia/ammonium is an increased demand for maintenance energy, caused by the need to maintain ion gradients over the cytoplasmic membrane."( Mechanisms of ammonia and ammonium ion toxicity in animal cells: transport across cell membranes.
Häggström, L; Martinelle, K, 1993
)
0.29
" Weak acids that are normal cellular metabolites are not toxic in vivo, but weak acids carrying cytotoxic groups offer the potential for selective uptake and toxicity under the conditions of low pHe that exist in many solid tumours."( Selective cellular acidification and toxicity of weak organic acids in an acidic microenvironment.
Dobrowsky, E; Karuri, AR; Tannock, IF, 1993
)
0.29
" We show that the toxic effect of this drug is relieved by low concentrations of thiamine (Th) and that the pyrimidine moiety of the Th molecule is responsible for growth inhibition release."( Amiloride toxicity in the fission yeast Schizosaccharomyces pombe is released by thiamine and mutations in the thiamine-repressible gene car1.
Edenharter, E; Fankhauser, H; Niederberger, C; Schweingruber, ME, 1996
)
1.74
" Neither UTP alone nor in combination with amiloride caused any clinically significant adverse effects on airway mechanics, (subdivisions of) lung volumes, or gas exchange."( Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults.
Bennett, WD; Boucher, RC; Edwards, LJ; Hohneker, KW; Knowles, MR; Olivier, KN; Zeman, KL, 1996
)
0.78
" In cells exposed to 50 microM Cd, generation of the toxic oxygen increased from 5 min after exposure, and reached a plateau at 15 min."( Mechanism of cadmium-induced cytotoxicity in rat hepatocytes: cadmium-induced active oxygen-related permeability changes of the plasma membrane.
Koizumi, T; Kumagai, H; Shirakura, H; Suzuki, KT; Tatsumoto, H, 1996
)
0.29
" AMIL markedly potentiated the toxic effect of METH on DA neurons."( Inhibitors of Na(+)/H(+) and Na(+)/Ca(2+) exchange potentiate methamphetamine-induced dopamine neurotoxicity: possible role of ionic dysregulation in methamphetamine neurotoxicity.
Callahan, BT; Cord, BJ; McCann, UD; Ricaurte, GA; Yuan, J, 2001
)
0.31
"In this study, the toxic effect of sanguinarine (SANG) on heart was studied with isolated cardiac muscle strip isolated from Wistar rat."( Induction of contracture and extracellular Ca2+ influx in cardiac muscle by sanguinarine: a study on cardiotoxicity of sanguinarine.
Cheng, HW; Cheng, YW; Hu, CM; Kang, JJ; Liao, JW, 2005
)
0.33
" From the viewpoint of developing effective and safe protein transduction technology, although Tat was the most versatile carrier among the peptides studied, PTDs should be selected based on their individual characteristics."( Comparative study on transduction and toxicity of protein transduction domains.
Imai, S; Kamada, H; Mukai, Y; Nagano, K; Nakagawa, S; Shibata, H; Sugita, T; Tsunoda, SI; Tsutsumi, Y; Yamanada, N; Yoshida, Y; Yoshikawa, T; Yoshioka, Y, 2008
)
0.35
"Antihypertensive therapy is effective in reducing the risk of major adverse cardiovascular events."( Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012
)
0.38
" Safety evaluations included monitoring of any adverse events (AEs)."( Combination of amlodipine plus angiotensin receptor blocker or diuretics in high-risk hypertensive patients: a 96-week efficacy and safety study.
Deng, Q; Liu, L; Liu, M; Ma, L; Sun, H; Wang, J; Wang, W; Zhang, Y; Zhao, Y, 2012
)
0.38
"Cultured cerebellar granule neurons (CGNs) are resistant to the toxic effect of ZnCl2 (0."( Acidosis and 5-(N-ethyl-N-isopropyl)amiloride (EIPA) Attenuate Zinc/Kainate Toxicity in Cultured Cerebellar Granule Neurons.
Amelkina, GA; Genrikhs, EE; Isaev, NK; Ivashkin, EG; Khaspekov, LG; Novikova, SV; Stelmashook, EV, 2015
)
0.69

Pharmacokinetics

The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine.

ExcerptReferenceRelevance
" As a result of the pharmacokinetic findings caution may be indicated in the clinical dosage of the diuretics particularly when in fixed dose combination."( The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly.
Ismail, Z; Parke, W; Smithurst, BA; Triggs, EJ, 1989
)
0.58
" No difference in any of the drug pharmacokinetic parameters could be detected between the hypertensives and the normal elderly subjects."( A comparative study of the pharmacokinetics and pharmacodynamics of atenolol, hydrochlorothiazide and amiloride in normal young and elderly subjects and elderly hypertensive patients.
Adam, HK; Castleden, CM; Fitzsimons, TJ; Ryan, J; Sabanathan, K, 1987
)
0.49
" Peak serum levels are seen at three hours, and the serum half-life is six hours."( Mechanism of action, pharmacokinetics, adverse effects, and therapeutic uses of amiloride hydrochloride, a new potassium-sparing diuretic.
Vidt, DG,
)
0.36
"Open-label, randomized, two-way crossover, single-dose pharmacokinetic study."( Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.
Boucher, RC; Dukes, GE; Henry, MM; Hohneker, K; Hsyu, PH; Jones, KM; Knowles, MR; Liao, E; Selinger, K; Turpin, S,
)
0.45
"After oral dosing, the mean +/- SD maximum peak concentration (Cmax) was 20."( Pharmacokinetics of amiloride after inhalation and oral administration in adolescents and adults with cystic fibrosis.
Boucher, RC; Dukes, GE; Henry, MM; Hohneker, K; Hsyu, PH; Jones, KM; Knowles, MR; Liao, E; Selinger, K; Turpin, S,
)
0.45
" The reported methods were applied to pharmacokinetic investigations of the two compounds taken in form of a drug combination."( Determination and pharmacokinetics of a furosemide-amiloride drug combination.
Jankowski, A; Lamparczyk, H; Skorek-Jankowska, A, 1997
)
0.55
"To compare the performance of the standard lag time model (LAG model) with the performance of an analytical solution of the transit compartment model (TRANSIT model) in the evaluation of four pharmacokinetic studies with four different compounds."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.34
"The population pharmacokinetic analyses were performed using NONMEM on concentration-time data of glibenclamide, furosemide, amiloride, and moxonidine."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.55
" The parameter estimates related to the absorption differed between the two models while the estimates of the pharmacokinetic disposition parameters were similar."( Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
Jonker, DM; Karlsson, MO; Kerbusch, T; Savic, RM, 2007
)
0.34
" Electrolyte content of EBC and serum was also assessed as a potential pharmacodynamic marker of drug activity."( Airway drug pharmacokinetics via analysis of exhaled breath condensate.
Ansede, JH; Boucher, RC; Donn, KH; Esther, CR; Ghio, AJ; Hirsh, AJ; Johnson, MR; O'Riordan, TG, 2014
)
0.4
"To develop a physiologically based pharmacokinetic (PBPK) model for amiloride, an acid-sensing ion channel (ASIC) antagonist, and to simulate its pharmacokinetics in plasma and the central nervous system following intranasal administration in a virtual human population."( Novel intranasal treatment for anxiety disorders using amiloride, an acid-sensing ion channel antagonist: Pharmacokinetic modeling and simulation.
Azzeh, M; Battaglia, M; Davies, S; Dogra, P; Strauss, J; Yellepeddi, V, 2022
)
1.2

Compound-Compound Interactions

Chlorthalidone and hydrochlorothiazide, in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and safety.

ExcerptReferenceRelevance
" The effects of timolol alone and in combination with a fixed dose of hydrochlorothiazide and amiloride have been studied in a double-blind, controlled study in fifty-four patients with mild to moderate essential hypertension."( Evaluation of the effect of timolol alone and in combination with hydrochlorothiazide and amiloride in the treatment of mild to moderate arterial hypertension: a double-blind, controlled study.
Agabiti-Rosei, E; Alicandri, C; Ambrosioni, E; Magnani, B; Miele, N; Muiesan, G, 1976
)
0.7
"A comparative study was undertaken to examine antihypertensive effects and impact of hydrochlorothiazide (HCT) alone or in combination with triamterene or amiloride on the hemodynamics of 79 patients with Stage II hypertension."( [Comparative study of the hypotensive action of monotherapy using hydrochlorothiazide and its combination with triamterene and amiloride and their effect on hemodynamics at rest and during exercise therapy].
Glezer, GA; Levinzon, AM; Lipko, DS, 1990
)
0.68
" It is concluded that in a clinical daily practice of a hypertension clinic low doses of spironolactone or of thiazides combined with potassium-sparing agents reduced BP without alteration in lipid or carbohydrate metabolism on long-term follow-up."( Long-term metabolic effects of spironolactone and thiazides combined with potassium-sparing agents for treatment of essential hypertension.
Charru, A; Chatellier, G; Corvol, P; Degoulet, P; Jeunemaitre, X; Julien, J; Ménard, J; Plouin, PF, 1988
)
0.27
" In these patients, the doubling of diuretic dose (hydrochlorothiazide 50 mg + amiloride 5 mg) in combination with atenolol resulted in a further drop in systolic pressure (to 142."( Effects of hydrochlorothiazide combined with amiloride in atenolol-resistant hypertensive patients.
Bentivoglio, M; Corea, L; Verdecchia, P, 1983
)
0.75
" We concluded that lowering the pHi by blocking the regulation of pHi in combination with hyperthermia may be a useful way to eliminate the radioresistant hypoxic cells."( Killing of hypoxic cells by lowering the intracellular pH in combination with hyperthermia.
Lyons, JC; Song, CW, 1995
)
0.29
"This study was performed to compare the effect of one month's treatment with hydrochlorothiazide (25 mg) in combination with either amiloride (2."( A study of plasma sodium levels in elderly people taking amiloride or triamterene in combination with hydrochlorothiazide.
Bielawska, CA; Fidler, HM; Goldman, J; Hoffbrand, BI; Rai, GS, 1993
)
0.74
"The anti-cryptosporidial activity of four cationic peptides alone and in combination with five ion transport system (ITS) inhibitors was investigated for six clinical isolates of Cryptosporidium parvum recovered from stools of AIDS patients."( In vitro anti-cryptosporidial activity of cationic peptides alone and in combination with inhibitors of ion transport systems.
Ancarani, F; Barchiesi, F; Cirioni, O; Giacometti, A; Scalise, G, 2000
)
0.31
" Thus, the goal of this study was to compare the effects of two resuscitation strategies alone and in combination with that of standard resuscitation with Ringer's lactate."( Amiloride combined with small-volume resuscitation with hypertonic saline is superior in ameliorating trauma-hemorrhagic shock-induced lung injury in rats to the administration of either agent alone.
Berezina, TL; Deitch, EA; Feketeova, E; Fujiyoshi, N; Haskó, G; Lu, Q; Machiedo, GW; Xu, DZ; Zaets, SB, 2005
)
1.77
" This trial aims to investigate the efficacy of chlorthalidone and hydrochlorothiazide, in combination with amiloride at different doses, for initial management of patients with primary hypertension."( Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.
Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019
)
0.96
" Chlorthalidone and hydrochlorothiazide, in combination with amiloride in multiple doses, will be tested in terms of blood pressure lowering efficacy and safety."( Efficacy of chlorthalidone and hydrochlorothiazide in combination with amiloride in multiple doses on blood pressure in patients with primary hypertension: a protocol for a factorial randomized controlled trial.
Bottino, LG; Ferrari, F; Fuchs, FD; Fuchs, SC; Helal, L; Martins, VM, 2019
)
0.99
" The proposed methods were applied to two pharmaceutical formulations; the method for HCT and AMH has proven as reliable assaying method, whereas the method for TML, when combined with HCT, is applicable to screening semi-quantitative analyses."( Simultaneous spectrofluorometric analysis of tablets containing hydrochlorothiazide combined with timolol maleate or amiloride hydrochloride.
Lataifeh, A; Mohammed, MS; Wedian, F, 2020
)
0.77

Bioavailability

Amiloride is a well-known inhibitor of the Na(+) -H+ exchanger. The absolute bioavailability of oral amoxicillin turned out to decrease by 27%.

ExcerptReferenceRelevance
" The rate of absorption (tmax = 3 h) and the bioavailability of the two diuretics were not significantly modified by their combination."( Combination of long-acting furosemide and instant-acting amiloride: pharmacokinetics and pharmacodynamics in human subjects.
Alexandre, JA; Flouvat, B; Leneveu, A; Prinseau, J; Roux, A, 1991
)
0.53
" These changes indicate a decreased absorption rate of endolymph in the endolymphatic sac."( Modulation of the endolymphatic sac function.
Bagger-Sjöbäck, D; Harada, Y; Rask-Andersen, H; Takumida, M, 1991
)
0.28
" With ouabain (10(-4) M) in the perfusate the fluid absorption rate fell to 57 nl/s (S."( Significance of active ion transport in transalveolar water absorption: a study on isolated rat lung.
Basset, G; Crone, C; Saumon, G, 1987
)
0.27
" The ratio of AUCs of the combination tablet to the reference drugs approached a limiting value many hours prior to complete elimination of the drug and hence reliable bioavailability comparisons were possible with blood sampling up to 24 hours post-dose."( Pharmacokinetics of an oral frusemide/amiloride combination tablet.
Brooks, SG; Christie, RB; Fairhead, AP; Muirhead, D; Roche, J; Shaw, HL; Townsend, HA, 1984
)
0.54
" The aim of the present study was to assess the in vivo relevance of these data in humans by examining the effect of amiloride, a well-known inhibitor of the Na(+) -H+ exchanger, on the bioavailability of amoxicillin in eight healthy volunteers."( Amoxicillin intestinal absorption reduction by amiloride: possible role of the Na(+) -H+ exchanger.
Brogard, JM; Carbon, C; Jehl, F; Westphal, JF, 1995
)
0.76
"To evaluate the role of Na(+)-glucose cotransport in fluid absorption across alveolar epithelial walls in isolated rat lungs, we measured the inhibitory effects of amiloride (a Na+ channel blocker) and phlorizin (a Na(+)-glucose cotrasport blocker) on the fluid absorption rate in fluid-filled lungs."( [Role of Na(+)-glucose cotransport in fluid absorption across alveolar epithelium in isolated rat lungs].
Fujimura, S; Koike, K; Noda, M; Ono, S; Sakuma, T; Sugita, M; Suzuki, S; Tanita, T, 1996
)
0.49
" Recently a new method has been proposed to determine absolute bioavailability in the absence of intravenous dose."( Prediction of absolute bioavailability for drugs using oral and renal clearance following a single oral dose: a critical view.
Mahmood, I, 1997
)
0.3
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Thus, 2-aminobenzimidazoles may have improved pharmacokinetic properties which could increase the bioavailability of inhibitors which contain this moiety."( Identification of novel inhibitors of urokinase via NMR-based screening.
Boyd, S; Davidson, D; Fesik, SW; Hajduk, PJ; Nettesheim, D; Nienaber, V; Rockway, T; Severin, J; Smith, R, 2000
)
0.31
" In control rats, the elimination half-life of pirfenidone following a single intravenous dose of 200 mg kg(-1) was 37 min while oral bioavailability at this dose was 25."( Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats.
Brown, L; Fenning, A; Margolin, SB; Mirkovic, S; Seymour, AM; Strachan, A; Taylor, SM, 2002
)
0.57
" High sodium intake increased HCO(3)(-) absorption rate by 60%."( High sodium intake increases HCO(3)- absorption in medullary thick ascending limb through adaptations in basolateral and apical Na+/H+ exchangers.
George, T; Good, DW; Watts, BA, 2011
)
0.37
"Nutrient transporters expressed on cell membrane have been targeted for enhancing bioavailability of poorly permeable drugs."( Molecular expression and functional activity of sodium dependent multivitamin transporter in human prostate cancer cells.
Mitra, AK; Patel, M; Shah, S; Vadlapatla, RK, 2012
)
0.38
" The CLP-induced reduction in intrinsic HCO(3)(-) absorption rate appears to involve loss of function of basolateral Na(+)/H(+) exchange."( A two-hit mechanism for sepsis-induced impairment of renal tubule function.
George, T; Good, DW; Sherwood, ER; Watts, BA, 2013
)
0.39
"An understanding of drug delivery system transport across epithelial cell monolayer is very important for improving the absorption and bioavailability of the drug payload."( Transport pathways of solid lipid nanoparticles across Madin-Darby canine kidney epithelial cell monolayer.
Chai, GH; Du, YZ; Hu, FQ; Sun, J; You, J; Yuan, H, 2014
)
0.4
" Resolving this problem will be significant in improving bioavailability and reducing side effects."( Effect of inhibitors of endocytosis and NF-kB signal pathway on folate-conjugated nanoparticle endocytosis by rat Kupffer cells.
Chen, H; Feng, X; Han, Z; Jia, Y; Li, X; Liu, Q; Liu, X; Tang, H; Wang, A, 2017
)
0.46
"To develop a nanoemulsion-nanoformulation in order to enhance brain bioavailability for Amiloride (Amilo) via intranasal (i."( Impact of ultrasonication techniques on the preparation of novel Amiloride-nanoemulsion used for intranasal delivery in the treatment of epilepsy.
Ahmad, FJ; Ahmad, N; Ahmad, R; Alam, MA; Amir, M, 2018
)
0.94
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Amiloride had a Hill coefficient of 1, and a dissociation constant (KD) of 5 x 10(-5) M. In contrast to the discrepancy in Tyrphostin dose-response curves, titration curves for 5-(N-ethyl-n-isopropyl)amil oride are comparable in SF- or GM-CSF-stimulated cells.

ExcerptRelevanceReference
"001), but a major determinant of the magnitude of the decrease was the dosage change of the timolol."( Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic.
Mikkelsen, E; Pedersen, OL, 1979
)
0.26
" Dose-response curves in two subjects showed that complete inhibition of rectal difference occurred at 4 x 10(-5) mol/l and 4 x 10(-6) mol/l respectively."( A comparison of methods for measurement of rectal potential difference in man: effects of rectal infusion of amiloride.
McSorley, P; Mohamed, F; Warren, DJ, 1978
)
0.47
" The average total daily dosage schedule for timolol ranged between 15 and 20 mg, with the same blood pressure lowering effect whether the divided dose was given twice or three times."( [The anti-hypertensive effect of timolol maleate (blocadren) in gradated combination with a diuretic].
Vorburger, C, 1976
)
0.26
" This suggests that some were apparent non-responders due to too low dosing of atenolol rather than true non-responders."( Haemodynamic findings and response rates to beta-blocker--and diuretic monotherapy in mild and moderate hypertension. A one year randomized, double blind study in 100 men.
Erikssen, J; Froeland, G; Otterstad, JE; Saltvedt, E; Soeyland, AK, 1992
)
0.28
" The dosage used did not affect the reabsorption of water, sodium and lithium in the proximal tubule, and also did not change the reabsorption of water and sodium in the loop segment."( Amiloride-sensitive lithium reabsorption in rats: a micropuncture study.
Boer, P; Boer, WH; Fransen, R; Koomans, HA, 1992
)
1.73
" Dose-response curves for EIPA indicated that the increased Na(+)-H+ antiport activity in PKE20 vesicles was due to an increased activity of the relatively amiloride-resistant form of the Na(+)-H+ antiporter with little or no change in the amiloride-sensitive form."( Increased Na(+)-H+ antiporter activity in apical membrane vesicles from mutant LLC-PK1 cells.
Adelberg, EA; Aronson, PS; Haggerty, JG; Reilly, RF; Slayman, CW, 1991
)
0.48
" The patients were treated for 3 months with monthly assessments, "uncontrolled" patients (DBP greater than 90 mm Hg) had their dosage doubled and then, if necessary, atenolol 50 mg was added."( A double-blind comparison of perindopril and hydrochlorothiazide-amiloride in mild to moderate essential hypertension.
Andrejak, M; Carré, A; Deruyttere, M; Gotzen, R; Magometschnigg, D; Santoni, JP; Stumpe, KO, 1991
)
0.52
" Low concentrations of pirenzepine (10(-8) M), produced a rightward shift in the dose-response curve to McN, without inhibiting responses to carbachol."( Functional subtyping of muscarinic receptors on canine esophageal mucosa.
Donoff, B; Lad, R; Rangachari, PK, 1991
)
0.28
" Amiloride shifted the dose-response curves for MSG to a higher concentration region, suggesting that amiloride inhibits the response to MSG in a competitive manner."( Canine taste nerve responses to monosodium glutamate and disodium guanylate: differentiation between umami and salt components with amiloride.
Kurihara, K; Nakamura, M, 1991
)
1.4
" When other anions (acetate, isethionate, methane sulfonate, gluconate, tartrate), which are generally impermeant in other Cl-selective pathways, were substituted for Cl, the dose-response curves for the chorda tympani response were shifted toward higher concentrations than the response to NaCl, but achieved the same maximum value at sufficiently high concentrations (1."( The anion in salt taste: a possible role for paracellular pathways.
Elliott, EJ; Simon, SA, 1990
)
0.28
" This study was designed to examine the dose-response nature and time-dependent effect of 4 beta-phorbol-12-myristate-13-acetate (PMA) on the rates of bicarbonate absorption (JHCO3) and fluid absorption (Jv) in the proximal convoluted tubule (PCT) of rat kidney."( Time- and dose-dependent effects of protein kinase C on proximal bicarbonate transport.
Chan, YL; Wang, T, 1990
)
0.28
" Dose-response curves for PE were shifted both to the right and downward by increasing concentrations of amiloride, which indicates both competitive and noncompetitive types of inhibition."( Influence of amiloride derivatives on alpha-1 adrenergic receptor-induced contractions of the rabbit aorta.
Cragoe, EJ; Deth, RC; Lesburg, C; Li, S, 1990
)
0.86
" Amiloride shifted the dose-response curves for the salt taste responses to a higher concentration region without appreciable effects on the maximal responses, suggesting that amiloride inhibits the salt responses in a competitive manner."( Non-specific inhibition by amiloride of canine chorda tympani nerve responses to various salts: do Na(+)-specific channels exist in canine taste receptor membranes?
Kurihara, K; Nakamura, M, 1990
)
1.49
" The conductance of the amiloride-sensitive pathway (Gamil) was assessed before and after replacement of Na+ in the mucosal bath by K+, using two independent measurements: (1) the slope conductance (GT), determined from current-voltage (I-V) relationships for control and amiloride-treated tissues and (2) the maximum amiloride-sensitive conductance (Gmax) calculated from the amiloride dose-response relationship."( Amiloride-sensitive Na+ transport across cultured renal (A6) epithelium: evidence for large currents and high Na:K selectivity.
Millinoff, LP; Wills, NK, 1990
)
2.03
" PC20MBS and PC20MC, the concentration of each agent needed to lower FEV1 by 20%, were calculated by linear interpolation of the log dose-response curves."( Effect of inhaled furosemide on metabisulfite- and methacholine-induced bronchoconstriction and nasal potential difference in asthmatic subjects.
Alton, EW; Barnes, PJ; Chung, KF; Geddes, DM; Nichol, GM; Nix, A, 1990
)
0.28
" The dose-response relationships of this effect were measured by equilibrating cell aliquots with various Ca2+-EGTA buffers, preparing membrane vesicles (in the absence of Ca2+ ions), and assaying them for amiloride-sensitive Na+ permeability."( Ca2+-induced down-regulation of Na+ channels in toad bladder epithelium.
Asher, C; Garty, H, 1986
)
0.46
"05) leftward shift in the dose-response relationship, that is, a smaller epinephrine concentration produced earlier onset of ventricular arrhythmias and mortality from fatal ventricular arrhythmias."( Effect of chronic diuretics on epinephrine-induced ventricular arrhythmias: a comparison of hydrochlorothiazide and amiloride in the rat.
Rabkin, SW; Roob, O, 1987
)
0.48
"The natriuretic agent amiloride induces a shift of the dose-response curve of particulate guanylate cyclase to atrial natriuretic factor (ANF) to the left."( Amiloride increases the sensitivity of particulate guanylate cyclase to atrial natriuretic factor.
Gerzer, R; Heim, JM; Ivanova, K, 1988
)
2.03
" A dose-response ouabain (1 mM) sensitive relationship exists between [Na+]o and retardation of the reversal phenomenon."( Induced interphase cell retraction: its reversal and EGF potentiation.
Sit, KH; Wong, KP, 1989
)
0.28
" The patients were re-examined monthly and their treatment was modified if their BP was insufficiently controlled (DAP greater than 90 mmHg): first, the dosage of the drug was doubled, then another antihypertensive agent was added, which was either a diuretic (studies with C or A) or a beta-blocker (studies with D)."( [Perindopril: first-line treatment of arterial hypertension].
Desche, P; Zanchetti, A, 1989
)
0.28
"To examine the effect of glucocorticoids on sulfate transport by the chick (domestic Gallus gallus) renal tubule we dosed 3-wk-old animals with 60 micrograms dexamethasone/100 g body wt at 24 and 6 h before isolation of renal brush-border (BBM) and basolateral membranes (BLM)."( Glucocorticoid inhibition of Na-SO4 transport by chick renal brush-border membranes.
Clark, NB; Lynch, MA; Metts, RE; Renfro, JL, 1989
)
0.28
" The time course and dose-response for the effect of PMA at 23 degrees C closely correlate with the phosphorylation of a set of relatively "slowly" phosphorylated proteins (P20, P35, P41, P60), but not the rapidly phosphorylated P47 protein."( Synergistic release of arachidonic acid from platelets by activators of protein kinase C and Ca2+ ionophores. Evidence for the role of protein phosphorylation in the activation of phospholipase A2 and independence from the Na+/H+ exchanger.
Banga, HS; Feinstein, MB; Halenda, SP; Lau, LF; Zavoico, GB, 1989
)
0.28
" A chronic dosing study was conducted in eight healthy subjects who received, in random order, amiloride (5 mg daily), cimetidine (400 mg twice daily), both drugs together, and a control phase in which no drug was present."( Renal tubular secretion of amiloride and its inhibition by cimetidine in humans and in an animal model.
Bochner, F; Hovens, CM; Muirhead, MR; Somogyi, AA,
)
0.65
" As a result of the pharmacokinetic findings caution may be indicated in the clinical dosage of the diuretics particularly when in fixed dose combination."( The pharmacokinetics of amiloride-hydrochlorothiazide combination in the young and elderly.
Ismail, Z; Parke, W; Smithurst, BA; Triggs, EJ, 1989
)
0.58
" The dose-response relations for exogenous noradrenaline measured in the absence or presence of 50 microM amiloride indicated that the drug acted as a reversible competitive alpha-adrenergic antagonist."( Amiloride acts as an alpha-adrenergic antagonist in the isolated rat tail artery.
Palatý, V, 1986
)
1.93
" The link between phospholipase C activation and these early events of the mitogenic response is demonstrated by the similarity of all dose-response curves for NaF and AlCl3 and by the common sensitivity of the four events to pertussis toxin."( Coupling between phosphoinositide breakdown and early mitogenic events in fibroblasts. Studies with fluoroaluminate, vanadate, and pertussis toxin.
Chambard, JC; Paris, S; Pouysségur, J, 1987
)
0.27
" The amiloride dose-response curve in the presence of stimulating dose of zwittergent was shown to shift to the left and yield a smaller apparent inhibition constant as predicted on the basis of such a removal and an unaltered intrinsic amiloride blocking kinetic."( Effects of detergents on sodium transport in toad urinary bladder.
Kau, ST; Li, JH; Zuzack, JS, 1986
)
0.78
" A dose-response curve for amiloride obtained in the presence of AVT showed that amiloride completely inhibits ISC."( Stimulation of sodium transport by aldosterone and arginine vasotocin in A6 cells.
Bindels, RJ; Reif, MC; Schafer, JA, 1988
)
0.57
" After the increase in dosage blood pressure was lowered further."( Felodipine versus Moduretic. A double-blind parallel-group multicentre study.
Flygt, G; Krönig, B, 1987
)
0.27
" The drug shifted to the right the dose-response curve for Ca in low K solution."( Na/Ca exchange and tension development in vascular smooth muscle: effect of amiloride.
Bova, S; Cargnelli, G; Luciani, S, 1988
)
0.5
" Patients were assigned at random to receive one or other combination for 8 weeks, dosage being determined by the severity of the individual patient's condition (range 1 to 3 tablets frusemide/amiloride; 2 to 6 tablets bumetanide/potassium chloride)."( An open comparative study of two diuretic combinations, frusemide/amiloride ('Frumil') and bumetanide/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients.
Allman, S; Bailey, R; Crawford, RJ; Martin, A; Ramsay, F, 1988
)
0.7
" Patients either remained on this regimen for a further 8 weeks or, if their blood pressure was not controlled, dosage was increased to 2 tablets daily."( An open study to compare the efficacy and tolerability of two diuretic combinations, frusemide plus amiloride and hydrochlorothiazide plus amiloride, in patients with mild to moderate essential hypertension.
Allman, S; Backhouse, CI; Crawford, RJ; Platt, J, 1988
)
0.49
" A dose-response study revealed that the concentration of phloretin causing half-maximal inhibition (K1/2) was 5 x 10(-4) M for adapted animals."( Active urea transport by the skin of Bufo viridis: amiloride- and phloretin-sensitive transport sites.
Abuful, A; Chaimovitz, C; Hays, RM; Noeh, Z; Rapoport, J, 1988
)
0.53
" Eumagnesaemia and eupotassaemia were preserved at all dosage of the piretanide monosubstance."( Lack of effect of piretanide (a potassium-stable diuretic) on serum magnesium.
de Looze, S; Irmisch, R; Rangoonwala, B; Verho, M, 1987
)
0.27
"After a run-in period of 8 weeks on a regimen of hydrochlorothiazide (HCT, median dosage 75 mg/day), patients with essential hypertension were randomly allocated to continued hydrochlorothiazide therapy (Group I) or additional treatment with amiloride (Group II, median dosage 15 mg/day, or 5 mg per 25 mg hydrochlorothiazide) for the following 12 weeks."( Effects of combined therapy with amiloride and hydrochlorothiazide on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in hypertensive patients.
Dige-Petersen, H; Giese, J; Ibsen, H; Leth, A; Nielsen, MD; Rasmussen, S; Svendsen, UG, 1986
)
0.73
" In examining the effects of diuretics on Mg and K metabolism, the following factors should be taken into account: site of action and duration of action of diuretics, duration of treatment and dosage used, concurrent drug therapy, underlying disease conditions and dietary intake of Mg."( Magnesium and potassium-sparing diuretics.
Ryan, MP, 1986
)
0.27
" In the dosage used, amiloride did not have a zinc-sparing effect."( Hydrochlorothiazide-amiloride causes excessive urinary zinc excretion.
Averbukh, Z; Cohen, N; Golik, A; Modai, D; Shaked, U; Sigler, E; Weissgarten, J; Zaidenstein, R, 1987
)
0.92
" Both nisoldipine and the diuretic had a flat dose-response curve."( Monotherapy with the calcium channel antagonist nisoldipine for systemic hypertension and comparison with diuretic drugs.
Daniels, AR; Opie, LH, 1987
)
0.27
" Pretreatment of aortic rings with high concentrations of nifedipine (5 X 10(-7) M) or verapamil (10(-5) M) caused a comparable displacement to the right (2-3 times) in the relaxant dose-response curve for acetylcholine, A23187 and sodium nitroprusside with little or no changes in the maximal relaxation obtained with these vasodilators."( Blockade of endothelium-dependent relaxation by the amiloride analog dichlorobenzamil: possible role of Na+/Ca++ exchange in the release of endothelium-derived relaxant factor.
Bunting, PB; Schofield, TL; Winquist, RJ, 1985
)
0.52
" The dose-response relationship between amiloride and current noise parameters was consistent with a two-state mechanism of blocker interaction with the channel."( Apical membrane properties and amiloride binding kinetics of the human descending colon.
Alles, WP; Binder, HJ; Sandle, GI; Wills, NK, 1984
)
0.82
" Analysis of the amiloride dose-response relations revealed a complex "non Michaelis-Menten" behavior."( Amiloride blockable sodium fluxes in toad bladder membrane vesicles.
Garty, H, 1984
)
2.05
" The ratios of the apparent off-rate and on-rate constants (the microscopic inhibition constants) thus obtained for triamterene, triaminopyrimidine (TAP), 5,6-diCl-amiloride, 5H-amiloride and amiloride itself are found to be in the mean about sevenfold smaller than the corresponding inhibition constants obtained from macroscopic dose-response curves."( Competitive blocking of epithelial sodium channels by organic cations: the relationship between macroscopic and microscopic inhibition constants.
Li, JH; Lindemann, B, 1983
)
0.46
" A dose-response relationship has been established for the effect of amiloride in reducing fractional excretion of magnesium and potassium during frusemide diuresis in rats."( Effects of diuretics on the renal handling of magnesium.
Counihan, TB; Devane, J; Ryan, MF; Ryan, MP, 1984
)
0.5
"Twenty patients with mild to moderate hypertension participated in a single-blind crossover comparison of treatment with 25 mg hydrochlorothiazide plus 50 mg triamterene and 50 mg hydrochlorothiazide plus 5 mg amiloride in once-daily dosage regimens."( Hydrochlorothiazide in combination with potassium-sparing agents in the treatment of hypertension.
Dean, S; Spencer-Mills, L, 1984
)
0.45
" The study was of 3-months' duration and patients received a dosage of 1 to 2 tablets once daily."( Frusemide/amiloride combination ('Frumil') in heart failure: an open, multi-centre study in general practice.
Eason, CT; Richards, HH; Townsend, HA; Waddy, AL, 1984
)
0.67
"An open, multi-centre study was carried out in general practice to compare the efficacy and tolerance of antihypertensive therapy with once-daily and twice-daily dosage of a fixed ratio combination of hydrochlorothiazide (25 mg), amiloride (2."( Comparison of a fixed ratio combination of hydrochlorothiazide, amiloride and timolol ('Moducren') given once versus twice daily in mild to moderate hypertension.
Currie, WJ; Isitt, VL; VandenBurg, MJ; Young, JH, 1984
)
0.69
" A dose-response relationship has been established for the actions of amiloride in reducing fractional excretion of magnesium and potassium during furosemide diuresis in rats."( Magnesium- and potassium-sparing effects of amiloride. Review and recent findings.
Ryan, MP, 1984
)
0.76
"Total body potassium content, plasma potassium concentration, blood pressure, and plasma concentrations of renin, angiotensin II, and aldosterone were measured in patients with essential hypertension after a run-in period of 8 wk on a regimen of hydrochlorothiazide (median dosage 75 mg/day)."( Effects of amiloride on plasma and total body potassium, blood pressure, and the renin-angiotensin-aldosterone system in thiazide-treated hypertensive patients.
Dige-Petersen, H; Giese, J; Ibsen, H; Leth, A; Nielsen, MD; Rasmussen, S; Svendsen, UG, 1983
)
0.66
" The effect of twice the dosage was evaluated in subjects with unsatisfactory blood pressure (BP) on the lower dose."( Potassium sparing by amiloride during thiazide therapy in hypertension.
Andersson, PO; H-Andersen, H; Hagman, A; Henning, R, 1984
)
0.59
" The results showed that the change in treatment led to a significant reduction in blood pressure in both groups, at a dosage of 1 tablet daily in over half the patients, and the majority (88%) preferred the new form of treatment."( A general practice study of timolol/hydrochlorothiazide/amiloride ('Moducren'), a new therapy for hypertension, and the doctor's influence on management.
Arr, S; Parry, EE; Tait, D, 1983
)
0.51
" The dosage of guanabenz was adjusted upward from 16 mg/day until blood pressure normalized or side effects intervened."( Preliminary clinical trial with a new hypotensive, guanabenz, in a group of hypertensive patients.
De Ridder, JH; Marchandise, P, 1980
)
0.26
" The dosage problem with HTZ + AMl is discussed."( Antihypertensive and metabolic effects of a combination of hydrochlorothiazide and amiloride.
Leary, WP; Reyes, AJ, 1981
)
0.49
" Dosage was 2 tablets per day of the 5 mg amiloride plus 50 mg hydrochlorothiazide combination or of 50 mg hydrochlorothiazide alone."( Potassium conservation with amiloride/hydrochlorothiazide ("Moduret') in thiazide-induced hypokalaemia in hypertension.
Campbell, N; Fernandez, PG; Galway, AB; Gill, V; Granter-Button, S; Kim, BK; MacDonald, J; Sharma, JN; Snedden, W, 1982
)
0.82
" For up to 20 hr amiloride induced linear log dose-urinary electrolyte response relationships but spironolactone dose-response trends were demonstrated only in the period from 10 to 20 hr after treatment."( Relative potency of amiloride and spironolactone in healthy man.
McInnes, GT, 1982
)
0.93
" In a smaller study potassium chloride induced a significant log dose-response on plasma potassium, but the effect was small in absolute terms."( Amiloride, spironolactone, and potassium chloride in thiazide-treated hypertensive patients.
Fraser, R; Hettiarachchi, J; Morton, JJ; Ramsay, LE, 1980
)
1.7
" In contrast to the discrepancy in Tyrphostin dose-response curves, titration curves for 5-(N-ethyl-n-isopropyl)amiloride and 5-(N,N-hexamethylene)amiloride are comparable in SF- or GM-CSF-stimulated cells."( Product of the steel locus suppresses apoptosis in hemopoietic cells. Comparison with pathways activated by granulocyte macrophage colony-stimulating factor.
Cáceres-Cortés, J; Dumouchel, J; Haddad, P; Hoang, T; Rajotte, D, 1994
)
0.5
" A dose-response inhibition of the exchanger showed that the mutant cells were very sensitive to dimethylamiloride (IC50 158 nM in mutant vs."( The effect of lethal acid stress on Na+/H+ exchanger isoforms in cultured inner medullary collecting duct cells: deletion of NHE-2 and over expression of NHE-1.
McAteer, JA; Singh, G; Soleimani, M, 1995
)
0.51
" A dose-response curve shows that phenobarbital possibly acts on two different sites, with different affinity constants and stoichiometries."( Opening of frog skin sodium channels by phenobarbital.
Ferreira, KT; Fonseca, PD; Moura, TF,
)
0.13
" After 3 months the drug dosage was doubled if the systolic blood pressure goal (SBP < 160 mmHg and SBP reduction of at least 20 mmHg) had not been reached."( Antihypertensive efficacy and tolerability of different drug regimens in isolated systolic hypertension in the elderly.
Alli, C; Avanzini, F; Bettelli, G; Colombo, F; Corso, R; Mariotti, G; Radice, M; Tognoni, G; Torri, V, 1994
)
0.29
" The sodium-blocker amiloride inhibits sodium absorption depending on the dosage of the drug."( [Amiloride inhalation therapy in mucoviscidosis].
Lindemann, H, 1993
)
1.52
" Despite the sodium restriction, amiloride had no effect on FELi, although the dosage was sufficient to cause a 6-fold increase in sodium excretion, and potassium retention."( Indomethacin- and desamino-8-D-arginine vasopressin-induced lithium reabsorption is not amiloride sensitive in humans.
Bijlsma, JA; Boer, WH; Dorhout Mees, EJ; Koomans, HA; van Rijn, HJ, 1993
)
0.79
" The sigmoidal dose-response functions corresponded quantitatively with electrophysiological findings."( Amiloride disrupts NaCl versus KCl discrimination performance: implications for salt taste coding in rats.
Guagliardo, NA; Spector, AC; St John, SJ, 1996
)
1.74
" However, inhibition reached the maximal level only at 50 mM sodium, and typical sigmoidal dose-response curves were obtained only in the presence of 118 mM sodium."( Regulation of mu-opioid receptor in neural cells by extracellular sodium.
Medzihradsky, F; Yabaluri, N, 1997
)
0.3
"Multiple dosing with recombinant adenoviral vectors containing the cystic fibrosis transmembrane conductance regulator (CFTR) cDNA to the nasal mucosa of cystic fibrosis (CF) transgenic mice reportedly results in only partial correction of the CF defect in chloride (Cl-) secretion without normalizing sodium (Na+) hyperabsorption, perhaps indicating inefficient gene transfer into the nasal airway epithelium in vivo."( Increased contact time improves adenovirus-mediated CFTR gene transfer to nasal epithelium of CF mice.
Akita, GY; Cheng, SH; Colledge, WH; Evans, MJ; Hehir, KM; Jiang, C; Ratcliff, RA; St George, JA; Wadsworth, SC, 1997
)
0.3
" In both bicarbonate and HEPES perfused hearts all drug dosing regimens caused a significant increase in the recovery of mechanical function after reperfusion and slowed the recovery of intracellular pH during reperfusion."( Na(+)-H+ exchange inhibition at reperfusion is cardioprotective during myocardial ischemia-reperfusion; 31P NMR studies.
Deslauriers, R; Docherty, JC; Pierce, GN; Yang, L, 1997
)
0.3
" Suppression of metastases was significant at high amiloride dosages in all groups, and at low dosage when administered prior to inoculation."( Time and dose dependency of the suppression of pulmonary metastases of rat mammary cancer by amiloride.
Arvan, M; Evans, DM; Guyton, DP; Sloan-Stakleff, K, 1998
)
0.77
" The dose-response curve to epinephrine was not changed by AMI."( [Effect of amiloride and its derivative dichlorobenzamil on guinea pig atria: interaction with other inotropic mechanisms].
Alfonso, C; Lamanna, V; Padrón-Nieves, M; Pérez-González, M, 1999
)
0.69
" Stimulation by stripped serum or oestradiol resulted in parallel increases of proliferation and pS2 release in both time course and dose-response experiments."( Association of pS2 (TFF1) release with breast tumour proliferative rate: in vitro and in vivo studies.
Casavola, V; Correale, M; Mangia, A; Paradiso, A; Reshkin, SJ; Tedone, T,
)
0.13
"The present investigation was undertaken to explore the ulcer healing and antiangiogenic efficacy of two dosage schedules of topically administered amiloride in mechanically produced corneal ulcers in rabbits and to compare its effect with the conventional topical antiinflammatory angiostatic agent flurbiprofen."( Topical amiloride accelerates healing and delays neovascularization in mechanically produced corneal ulcers in rabbits.
Chugh, P; Gupta, B; Sood, AK, 1999
)
0.94
"Rapid, precise, accurate and specific ratio spectra derivative spectrophotometry and high-performance liquid chromatographic procedures were described for the simultaneous determination of hydrochlorothiazide and amiloride hydrochloride in combined pharmaceutical dosage forms."( Simultaneous determination of hydrochlorothiazide and amiloride hydrochloride by ratio spectra derivative spectrophotometry and high-performance liquid chromatography.
Erk, N; Kartal, M, 1999
)
0.74
" Increased dosage levels of inhibitors might be expected to enhance levels of suppression of metastases."( Maximum effect of urokinase plasminogen activator inhibitors in the control of invasion and metastasis of rat mammary cancer.
Evans, DM; Sloan-Stakleff, KD,
)
0.13
"The present investigation was undertaken to explore the ulcer healing properties of three dosage schedules of various concentrations of topically administered amiloride solution in mechanically produced skin ulcers in albino rats."( Topical amiloride solution accelerates healing of mechanical skin ulcers in albino rats.
Gupta, B; Saxena, KK; Singh, N; Srivastava, VK, 2000
)
0.94
"Amiloride, which blocks the Na(+)/H(+) antiport, shifted the CHS 828 dose-response curve to the left in a synergistic manner according to the additive interaction model."( Interactions between the new cytotoxic drug CHS 828 and amiloride and mitomycin C in a human tumour cell line and in tumour cells from patients.
Ekelund, S; Larsson, R; Nygren, P; Persson, I, 2002
)
2
" A biphasic dose-response curve for HOE-694 and N-methylisopropylamiloride (MIA) suggested that two isoforms (putatively NHE1 and NHE3) are active in the oocyte, 1-cell, and 2-cell stages."( Developmental changes in the management of acid loads during preimplantation mouse development.
Cook, DI; Day, ML; Gibb, CA; Harding, EA; Johnson, MH, 2002
)
0.55
" Evidence of systemic toxicity was observed in animals dosed chronically with pyrimethamine or amiloride, but no skin papillomas were observed in mice treated with amiloride, dipyridamole, or pyrimethamine for 26 weeks."( Evaluation of the Tg.AC assay: specificity testing with three noncarcinogenic pharmaceuticals that induce selected stress gene promoters in vitro and the inhibitory effects of solvent components.
Lin, KK; Rosenzweig, BA; Sistare, FD; Thompson, KL; Weaver, JL; Zhang, J, 2003
)
0.54
" A dose-response relationship to Moli1901 was observed in non-CF participants, but a greater range of variability within the CF participants contributed to the lack of a clear dose-response relationship in this group."( A phase I trial of intranasal Moli1901 for cystic fibrosis.
Boyle, MP; Guggino, WB; Molina, L; Zeitlin, PL, 2004
)
0.32
" The components in each mixture have been simultaneously determined in three commercial dosage forms with high accuracy and without interference from commonly encountered excipients and additives."( Determination of antihypertensive mixtures by use of a chemometrics-assisted spectrophotometric method.
Mohamed, Ael-M; Salem, H, 2005
)
0.33
" We carried out a dose-response analysis where rats were given 0-200 microg/kg body wt pSi-4, and alpha-ENaC mRNA and protein expressions were analyzed."( RNA interference for alpha-ENaC inhibits rat lung fluid absorption in vivo.
Folkesson, HG; Li, T, 2006
)
0.33
"d(-1)) was intraperitoneally injected 3 days before balloon injuries and the same dosage normal saline was used in the same way in the BG group for 28 days after operation."( [Na+-H+ exchanger protein changes in vascular smooth muscle and effect of Na+-H+ exchange inhibitor on vessel stenosis after balloon injuries in rabbits].
Fang, XY; Li, YG; Lin, JJ; Zeng, X, 2005
)
0.33
" Amiloride at both dosages also significantly decreased the labeling index of enzyme-altered lesions and amiloride at higher dosage significantly decreased the labeling index of adjacent hepatocytes."( Chemoprevention by amiloride against experimental hepatocarcinogenesis induced by N-nitrosomorpholine in Sprague-Dawley rats.
Baba, M; Iishi, H; Nakaizumi, A; Sakai, N; Tatsuta, M; Uehara, H; Yano, H, 1997
)
1.54
"4-dihydroxyphenyl)methylene glycine hydrazide (GlyH-101) and glibenclamide and their dose-response effect was investigated."( Electrophysiological characterization of electrolyte and nutrient transport across the small intestine in horses.
Breves, G; Burmester, M; Cehak, A; Feige, K; Geburek, F, 2009
)
0.35
" Dose-response studies suggest a rather small effective concentration range and time-effect data show a primary and transient up-regulation of GR-α mRNA levels and a down-regulation of GR-β mRNA levels after 16 h of treatment."( Hypericum perforatum differentially affects corticosteroid receptor-mRNA expression in human monocytic U-937 cells.
Enning, F; Krieg, JC; Murck, H; Vedder, H, 2011
)
0.37
"Published or unpublished randomised controlled trials (RCTs) or quasi-randomised controlled trials of sodium channel blockers compared to placebo or another sodium channel blocker or the same sodium channel blocker at a different dosing regimen."( Sodium channel blockers for cystic fibrosis.
Burrows, EF; Noone, PG; Southern, KW, 2012
)
0.38
"Two stability-indicating chromatographic methods are described for simultaneous determination of amiloride hydrochloride (AMI), atenolol (ATE), and chlorthalidone (CHL) in combined dosage forms."( Validated stability-indicating methods for the simultaneous determination of amiloride hydrochloride, atenolol, and chlorthalidone using HPTLC and HPLC with photodiode array detector.
Barary, MH; El-Kimary, EI; Hassan, EM; Maher, HM; Youssef, RM,
)
0.58
"Published or unpublished randomised controlled trials (RCTs) or quasi-randomised controlled trials of sodium channel blockers compared to placebo or another sodium channel blocker or the same sodium channel blocker at a different dosing regimen."( Sodium channel blockers for cystic fibrosis.
Burrows, EF; Noone, PG; Southern, KW, 2014
)
0.4
" Moreover, the methods were successfully applied for the determination of HCZ and BZ and AM in pure form and pharmaceutical dosage forms."( Simultaneous determination of hydrochlorothiazide and benazepril hydrochloride or amiloride hydrochloride in presence of hydrochlorothiazide impurities: chlorothiazide and salamide by HPTLC method.
Abdelaleem, EA; Draz, ME; Naguib, IA; Zaazaa, HE, 2015
)
0.64
"Resistant hypertension is a clinically distinct subgroup of hypertension defined by the failure to achieve blood pressure control on optimal dosing of at least 3 antihypertensive medications of different classes, including a diuretic."( Pathophysiology and treatment of resistant hypertension: the role of aldosterone and amiloride-sensitive sodium channels.
Calhoun, DA; Judd, EK; Warnock, DG, 2014
)
0.63
"The present investigation was undertaken to explore the ulcer healing properties of three dosage schedules of different strengths of topically administered amiloride solution in thermally produced skin ulcers on the side of the midline on the back of the rabbits."( Topical amiloride delays healing of deep thermal wounds in albino rabbits.
Gupta, B; Sharma, RK,
)
0.76
" When dosed orally, the optimized compound reduced blood pressure in mice overexpressing human WNK1, and induced diuresis, natriuresis and kaliuresis in spontaneously hypertensive rats (SHR), confirming that this mechanism of inhibition of WNK kinase activity is effective at regulating cardiovascular homeostasis."( Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
Argikar, UA; DiPetrillo, K; Idamakanti, N; Imase, H; Iwaki, Y; Jain, M; Kato, M; Kawanami, T; Kohls, D; Kunjathoor, V; Levell, J; Monovich, L; Park, HM; Rigel, DF; Robinson, Z; Taslimi, P; Xie, X; Xu, L; Yagi, YI; Yamada, K; Yasoshima, K; Yoon, T; Yowe, D; Yuan, J; Zhu, M, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
sodium channel blockerAn agent that inhibits sodium influx through cell membranes.
diureticAn agent that promotes the excretion of urine through its effects on kidney function.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
pyrazines
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
aromatic amineAn amino compound in which the amino group is linked directly to an aromatic system.
guanidinesAny organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (2)

PathwayProteinsCompounds
Amiloride Action Pathway319
Iron uptake and transport030

Protein Targets (64)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency39.81070.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency24.97010.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency24.97010.025120.237639.8107AID886; AID893
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency35.48130.177814.390939.8107AID2147
acid sphingomyelinaseHomo sapiens (human)Potency25.118914.125424.061339.8107AID504937
acetylcholinesteraseHomo sapiens (human)Potency14.54450.002541.796015,848.9004AID1347395; AID1347398
thioredoxin reductaseRattus norvegicus (Norway rat)Potency19.57110.100020.879379.4328AID488772; AID588456
TDP1 proteinHomo sapiens (human)Potency35.04910.000811.382244.6684AID686978; AID686979
AR proteinHomo sapiens (human)Potency25.37350.000221.22318,912.5098AID743035; AID743063
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency30.30010.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency39.81070.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency15.00300.531815.435837.6858AID504845
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency14.92160.000214.376460.0339AID720691; AID720692
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.07070.000229.305416,493.5996AID743069; AID743075; AID743080
glucocerebrosidaseHomo sapiens (human)Potency31.62280.01268.156944.6684AID2101
arylsulfatase AHomo sapiens (human)Potency8.49211.069113.955137.9330AID720538
alpha-galactosidaseHomo sapiens (human)Potency37.35224.466818.391635.4813AID1467; AID2107
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency33.58750.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency39.81070.540617.639296.1227AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency19.95260.00207.533739.8107AID891
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency44.66840.036619.637650.1187AID2112
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency20.73390.000323.4451159.6830AID743065; AID743067
huntingtin isoform 2Homo sapiens (human)Potency35.48130.000618.41981,122.0200AID1688
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency30.73120.000627.21521,122.0200AID743202; AID743219
gemininHomo sapiens (human)Potency2.59290.004611.374133.4983AID624296
lamin isoform A-delta10Homo sapiens (human)Potency0.70790.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631; AID720552
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain U, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki5.30005.300092.6500180.0000AID977610
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki5.30005.300092.6500180.0000AID977610
Chain A, UROKINASE-TYPE PLASMINOGEN ACTIVATORHomo sapiens (human)Ki5.30005.300092.6500180.0000AID977610
Membrane primary amine oxidase Rattus norvegicus (Norway rat)Ki10.000010.000010.000010.0000AID202892
Solute carrier family 22 member 1 Homo sapiens (human)IC50 (µMol)57.00000.21005.553710.0000AID386625
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
ProthrombinHomo sapiens (human)IC50 (µMol)135.00000.00000.710710.0000AID1611192; AID210807
Coagulation factor XHomo sapiens (human)IC50 (µMol)50.00000.00030.593710.0000AID1611194
PlasminogenHomo sapiens (human)IC50 (µMol)93.99330.02503.628010.0000AID1265722; AID1611191; AID654830
Urokinase-type plasminogen activatorHomo sapiens (human)IC50 (µMol)22.96330.03703.385910.0000AID1265722; AID1611189; AID1611202; AID215821; AID215985; AID654828
Urokinase-type plasminogen activatorHomo sapiens (human)Ki150.89210.01702.62687.0000AID1385920; AID1385965; AID1797476; AID1820895; AID419413
Tissue-type plasminogen activatorHomo sapiens (human)IC50 (µMol)163.33330.03402.54256.6000AID1611190; AID210740; AID654829
Tissue-type plasminogen activatorHomo sapiens (human)Ki345.76670.01703.71968.6000AID1797476
Cationic trypsinBos taurus (cattle)Ki345.76670.00001.07539.0000AID1797476
Coagulation factor XIHomo sapiens (human)IC50 (µMol)50.00000.00282.639110.0000AID1611195
Plasma kallikreinHomo sapiens (human)IC50 (µMol)50.00000.00312.024110.0000AID1611188
Vitamin K-dependent protein CHomo sapiens (human)IC50 (µMol)50.00000.03000.68512.6900AID1611196
Urokinase-type plasminogen activatorMus musculus (house mouse)IC50 (µMol)2.30000.09102.92026.6000AID1611201
Urokinase-type plasminogen activatorMus musculus (house mouse)Ki2.31302.31305.81059.3080AID1385942
Trypsin-1Homo sapiens (human)IC50 (µMol)50.00000.00351.532110.0000AID1611193
Trypsin-2Homo sapiens (human)IC50 (µMol)50.00000.00351.58464.4000AID1611193
Sodium/hydrogen exchanger 1Homo sapiens (human)IC50 (µMol)63.36500.00500.56013.5000AID1435501; AID358119
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)3.90900.00002.37899.7700AID625150
Sodium/hydrogen exchanger 1Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.01000.64613.9000AID1411092
Sodium/hydrogen exchanger 1Rattus norvegicus (Norway rat)Ki1.00000.01000.26151.0000AID1341114; AID1341845
Sodium/hydrogen exchanger 3Rattus norvegicus (Norway rat)IC50 (µMol)100.00000.00930.60862.4000AID1411098
Sodium/hydrogen exchanger 3Rattus norvegicus (Norway rat)Ki100.00002.40002.40002.4000AID1341116; AID1341851
Adenosine receptor A2aHomo sapiens (human)Ki8.96000.00001.06099.7920AID34237; AID34238; AID34239
Trypsin-3Homo sapiens (human)IC50 (µMol)50.00000.00351.58464.4000AID1611193
Amiloride-sensitive sodium channel subunit alphaHomo sapiens (human)IC50 (µMol)0.77600.06600.41430.7760AID268105
5-hydroxytryptamine receptor 7Cavia porcellus (domestic guinea pig)IC50 (µMol)57.00002.03005.53139.9000AID386625
Sodium/hydrogen exchanger 2Oryctolagus cuniculus (rabbit)IC50 (µMol)1.00000.00800.26131.0000AID1411096
Sodium/hydrogen exchanger 2Oryctolagus cuniculus (rabbit)Ki1.00000.50000.75001.0000AID1341115; AID1341849
Acid-sensing ion channel 1Rattus norvegicus (Norway rat)IC50 (µMol)30.20002.00002.00002.0000AID1495489
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)30.00000.00091.901410.0000AID1733546
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)30.00000.00033.64849.2000AID1733547
Sodium/hydrogen exchanger 5Homo sapiens (human)IC50 (µMol)21.00000.42000.42000.4200AID1411100
Sodium/hydrogen exchanger 5Homo sapiens (human)Ki21.00000.37000.39500.4200AID1341117; AID1341852
Solute carrier family 22 member 1Rattus norvegicus (Norway rat)Ki6.90000.13002.37856.9000AID681375
Solute carrier family 22 member 2Rattus norvegicus (Norway rat)Ki4.70000.39002.32959.4000AID681368
Acid-sensing ion channel 3Homo sapiens (human)IC50 (µMol)4.40004.40004.40004.4000AID352717
Sodium/hydrogen exchangerAmphiuma tridactylum (three-toed salamander)IC50 (µMol)98.00008.70008.70008.7000AID358118
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (394)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processSolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin transportSolute carrier family 22 member 1 Homo sapiens (human)
establishment or maintenance of transmembrane electrochemical gradientSolute carrier family 22 member 1 Homo sapiens (human)
organic cation transportSolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transportSolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transportSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transportSolute carrier family 22 member 1 Homo sapiens (human)
putrescine transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transportSolute carrier family 22 member 1 Homo sapiens (human)
acetylcholine transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine transportSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transportSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transportSolute carrier family 22 member 1 Homo sapiens (human)
epinephrine transportSolute carrier family 22 member 1 Homo sapiens (human)
serotonin uptakeSolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
metanephric proximal tubule developmentSolute carrier family 22 member 1 Homo sapiens (human)
purine-containing compound transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
dopamine uptakeSolute carrier family 22 member 1 Homo sapiens (human)
monoatomic cation transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
acyl carnitine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transportSolute carrier family 22 member 1 Homo sapiens (human)
cellular detoxificationSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transport across blood-brain barrierSolute carrier family 22 member 1 Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
positive regulation of protein phosphorylationProthrombinHomo sapiens (human)
proteolysisProthrombinHomo sapiens (human)
acute-phase responseProthrombinHomo sapiens (human)
cell surface receptor signaling pathwayProthrombinHomo sapiens (human)
G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell population proliferationProthrombinHomo sapiens (human)
regulation of cell shapeProthrombinHomo sapiens (human)
response to woundingProthrombinHomo sapiens (human)
negative regulation of platelet activationProthrombinHomo sapiens (human)
platelet activationProthrombinHomo sapiens (human)
regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of blood coagulationProthrombinHomo sapiens (human)
positive regulation of cell growthProthrombinHomo sapiens (human)
positive regulation of insulin secretionProthrombinHomo sapiens (human)
positive regulation of collagen biosynthetic processProthrombinHomo sapiens (human)
fibrinolysisProthrombinHomo sapiens (human)
negative regulation of proteolysisProthrombinHomo sapiens (human)
positive regulation of receptor signaling pathway via JAK-STATProthrombinHomo sapiens (human)
negative regulation of astrocyte differentiationProthrombinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolProthrombinHomo sapiens (human)
regulation of cytosolic calcium ion concentrationProthrombinHomo sapiens (human)
cytolysis by host of symbiont cellsProthrombinHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionProthrombinHomo sapiens (human)
negative regulation of fibrinolysisProthrombinHomo sapiens (human)
antimicrobial humoral immune response mediated by antimicrobial peptideProthrombinHomo sapiens (human)
neutrophil-mediated killing of gram-negative bacteriumProthrombinHomo sapiens (human)
positive regulation of lipid kinase activityProthrombinHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responseProthrombinHomo sapiens (human)
positive regulation of protein localization to nucleusProthrombinHomo sapiens (human)
positive regulation of phospholipase C-activating G protein-coupled receptor signaling pathwayProthrombinHomo sapiens (human)
ligand-gated ion channel signaling pathwayProthrombinHomo sapiens (human)
positive regulation of reactive oxygen species metabolic processProthrombinHomo sapiens (human)
proteolysisCoagulation factor XHomo sapiens (human)
blood coagulationCoagulation factor XHomo sapiens (human)
positive regulation of cell migrationCoagulation factor XHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor XHomo sapiens (human)
proteolysisPlasminogenHomo sapiens (human)
blood coagulationPlasminogenHomo sapiens (human)
negative regulation of cell population proliferationPlasminogenHomo sapiens (human)
negative regulation of cell-substrate adhesionPlasminogenHomo sapiens (human)
extracellular matrix disassemblyPlasminogenHomo sapiens (human)
tissue regenerationPlasminogenHomo sapiens (human)
fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationPlasminogenHomo sapiens (human)
myoblast differentiationPlasminogenHomo sapiens (human)
muscle cell cellular homeostasisPlasminogenHomo sapiens (human)
tissue remodelingPlasminogenHomo sapiens (human)
biological process involved in interaction with symbiontPlasminogenHomo sapiens (human)
negative regulation of fibrinolysisPlasminogenHomo sapiens (human)
positive regulation of fibrinolysisPlasminogenHomo sapiens (human)
trophoblast giant cell differentiationPlasminogenHomo sapiens (human)
labyrinthine layer blood vessel developmentPlasminogenHomo sapiens (human)
mononuclear cell migrationPlasminogenHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionPlasminogenHomo sapiens (human)
negative regulation of cell-cell adhesion mediated by cadherinPlasminogenHomo sapiens (human)
positive regulation of cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaUrokinase-type plasminogen activatorHomo sapiens (human)
proteolysisUrokinase-type plasminogen activatorHomo sapiens (human)
chemotaxisUrokinase-type plasminogen activatorHomo sapiens (human)
signal transductionUrokinase-type plasminogen activatorHomo sapiens (human)
blood coagulationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of signaling receptor activityUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell migrationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
plasminogen activationUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell adhesion mediated by integrinUrokinase-type plasminogen activatorHomo sapiens (human)
urokinase plasminogen activator signaling pathwayUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of cell population proliferationUrokinase-type plasminogen activatorHomo sapiens (human)
fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of wound healingUrokinase-type plasminogen activatorHomo sapiens (human)
regulation of smooth muscle cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
response to hypoxiaTissue-type plasminogen activatorHomo sapiens (human)
proteolysisTissue-type plasminogen activatorHomo sapiens (human)
blood coagulationTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
plasminogen activationTissue-type plasminogen activatorHomo sapiens (human)
protein modification processTissue-type plasminogen activatorHomo sapiens (human)
fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of proteolysisTissue-type plasminogen activatorHomo sapiens (human)
negative regulation of fibrinolysisTissue-type plasminogen activatorHomo sapiens (human)
prevention of polyspermyTissue-type plasminogen activatorHomo sapiens (human)
trans-synaptic signaling by BDNF, modulating synaptic transmissionTissue-type plasminogen activatorHomo sapiens (human)
platelet-derived growth factor receptor signaling pathwayTissue-type plasminogen activatorHomo sapiens (human)
smooth muscle cell migrationTissue-type plasminogen activatorHomo sapiens (human)
proteolysisCationic trypsinBos taurus (cattle)
digestionCationic trypsinBos taurus (cattle)
blood coagulationCoagulation factor XIHomo sapiens (human)
plasminogen activationCoagulation factor XIHomo sapiens (human)
positive regulation of fibrinolysisCoagulation factor XIHomo sapiens (human)
Factor XII activationPlasma kallikreinHomo sapiens (human)
proteolysisPlasma kallikreinHomo sapiens (human)
blood coagulationPlasma kallikreinHomo sapiens (human)
zymogen activationPlasma kallikreinHomo sapiens (human)
plasminogen activationPlasma kallikreinHomo sapiens (human)
fibrinolysisPlasma kallikreinHomo sapiens (human)
positive regulation of fibrinolysisPlasma kallikreinHomo sapiens (human)
proteolysisVitamin K-dependent protein CHomo sapiens (human)
blood coagulationVitamin K-dependent protein CHomo sapiens (human)
negative regulation of blood coagulationVitamin K-dependent protein CHomo sapiens (human)
negative regulation of apoptotic processVitamin K-dependent protein CHomo sapiens (human)
negative regulation of inflammatory responseVitamin K-dependent protein CHomo sapiens (human)
negative regulation of coagulationVitamin K-dependent protein CHomo sapiens (human)
positive regulation of establishment of endothelial barrierVitamin K-dependent protein CHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
digestionTrypsin-1Homo sapiens (human)
extracellular matrix disassemblyTrypsin-1Homo sapiens (human)
proteolysisTrypsin-1Homo sapiens (human)
proteolysisTrypsin-2Homo sapiens (human)
digestionTrypsin-2Homo sapiens (human)
antimicrobial humoral responseTrypsin-2Homo sapiens (human)
extracellular matrix disassemblyTrypsin-2Homo sapiens (human)
positive regulation of cell growthTrypsin-2Homo sapiens (human)
collagen catabolic processTrypsin-2Homo sapiens (human)
positive regulation of cell adhesionTrypsin-2Homo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 1Homo sapiens (human)
intracellular sodium ion homeostasisSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of pHSodium/hydrogen exchanger 1Homo sapiens (human)
response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cardiac muscle hypertrophySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle contraction by calcium ion signalingSodium/hydrogen exchanger 1Homo sapiens (human)
cell migrationSodium/hydrogen exchanger 1Homo sapiens (human)
maintenance of cell polaritySodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of cell growthSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to insulin stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilitySodium/hydrogen exchanger 1Homo sapiens (human)
response to muscle stretchSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion export across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
negative regulation of apoptotic processSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of action potentialSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IISodium/hydrogen exchanger 1Homo sapiens (human)
stem cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
protein complex oligomerizationSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of stress fiber assemblySodium/hydrogen exchanger 1Homo sapiens (human)
regulation of focal adhesion assemblySodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell differentiationSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to coldSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcineurin-NFAT signaling cascadeSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to antibioticSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to electrical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to mechanical stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to organic cyclic compoundSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to hypoxiaSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to acidic pHSodium/hydrogen exchanger 1Homo sapiens (human)
cellular response to epinephrine stimulusSodium/hydrogen exchanger 1Homo sapiens (human)
cardiac muscle cell contractionSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
regulation of the force of heart contraction by cardiac conductionSodium/hydrogen exchanger 1Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of the force of heart contractionSodium/hydrogen exchanger 1Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
positive regulation of calcium:sodium antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 1Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
synaptic transmission, dopaminergicAdenosine receptor A2aHomo sapiens (human)
response to amphetamineAdenosine receptor A2aHomo sapiens (human)
regulation of DNA-templated transcriptionAdenosine receptor A2aHomo sapiens (human)
phagocytosisAdenosine receptor A2aHomo sapiens (human)
apoptotic processAdenosine receptor A2aHomo sapiens (human)
inflammatory responseAdenosine receptor A2aHomo sapiens (human)
cellular defense responseAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
cell-cell signalingAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, cholinergicAdenosine receptor A2aHomo sapiens (human)
central nervous system developmentAdenosine receptor A2aHomo sapiens (human)
blood coagulationAdenosine receptor A2aHomo sapiens (human)
sensory perceptionAdenosine receptor A2aHomo sapiens (human)
locomotory behaviorAdenosine receptor A2aHomo sapiens (human)
blood circulationAdenosine receptor A2aHomo sapiens (human)
negative regulation of cell population proliferationAdenosine receptor A2aHomo sapiens (human)
response to xenobiotic stimulusAdenosine receptor A2aHomo sapiens (human)
response to inorganic substanceAdenosine receptor A2aHomo sapiens (human)
positive regulation of glutamate secretionAdenosine receptor A2aHomo sapiens (human)
positive regulation of acetylcholine secretion, neurotransmissionAdenosine receptor A2aHomo sapiens (human)
regulation of norepinephrine secretionAdenosine receptor A2aHomo sapiens (human)
response to purine-containing compoundAdenosine receptor A2aHomo sapiens (human)
response to caffeineAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, GABAergicAdenosine receptor A2aHomo sapiens (human)
synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
positive regulation of urine volumeAdenosine receptor A2aHomo sapiens (human)
vasodilationAdenosine receptor A2aHomo sapiens (human)
eating behaviorAdenosine receptor A2aHomo sapiens (human)
negative regulation of vascular permeabilityAdenosine receptor A2aHomo sapiens (human)
negative regulation of neuron apoptotic processAdenosine receptor A2aHomo sapiens (human)
positive regulation of circadian sleep/wake cycle, sleepAdenosine receptor A2aHomo sapiens (human)
negative regulation of alpha-beta T cell activationAdenosine receptor A2aHomo sapiens (human)
astrocyte activationAdenosine receptor A2aHomo sapiens (human)
neuron projection morphogenesisAdenosine receptor A2aHomo sapiens (human)
positive regulation of protein secretionAdenosine receptor A2aHomo sapiens (human)
negative regulation of inflammatory responseAdenosine receptor A2aHomo sapiens (human)
regulation of mitochondrial membrane potentialAdenosine receptor A2aHomo sapiens (human)
membrane depolarizationAdenosine receptor A2aHomo sapiens (human)
regulation of calcium ion transportAdenosine receptor A2aHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicAdenosine receptor A2aHomo sapiens (human)
excitatory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
inhibitory postsynaptic potentialAdenosine receptor A2aHomo sapiens (human)
prepulse inhibitionAdenosine receptor A2aHomo sapiens (human)
apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAdenosine receptor A2aHomo sapiens (human)
positive regulation of long-term synaptic potentiationAdenosine receptor A2aHomo sapiens (human)
positive regulation of apoptotic signaling pathwayAdenosine receptor A2aHomo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayAdenosine receptor A2aHomo sapiens (human)
proteolysisTrypsin-3Homo sapiens (human)
digestionTrypsin-3Homo sapiens (human)
antimicrobial humoral responseTrypsin-3Homo sapiens (human)
zymogen activationTrypsin-3Homo sapiens (human)
endothelial cell migrationTrypsin-3Homo sapiens (human)
intracellular sodium ion homeostasisAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
regulation of blood pressureAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sodium ion transmembrane transportAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
multicellular organismal-level water homeostasisAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sensory perception of salty tasteAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sensory perception of sour tasteAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sodium ion homeostasisAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
cellular response to acidic pHAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sodium ion import across plasma membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
cellular response to aldosteroneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
cellular response to vasopressinAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
monoatomic ion transportSodium/hydrogen exchanger 5Homo sapiens (human)
sodium ion transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
regulation of intracellular pHSodium/hydrogen exchanger 5Homo sapiens (human)
proton transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
potassium ion transmembrane transportSodium/hydrogen exchanger 5Homo sapiens (human)
sodium ion import across plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
signal transductionAcid-sensing ion channel 3Homo sapiens (human)
sensory perceptionAcid-sensing ion channel 3Homo sapiens (human)
response to heatAcid-sensing ion channel 3Homo sapiens (human)
response to acidic pHAcid-sensing ion channel 3Homo sapiens (human)
enterobactin transportAcid-sensing ion channel 3Homo sapiens (human)
sensory perception of sour tasteAcid-sensing ion channel 3Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painAcid-sensing ion channel 3Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painAcid-sensing ion channel 3Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painAcid-sensing ion channel 3Homo sapiens (human)
establishment of localization in cellAcid-sensing ion channel 3Homo sapiens (human)
sodium ion transmembrane transportAcid-sensing ion channel 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (121)

Processvia Protein(s)Taxonomy
acetylcholine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
neurotransmitter transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
dopamine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
norepinephrine:sodium symporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
monoamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
secondary active organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic anion transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
organic cation transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
prostaglandin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
pyrimidine nucleoside transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
thiamine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
putrescine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
spermidine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
quaternary ammonium group transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
toxin transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
identical protein bindingSolute carrier family 22 member 1 Homo sapiens (human)
xenobiotic transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
(R)-carnitine transmembrane transporter activitySolute carrier family 22 member 1 Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
lipopolysaccharide bindingProthrombinHomo sapiens (human)
serine-type endopeptidase activityProthrombinHomo sapiens (human)
signaling receptor bindingProthrombinHomo sapiens (human)
calcium ion bindingProthrombinHomo sapiens (human)
protein bindingProthrombinHomo sapiens (human)
growth factor activityProthrombinHomo sapiens (human)
heparin bindingProthrombinHomo sapiens (human)
thrombospondin receptor activityProthrombinHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor XHomo sapiens (human)
calcium ion bindingCoagulation factor XHomo sapiens (human)
protein bindingCoagulation factor XHomo sapiens (human)
phospholipid bindingCoagulation factor XHomo sapiens (human)
protease bindingPlasminogenHomo sapiens (human)
endopeptidase activityPlasminogenHomo sapiens (human)
serine-type endopeptidase activityPlasminogenHomo sapiens (human)
signaling receptor bindingPlasminogenHomo sapiens (human)
protein bindingPlasminogenHomo sapiens (human)
serine-type peptidase activityPlasminogenHomo sapiens (human)
enzyme bindingPlasminogenHomo sapiens (human)
kinase bindingPlasminogenHomo sapiens (human)
protein domain specific bindingPlasminogenHomo sapiens (human)
apolipoprotein bindingPlasminogenHomo sapiens (human)
protein-folding chaperone bindingPlasminogenHomo sapiens (human)
protein antigen bindingPlasminogenHomo sapiens (human)
serine-type endopeptidase activityUrokinase-type plasminogen activatorHomo sapiens (human)
protein bindingUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase activityTissue-type plasminogen activatorHomo sapiens (human)
signaling receptor bindingTissue-type plasminogen activatorHomo sapiens (human)
protein bindingTissue-type plasminogen activatorHomo sapiens (human)
phosphoprotein bindingTissue-type plasminogen activatorHomo sapiens (human)
endopeptidase activityCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCationic trypsinBos taurus (cattle)
protein bindingCationic trypsinBos taurus (cattle)
metal ion bindingCationic trypsinBos taurus (cattle)
serpin family protein bindingCationic trypsinBos taurus (cattle)
serine-type endopeptidase activityCoagulation factor XIHomo sapiens (human)
protein bindingCoagulation factor XIHomo sapiens (human)
heparin bindingCoagulation factor XIHomo sapiens (human)
serine-type aminopeptidase activityCoagulation factor XIHomo sapiens (human)
serine-type endopeptidase activityPlasma kallikreinHomo sapiens (human)
protein bindingPlasma kallikreinHomo sapiens (human)
serine-type endopeptidase activityVitamin K-dependent protein CHomo sapiens (human)
calcium ion bindingVitamin K-dependent protein CHomo sapiens (human)
protein bindingVitamin K-dependent protein CHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
serine-type endopeptidase activityTrypsin-1Homo sapiens (human)
metal ion bindingTrypsin-1Homo sapiens (human)
metalloendopeptidase activityTrypsin-2Homo sapiens (human)
serine-type endopeptidase activityTrypsin-2Homo sapiens (human)
calcium ion bindingTrypsin-2Homo sapiens (human)
protein bindingTrypsin-2Homo sapiens (human)
serine-type peptidase activityTrypsin-2Homo sapiens (human)
protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calmodulin bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phospholipid bindingSodium/hydrogen exchanger 1Homo sapiens (human)
phosphatidylinositol-4,5-bisphosphate bindingSodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein phosphatase 2B bindingSodium/hydrogen exchanger 1Homo sapiens (human)
protein-macromolecule adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
identical protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
calcium-dependent protein bindingSodium/hydrogen exchanger 1Homo sapiens (human)
molecular adaptor activitySodium/hydrogen exchanger 1Homo sapiens (human)
sodium:proton antiporter activity involved in regulation of cardiac muscle cell membrane potentialSodium/hydrogen exchanger 1Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 1Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
G protein-coupled adenosine receptor activityAdenosine receptor A2aHomo sapiens (human)
protein bindingAdenosine receptor A2aHomo sapiens (human)
calmodulin bindingAdenosine receptor A2aHomo sapiens (human)
lipid bindingAdenosine receptor A2aHomo sapiens (human)
enzyme bindingAdenosine receptor A2aHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingAdenosine receptor A2aHomo sapiens (human)
identical protein bindingAdenosine receptor A2aHomo sapiens (human)
protein-containing complex bindingAdenosine receptor A2aHomo sapiens (human)
alpha-actinin bindingAdenosine receptor A2aHomo sapiens (human)
serine-type endopeptidase activityTrypsin-3Homo sapiens (human)
calcium ion bindingTrypsin-3Homo sapiens (human)
protein bindingTrypsin-3Homo sapiens (human)
serine-type peptidase activityTrypsin-3Homo sapiens (human)
ligand-gated sodium channel activityAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
protein bindingAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
WW domain bindingAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium/hydrogen exchanger 5Homo sapiens (human)
sodium:proton antiporter activitySodium/hydrogen exchanger 5Homo sapiens (human)
arrestin family protein bindingSodium/hydrogen exchanger 5Homo sapiens (human)
potassium:proton antiporter activitySodium/hydrogen exchanger 5Homo sapiens (human)
monoatomic cation channel activityAcid-sensing ion channel 3Homo sapiens (human)
sodium channel activityAcid-sensing ion channel 3Homo sapiens (human)
enterobactin transmembrane transporter activityAcid-sensing ion channel 3Homo sapiens (human)
pH-gated monoatomic ion channel activityAcid-sensing ion channel 3Homo sapiens (human)
ligand-gated sodium channel activityAcid-sensing ion channel 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (85)

Processvia Protein(s)Taxonomy
plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
basal plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
membraneSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
apical plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
lateral plasma membraneSolute carrier family 22 member 1 Homo sapiens (human)
presynapseSolute carrier family 22 member 1 Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
external side of plasma membraneProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular regionProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
endoplasmic reticulum lumenProthrombinHomo sapiens (human)
Golgi lumenProthrombinHomo sapiens (human)
plasma membraneProthrombinHomo sapiens (human)
extracellular exosomeProthrombinHomo sapiens (human)
blood microparticleProthrombinHomo sapiens (human)
collagen-containing extracellular matrixProthrombinHomo sapiens (human)
extracellular spaceProthrombinHomo sapiens (human)
extracellular regionCoagulation factor XHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor XHomo sapiens (human)
Golgi lumenCoagulation factor XHomo sapiens (human)
plasma membraneCoagulation factor XHomo sapiens (human)
external side of plasma membraneCoagulation factor XHomo sapiens (human)
extracellular spaceCoagulation factor XHomo sapiens (human)
extracellular regionPlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
plasma membranePlasminogenHomo sapiens (human)
external side of plasma membranePlasminogenHomo sapiens (human)
cell surfacePlasminogenHomo sapiens (human)
platelet alpha granule lumenPlasminogenHomo sapiens (human)
collagen-containing extracellular matrixPlasminogenHomo sapiens (human)
extracellular exosomePlasminogenHomo sapiens (human)
blood microparticlePlasminogenHomo sapiens (human)
Schaffer collateral - CA1 synapsePlasminogenHomo sapiens (human)
glutamatergic synapsePlasminogenHomo sapiens (human)
extracellular spacePlasminogenHomo sapiens (human)
extracellular regionUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
focal adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
external side of plasma membraneUrokinase-type plasminogen activatorHomo sapiens (human)
cell surfaceUrokinase-type plasminogen activatorHomo sapiens (human)
specific granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular exosomeUrokinase-type plasminogen activatorHomo sapiens (human)
tertiary granule membraneUrokinase-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexUrokinase-type plasminogen activatorHomo sapiens (human)
protein complex involved in cell-matrix adhesionUrokinase-type plasminogen activatorHomo sapiens (human)
serine-type endopeptidase complexUrokinase-type plasminogen activatorHomo sapiens (human)
extracellular spaceUrokinase-type plasminogen activatorHomo sapiens (human)
collagen-containing extracellular matrixTissue-type plasminogen activatorHomo sapiens (human)
extracellular regionTissue-type plasminogen activatorHomo sapiens (human)
cytoplasmTissue-type plasminogen activatorHomo sapiens (human)
cell surfaceTissue-type plasminogen activatorHomo sapiens (human)
secretory granuleTissue-type plasminogen activatorHomo sapiens (human)
apical part of cellTissue-type plasminogen activatorHomo sapiens (human)
extracellular exosomeTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexTissue-type plasminogen activatorHomo sapiens (human)
Schaffer collateral - CA1 synapseTissue-type plasminogen activatorHomo sapiens (human)
glutamatergic synapseTissue-type plasminogen activatorHomo sapiens (human)
extracellular spaceTissue-type plasminogen activatorHomo sapiens (human)
serine protease inhibitor complexCationic trypsinBos taurus (cattle)
extracellular regionCoagulation factor XIHomo sapiens (human)
extracellular spaceCoagulation factor XIHomo sapiens (human)
plasma membraneCoagulation factor XIHomo sapiens (human)
membraneCoagulation factor XIHomo sapiens (human)
extracellular exosomeCoagulation factor XIHomo sapiens (human)
extracellular regionPlasma kallikreinHomo sapiens (human)
extracellular spacePlasma kallikreinHomo sapiens (human)
plasma membranePlasma kallikreinHomo sapiens (human)
extracellular exosomePlasma kallikreinHomo sapiens (human)
extracellular regionVitamin K-dependent protein CHomo sapiens (human)
endoplasmic reticulumVitamin K-dependent protein CHomo sapiens (human)
endoplasmic reticulum lumenVitamin K-dependent protein CHomo sapiens (human)
Golgi apparatusVitamin K-dependent protein CHomo sapiens (human)
Golgi lumenVitamin K-dependent protein CHomo sapiens (human)
extracellular spaceVitamin K-dependent protein CHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
extracellular regionTrypsin-1Homo sapiens (human)
collagen-containing extracellular matrixTrypsin-1Homo sapiens (human)
blood microparticleTrypsin-1Homo sapiens (human)
extracellular spaceTrypsin-1Homo sapiens (human)
extracellular regionTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
extracellular matrixTrypsin-2Homo sapiens (human)
azurophil granule lumenTrypsin-2Homo sapiens (human)
extracellular spaceTrypsin-2Homo sapiens (human)
nucleoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
mitochondrionSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 1Homo sapiens (human)
cell surfaceSodium/hydrogen exchanger 1Homo sapiens (human)
intercalated discSodium/hydrogen exchanger 1Homo sapiens (human)
membraneSodium/hydrogen exchanger 1Homo sapiens (human)
basolateral plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
apical plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
lamellipodiumSodium/hydrogen exchanger 1Homo sapiens (human)
T-tubuleSodium/hydrogen exchanger 1Homo sapiens (human)
membrane raftSodium/hydrogen exchanger 1Homo sapiens (human)
perinuclear region of cytoplasmSodium/hydrogen exchanger 1Homo sapiens (human)
extracellular exosomeSodium/hydrogen exchanger 1Homo sapiens (human)
cation-transporting ATPase complexSodium/hydrogen exchanger 1Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 1Homo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
intermediate filamentAdenosine receptor A2aHomo sapiens (human)
plasma membraneAdenosine receptor A2aHomo sapiens (human)
membraneAdenosine receptor A2aHomo sapiens (human)
dendriteAdenosine receptor A2aHomo sapiens (human)
axolemmaAdenosine receptor A2aHomo sapiens (human)
asymmetric synapseAdenosine receptor A2aHomo sapiens (human)
presynaptic membraneAdenosine receptor A2aHomo sapiens (human)
neuronal cell bodyAdenosine receptor A2aHomo sapiens (human)
postsynaptic membraneAdenosine receptor A2aHomo sapiens (human)
presynaptic active zoneAdenosine receptor A2aHomo sapiens (human)
glutamatergic synapseAdenosine receptor A2aHomo sapiens (human)
extracellular regionTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
tertiary granule lumenTrypsin-3Homo sapiens (human)
extracellular spaceTrypsin-3Homo sapiens (human)
acrosomal vesicleAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
cytoplasmAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
cytosolAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
plasma membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
external side of plasma membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
apical plasma membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
motile ciliumAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sodium channel complexAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
ciliary membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
extracellular exosomeAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
sperm principal pieceAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
plasma membraneAmiloride-sensitive sodium channel subunit alphaHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
focal adhesionSodium/hydrogen exchanger 5Homo sapiens (human)
membraneSodium/hydrogen exchanger 5Homo sapiens (human)
dendritic spine membraneSodium/hydrogen exchanger 5Homo sapiens (human)
neuron spineSodium/hydrogen exchanger 5Homo sapiens (human)
synapseSodium/hydrogen exchanger 5Homo sapiens (human)
postsynaptic membraneSodium/hydrogen exchanger 5Homo sapiens (human)
recycling endosome membraneSodium/hydrogen exchanger 5Homo sapiens (human)
plasma membraneSodium/hydrogen exchanger 5Homo sapiens (human)
plasma membraneAcid-sensing ion channel 3Homo sapiens (human)
perinuclear region of cytoplasmAcid-sensing ion channel 3Homo sapiens (human)
plasma membraneAcid-sensing ion channel 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (374)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID215821Inhibitory activity against Urokinase-type plasminogen activator2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
AID17171Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID17750Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID29844Fraction absorbed after oral administration in humans2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID771315Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID175992Urine volumes was determined at time period of 0-5 hours for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID16953Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1611205Diuretic activity in Sprague-Dawley rat model of acetazolamide-induced diuresis assessed as increase in sodium excretion at 1.5 mg/kg, ip pretreated with acetazolamide followed by compound treatment measured after 6 hrs relative to control2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID17177Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID28392Apparent permeability coefficient (Papp) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1820893Selectivity ratio of Ki for inhibition of human uPA H99Y mutant to Ki for inhibition of human uPA2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
AID17173Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1385943Selectivity ratio of IC50 for mouse uPA to Ki for human uPA2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID210740Inhibitory activity against Tissue type plasminogen activator2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
AID358121Inhibition of Pleuronectes americanus NHE1 C-terminal mutant containing TM10 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1733601Clearance in Sprague-Dawley rat renal blood at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID771314Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis relative to passive uptake2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID58405Compound was evaluated for percentage recovery from urine after administration of 0.3 mg/kg dose1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1733542Permeability across basolateral to apical side in human Caco2 cells assessed as mass balance at 20 uM after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733532Half life in human liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1308476Displacement of [3H]ZM-241,385 from human N-terminal FLAG-tagged adenosine A2A receptor W246A 6.48 mutant expressed in HEK293 cell membrane assessed as radioligand binding at 10 uM by microbeta scintillation counting method relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor.
AID215985Inhibitory activity against Urokinase-type plasminogen activator2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Identification of novel inhibitors of urokinase via NMR-based screening.
AID1733554Clearance in Balb/C mouse blood at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733551Volume of distribution at steady state in Balb/C mouse plasma at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1611211Antimetastatic activity against luciferase-tagged human HT1080 cells xenografted in NSG mouse assessed as reduction in lung burden at 7.5 mg/kg/day, ip for 21 days by luciferase assay2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1733552AUC(0 to infinity) in Balb/C mouse plasma at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175985Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1611189Inhibition of human kidney uPA using chromogenic H-D-Ile-L-propyl-L-arginine-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID352717Inhibition of ASIC3 assessed as inhibition of peak current by patch clamp electrophysiology2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Amiloride derived inhibitors of acid-sensing ion channel-3 (ASIC3).
AID231333Ratio of [(apical to basal)/(basal to apical)] (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1733653Glomerular filtration rate in rat2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID62812Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 0-24 hr1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1476055Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of peak current amplitude at 300 uM at membrane potential -60 mV by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID481442Transcellular permeability at pH 6.5 calculated from in vitro P app values in Caco-2 and/or MDCK cells2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1733544Apparent permeability across basolateral to apical side in human Caco2 cells at 20 uM after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175982Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1611206Antikaliuretic activity in Sprague-Dawley rat model of acetazolamide-induced diuresis assessed as decrease in potassium secretion at 1.5 mg/kg, ip pretreated with acetazolamide followed by compound treatment measured after 6 hrs relative to control2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID175835Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1733594Plasma clearance in Sprague-Dawley rat at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID476929Human intestinal absorption in po dosed human2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
AID268105Inhibition of dog bronchi prototypical epithelial sodium channel by electrophysiological assay2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID358113Inhibition of osmotic cell shrinkage-induced NHE1 activity in Pleuronectes americanus RBC at 1 mM2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1733531Kinetic solubility of compound in PBS at pH 6.5 by nephelometric analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175984Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID230275Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 11.3 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID62814Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 6-24h1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID17559Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1385944Inhibition of S-3969-stimulated recombinant human ENaC alpha subunit expressed in HEK293 cells at 10 uM preincubated for 5 mins followed by S-3969 stimulation by FLIPR assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID1733543Apparent permeability across apical to basolateral side in human Caco2 cells at 20 uM after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733597Ratio of drug level in blood to plasma in Sprague-Dawley rat at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID230279Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 37.6 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1611199Cytotoxicity against human HEK293 cells measured after 48 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1660442Diuretic activity in normotensive Wistar rat assessed as urinary calcium excretion at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 5.93 to 6.87 mg/dl)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID656542Blockade of human ENaC expressed in HBE cells by short-circuit current assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines.
AID1733533Intrinsic clearance in human liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID22057Tested for the diuretic activity by measuring the urinary volume after peroral administering 3.76 uM/Kg of drug in dogs1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID481441Aqueous diffusivity at 37C2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID175981Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID358314Inhibition of Pleuronectes americanus NHE1 C-terminal mutant with replacement of residues C-terminal to 489 position with corresponding residues of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammon2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1495485Inhibition of acid-induced ASIC1a protein expression in rat articular chondrocytes at 100 uM pretreated for 24 hrs followed by acid medium stimulation at pH 6 for 3 hrs by Western blot analysis2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel amidrazone derivatives: Design, synthesis and activity evaluation.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID481439Absolute bioavailability in human2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID175827Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID175986Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID681368TP_TRANSPORTER: inhibition of TEA uptake in OCT2-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID16799Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID175975Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175977Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1611188Inhibition of human plasma kallikrein using chromogenic L-pyroGlu-L-Pro-L-Arg-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1733530Kinetic solubility of compound in HCL at pH 2 by nephelometric analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID588966Substrates of transporters of clinical importance in the absorption and disposition of drugs, OCT22010Nature reviews. Drug discovery, Mar, Volume: 9, Issue:3
Membrane transporters in drug development.
AID17168Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1265728Inhibition of bovine pancreatic trypsin using Nalpha-benzoyl-D,L-Arg-pNA-HCl as substrate measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID17554Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID34238Binding affinity for HA-tagged mutant human Adenosine A2A receptor (V84L), using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID175993Urine volumes was determined at time period of 0-5 hours for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID191515Urine volumes was determined in Sprague-Dawley rats at time period of 0-5 hours at 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID22217Tested for the diuretic activity by measuring the urinary volume after peroral administering 37.6 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID175989Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1435501Inhibition of platelet NHE1 in human platelet rich plasma assessed as decrease in platelet swelling preincubated for 3 mins followed by sodium propionate addition measured after 4 mins by spectrophotometric method2017European journal of medicinal chemistry, Jan-27, Volume: 126Sodium hydrogen exchanger inhibitory activity of benzotriazole derivatives.
AID62813Compound was evaluated for urinary levels (mg) after administration of 0.1 mg/kg at time period 0-6 hr1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID28399Cellular permeability (Pc) (Caco-2 cell monolayer)2001Journal of medicinal chemistry, Jun-07, Volume: 44, Issue:12
Experimental and computational screening models for the prediction of intestinal drug absorption.
AID1733537Unbound intrinsic clearance in mouse liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1660402Diuretic activity in normotensive Wistar rat assessed as urine pH at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 6.14 to 6.21 No_unit)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID1733539Drug degradation in Balb/C mouse plasma at 1 ug/ml after 4 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733599Volume of distribution at steady state in Sprague-Dawley rat blood at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID191513Urine volumes was determined in Sprague-Dawley rats at time period of 0-5 hours at 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1733598Clearance in Sprague-Dawley rat blood at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733600Drug excretion in Sprague-Dawley rat urine at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175988Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1265729Inhibition of purified human factor 7a using MeSO2-Cha-Abu-Arg-pNA as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID1733536Intrinsic clearance in mouse liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID481444Octanol-water partition coefficient, log P of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID1385951Antimetastatic activity against luciferase-tagged human HT1080 cells xenografted in NOD.Cg-Prkdc-IL2rgSzJAusb mouse assessed as inhibition of late-stage lung metastasis at 7.5 mg/kg/day, ip administered from day 1 to day 20 measured day 212018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID175830Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID16976Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID175995Urine volumes was determined at time period of 0-5 hours for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175978Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID358111Inhibition of osmotic cell shrinkage-induced NHE1 activity in Amphiuma tridactylum RBC at 1 mM2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID358118Inhibition of Amphiuma tridactylum wild type NHE1 expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID643899Inhibition of guinea pig ENaCbeta1/gamma1 expressed in FRT cells by short-circuit current technique2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines.
AID1733654Clearance in Sprague-Dawley rat assessed as hepatic blood flow at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1611198Cytotoxicity against human HepG2 cells measured after 48 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID771317Cellular uptake in human HEK293 cells assessed as human OCT1-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID1733538Plasma protein binding in Balb/C mouse at 1 ug/ml after 4.2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID230278Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1385948Antikaliuretic effect in Sprague-Dawley rat assessed as increase in acetazolamide-induced Na+ excretion at 1.5 mg/kg, iv measured after 6 hrs post dose relative to acetazolamide-treated control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID1495488Inhibition of ASIC1a in rat articular chondrocytes assessed as decrease in acid-induced intracellular calcium level at 100 uM pretreated with compound followed by acid medium stimulation in presence of voltage gated calcium channel inhibitor nimodipine af2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel amidrazone derivatives: Design, synthesis and activity evaluation.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1265732Inhibition of purified human factor 10a using Suc-Ile-Glu(yPip)-GlyArg-pNa-HCl as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID58404Compound was evaluated for percentage recovery from urine after administration of 0.1 mg/kg dose1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1385949Antikaliuretic effect in Sprague-Dawley rat assessed as acetazolamide-induced Na+/K+ ratio at 1.5 mg/kg, iv measured after 6 hrs post dose2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID386623Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID1611202Inhibition of human uPA2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID28679Partition coefficient (logD6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID175831Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1733534Unbound intrinsic clearance in human liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175991Compound was evaluated for diuretic activity to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1385946Inhibition of S-3969-stimulated recombinant human ENaC gamma subunit expressed in HEK293 cells at 10 uM preincubated for 5 mins followed by S-3969 stimulation by FLIPR assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID34237Binding affinity for HA-tagged mutant human Adenosine A2A receptor (H250N) using [3H]-CGS-21,680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID1226994Inhibition of human ASIC1a endogenously expressed in HEK293 cells clamped at -20 mV gated ionic current at 10 uM by standard whole cell patch clamp assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Potent Orthosteric Antagonist of ASIC1a Prevents NMDAR-Dependent LTP Induction.
AID358120Inhibition of Pleuronectes americanus NHE1 C-terminal mutant containing TM7 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID567091Drug absorption in human assessed as human intestinal absorption rate2011European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
AID1733592Oral bioavailability in human2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733596AUC(0 to infinity) in Sprague-Dawley rat plasma at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1733546Inhibition of recombinant human ERG expressed in CHO cells incubated for 12 mins by whole cell voltage clamp method2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1308475Displacement of [3H]ZM-241,385 from human N-terminal FLAG-tagged adenosine A2A receptor expressed in HEK293 cell membrane assessed as radioligand binding at 10 uM by microbeta scintillation counting method relative to control2016Journal of medicinal chemistry, 05-26, Volume: 59, Issue:10
5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor.
AID1495489Inhibition of ASIC1 in Sprague-Dawley rat articular chondrocytes assessed as decrease in acid-induced intracellular calcium level by Fluo-3AM dye based laser scanning confocal microscopy2018Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12
Novel amidrazone derivatives: Design, synthesis and activity evaluation.
AID1476093Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of peak current amplitude at 300 uM at membrane potential +20 mV by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID1660426Diuretic activity in normotensive Wistar rat assessed as urinary potassium excretion at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 22.39 to 24.21 mmol/L)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID1385947Diuretic effect in Sprague-Dawley rat assessed as increase in acetazolamide-induced urine volume at 1.5 mg/kg, iv measured after 6 hrs post dose relative to acetazolamide-treated control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID26304Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID175983Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-24 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID654830Inhibition of plasmin using tosyl-Gly-Pro-Lys-pNA as substrate by spectrofluorometry2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
AID17558Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1265733Inhibition of human plasma plasmin using pyroGlu-Pro-Arg-pNA-HCl as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID1660410Diuretic activity in normotensive Wistar rat assessed as urine conductivity at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 19.54 +/- 0.98 mS/cm)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID654828Inhibition of urokinase-type plasminogen activator using Glt-Gly-Arg-AMC as substrate by spectrofluorometry2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
AID28924Effective permeability (Pe) across a hexadecane membrane (pH 6.8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID481446Effective permeability across human jejunum2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID22025Tested for the diuretic activity by measuring the urinary volume after peroral administering 0 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID202892Inhibitory activity against porcine kidney amine oxidase2001Bioorganic & medicinal chemistry letters, Oct-08, Volume: 11, Issue:19
Combinatorial synthesis of SSAO inhibitors using sonogashira coupling: SAR of aryl propargylic amines.
AID1611201Inhibition of mouse uPA2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1611204Diuretic activity in Sprague-Dawley rat model of acetazolamide-induced diuresis assessed as increase in urine volume at 1.5 mg/kg, ip pretreated with acetazolamide followed by compound treatment measured after 6 hrs relative to control2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID16946Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID17738Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID22033Tested for the diuretic activity by measuring the urinary volume after peroral administering 11.3 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1265734Inhibition of human plasma kallikrein using D-Pro-Phe-Arg-pNA-2HCl as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1733553Ratio of drug level in blood to plasma in Balb/C mouse plasma at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID52020Inhibitory activity against Coagulation factor Xa at a concentration of 250 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
AID643893Inhibition of human ENaC in HBE cells by short-circuit current technique2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines.
AID681375TP_TRANSPORTER: inhibition of TEA uptake in OCT1-expressing MDCK cells2001Pharmaceutical research, Nov, Volume: 18, Issue:11
Distinct characteristics of organic cation transporters, OCT1 and OCT2, in the basolateral membrane of renal tubules.
AID1733548Inhibition of Cav1.2beta (unknown origin) expressed in HEK293 cells incubated for 10 mins by voltage clamp method2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID175833Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID175979Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID230273Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 1.13 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID358310Inhibition of Pleuronectes americanus NHE1 mutant containing TM10-12 domain of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID16988Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID771316Cellular uptake in human HEK293 cells assessed as human OCT2-mediated drug transport at 2.5 uM after 4 mins by LC-MS/MS analysis2013Journal of medicinal chemistry, Sep-26, Volume: 56, Issue:18
Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2.
AID16952Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID656544Blockade of ENaC in intratracheally dosed Dunkin Hartley guinea pig tracheal potential difference model after 1 hr2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines.
AID1611197Cytotoxicity against human MDA-MB-231 cells measured after 48 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1476092Inhibition of rat ASIC1a receptor expressed in xenopus lavies oocytes assessed as inhibition of peak current amplitude at 300 uM at membrane potential -20 mV by two electrode voltage clamp2017Journal of medicinal chemistry, 10-12, Volume: 60, Issue:19
Molecular Basis for Allosteric Inhibition of Acid-Sensing Ion Channel 1a by Ibuprofen.
AID358312Inhibition of Pleuronectes americanus NHE1 TM4 mutant containing VFFLF sequence of human expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1265722Inhibition of human uPA using pyro-Glu-Gly-Arg-pNA as substrate assessed as para-nitroaniline release from substrate measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID28925Highest effective permeability across hexadecane membrane (pH 4-8)2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID352716Inhibition of ASIC3 at 20 uM assessed as inhibition of peak current by patch clamp electrophysiology relative to baseline2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Amiloride derived inhibitors of acid-sensing ion channel-3 (ASIC3).
AID16948Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1733550Plasma clearance in Balb/C mouse at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID386625Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells by confocal microscopy2008Journal of medicinal chemistry, Oct-09, Volume: 51, Issue:19
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
AID419413Inhibition of urokinase2009Journal of medicinal chemistry, May-28, Volume: 52, Issue:10
Large-scale application of high-throughput molecular mechanics with Poisson-Boltzmann surface area for routine physics-based scoring of protein-ligand complexes.
AID1385965Inhibition of uPA (unknown origin) using L-pyroglutamyl-glycyl-L-arginine-p-nitro-anilide as susbtrate by Lineweaver-Burk plot analysis2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID1385950Antikaliuretic effect in Sprague-Dawley rat assessed as decrease in acetazolamide-induced K+ excretion at 1.5 mg/kg, iv measured after 6 hrs post dose relative to acetazolamide-treated control2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID213433Acid dissociation constant (pKa) of the compound2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Identification of novel inhibitors of urokinase via NMR-based screening.
AID191514Urine volumes was determined in Sprague-Dawley rats at time period of 0-5 hours at 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID358313Inhibition of Pleuronectes americanus NHE1 TM4 mutant containing TFFLF sequence of Amphiuma tridactylum expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID1733593Half life in Sprague-Dawley rat at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID681444TP_TRANSPORTER: inhibition of TEA uptake by Amiloride at 1mM in Octn1-HRPE cells2000Biochimica et biophysica acta, Jun-01, Volume: 1466, Issue:1-2
Structural and functional characteristics and tissue distribution pattern of rat OCTN1, an organic cation transporter, cloned from placenta.
AID1733541Permeability across apical to basolateral side in human Caco2 cells assessed as mass balance at 20 uM after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1611195Inhibition of factor 11a (unknown origin) using chromogenic L-pyroGlu-L-Pro-L-Arg-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID352715Inhibition of ASIC3 assessed as inhibition of peak current at 1 uM by patch clamp electrophysiology relative to baseline2009Bioorganic & medicinal chemistry letters, May-01, Volume: 19, Issue:9
Amiloride derived inhibitors of acid-sensing ion channel-3 (ASIC3).
AID1611192Inhibition of thrombin (unknown origin) using chromogenic H-D-Ile-L-propyl-L-arginine-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID656543Blockade of guinea pig ENaC expressed in FRT cells by short-circuit current assay2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 2: α-Branched quaternary amines.
AID1518701Permeability of compound in PBS at pH 7.4 incubated for 5 hrs by UV spectroscopic assay based PAMPA2019European journal of medicinal chemistry, Dec-15, Volume: 184Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1611200Cytotoxicity against human HT1080 cells measured after 48 hrs by MTS assay2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID157960Inhibitory activity against plasmin at a concentration of 250 uM2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
AID1265731Inhibition of recombinant human tPA using H-D-Ile-Pro-L-Arg-pNA-2HCl as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID175976Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1733529Distribution coefficient, log D of the compound at pH 7.4 by HPLC analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1733602Clearance in Sprague-Dawley rat non-renal blood at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1611194Inhibition of factor Xa (unknown origin)2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID358311Inhibition of Amphiuma tridactylum NHE1 mutant containing TM10-12 domain of Pleuronectes americanus expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID726077Blockade of ASIC (unknown origin)2013Journal of medicinal chemistry, Feb-14, Volume: 56, Issue:3
Ion channels as therapeutic targets: a drug discovery perspective.
AID1385942Inhibition of mouse uPA using Z-Gly-Gly-Arg-AMC as substrate after 15 mins by fluorescence assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID22034Tested for the diuretic activity by measuring the urinary volume after peroral administering 113 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID28234% absorbed in human GI-tract2001Journal of medicinal chemistry, Mar-15, Volume: 44, Issue:6
High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes.
AID22058Tested for the diuretic activity by measuring the urinary volume after peroral administering 3.76 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID17178Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID34239Binding affinity for HA-tagged wild type human Adenosine A2A receptor (WT) using [3H]CGS-21680 as radioligand expressed in COS-7 cells1997Journal of medicinal chemistry, Aug-01, Volume: 40, Issue:16
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.
AID643900Blockade of tracheal potential difference in it dosed Dunkin Hartley guinea pig at 1hr2012Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
Discovery of a novel chemotype of potent human ENaC blockers using a bioisostere approach. Part 1: quaternary amines.
AID455986Permeability across human Caco-2 cells2009Bioorganic & medicinal chemistry, Oct-01, Volume: 17, Issue:19
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
AID654829Inhibition of tPA using CH3SO2-D-HHT-Gly-Arg-pNA as substrate by spectrofluorometry2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
AID1611193Inhibition of trypsin (unknown origin) using chromogenic H-D-Ile-L-propyl-L-arginine-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID175832Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1226993Inhibition of human ASIC1a endogenously expressed in HEK293 cells clamped at -100 mV gated ionic current at 10 uM by standard whole cell patch clamp assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Potent Orthosteric Antagonist of ASIC1a Prevents NMDAR-Dependent LTP Induction.
AID175980Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (K+) at a time period of 0-5 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1733595Volume of distribution at steady state in Sprague-Dawley rat plasma at 1.6 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1611196Inhibition of activated protein C (unknown origin) using chromogenic L-pyroGlu-L-Pro-L-Arg-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1820895Inhibition of uPA (unknown origin) using L-pyroglutamyl-glycyl-L-arginine-p-nitroanilide as substrate by Lineweaver-Burk plot analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
AID1265730Inhibition of human plasma thrombin using pyroGlu-Pro-Arg-pNA-HCl as substrate at 100 uM measured for 5 mins by spectrophotometric assay2015Journal of medicinal chemistry, Dec-10, Volume: 58, Issue:23
Discovery and SAR of Novel and Selective Inhibitors of Urokinase Plasminogen Activator (uPA) with an Imidazo[1,2-a]pyridine Scaffold.
AID358119Inhibition of human wild type NHE1 expressed in chinese hamster AP1 cells assessed as intracellular pHi recovery by ammonium chloride prepulse protocol2007The Journal of biological chemistry, Jul-06, Volume: 282, Issue:27
NHE1 inhibition by amiloride- and benzoylguanidine-type compounds. Inhibitor binding loci deduced from chimeras of NHE1 homologues with endogenous differences in inhibitor sensitivity.
AID230276Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 113 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID210807Inhibitory activity against thrombin2004Journal of medicinal chemistry, May-06, Volume: 47, Issue:10
Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator.
AID175834Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-5 hr for dose 9 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID17545Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID175829Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Cl-) at a time period of 0-24 hr for dose 81 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1611191Inhibition of plasmin (unknown origin) using chromogenic H-D-Ile-L-propyl-L-arginine-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1733555Volume of distribution at steady state in Balb/C mouse blood at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID481440Dissociation constant, pKa of the compound2010Journal of medicinal chemistry, May-13, Volume: 53, Issue:9
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID654832Cytotoxicity against human U87 cells at 250 uM after 24 hrs by lactate dehydrogenase assay2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1226997Inhibition of human ASIC1a endogenously expressed in HEK293 cells clamped at -100 mV gated ionic current at 10 uM in presence of cellular membrane depolarization by standard whole cell patch clamp assay2015Journal of medicinal chemistry, Jun-11, Volume: 58, Issue:11
Novel Potent Orthosteric Antagonist of ASIC1a Prevents NMDAR-Dependent LTP Induction.
AID1660434Diuretic activity in normotensive Wistar rat assessed as urinary chloride excretion at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 135.10 to 143.70 mmol/L)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID1820892Inhibition of human uPA H99Y mutant using pyroGlu-Gly-Arg-pNA as substrate by absorbance based analysis2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Disruption of Water Networks is the Cause of Human/Mouse Species Selectivity in Urokinase Plasminogen Activator (uPA) Inhibitors Derived from Hexamethylene Amiloride (HMA).
AID17552Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID17352Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1733547Inhibition of recombinant human Nav1.5alpha expressed in HEK293 cells incubated for 10 mins by voltage clamp method2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1385920Inhibition of human kidney uPA using Z-Gly-Gly-Arg-AMC as substrate measured over 15 mins by fluorescence assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID22293Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID175987Compound was evaluated for diuretic activity determined by the ability to induce electrolytic excretion (Na+) at a time period of 0-5 hr for dose 3 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID1385945Inhibition of S-3969-stimulated recombinant human ENaC beta subunit expressed in HEK293 cells at 10 uM preincubated for 5 mins followed by S-3969 stimulation by FLIPR assay2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
AID1611190Inhibition of tissue-type plasminogen activator (unknown origin) using chromogenic H-D-Ile-L-propyl-L-arginine-p-nitroaniline as substrate2019Bioorganic & medicinal chemistry letters, 12-15, Volume: 29, Issue:24
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
AID1733545Efflux ratio of apparent permeability across basolateral to apical membrane over apical to basolateral membrane in human Caco2 cells at 20 uM after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID268106Recovery of short-circuit current in dog primary bronchial epithelial cells2006Journal of medicinal chemistry, Jul-13, Volume: 49, Issue:14
Design, synthesis, and structure-activity relationships of novel 2-substituted pyrazinoylguanidine epithelial sodium channel blockers: drugs for cystic fibrosis and chronic bronchitis.
AID230272Ratio of Total electrolytic excretion of sodium and potassium in urine of dogs after peroral administration of 0 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID1660418Diuretic activity in normotensive Wistar rat assessed as urinary sodium excretion at 3 mg/kg, po administered via gavage after 8 hrs (Rvb = 61.82 to 80.81 mmol/L)2020Journal of natural products, 06-26, Volume: 83, Issue:6
Diuretic and Renal Protective Effect of Kaempferol 3-
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1733591Oral bioavailability in Balb/C mouse at 1.9 to 3.5 mg/kg up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1458717Anti-hypertensive activity in SRH rat assessed as induction of diuresis at 10 mg/kg, po administered as single dose on day 2,3 and 4 measured for 7 hrs post dose2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
AID1733540Stability in Balb/C mouse whole blood assessed as drug degradation at 1 ug/ml after 2 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID17364Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1458723Anti-hypertensive activity in SRH rat assessed as induction of natriuresis at 10 mg/kg, po administered as single dose on day 2,3 and 4 measured for 7 hrs post dose2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Optimization of Allosteric With-No-Lysine (WNK) Kinase Inhibitors and Efficacy in Rodent Hypertension Models.
AID1733535Half life in mouse liver microsomes at 1 uM up to 60 mins in presence of NADPH2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID22027Tested for the diuretic activity by measuring the urinary volume after peroral administering 1.13 uM/Kg of drug in rats1994Journal of medicinal chemistry, Oct-28, Volume: 37, Issue:22
Synthesis and diuretic activity of alkyl- and arylguanidine analogs of N,N'-dicyclohexyl-4-morpholinecarboxamidine in rats and dogs.
AID191512Urine volumes was determined in Sprague-Dawley rats at time period of 0-5 hours at 27 mg/kg1986Journal of medicinal chemistry, Aug, Volume: 29, Issue:8
Synthesis and biological activity of 3-amino-5-(3,5-diamino-6-chloropyrazin-2-yl)-1,2,4-oxadiazole: an amiloride prodrug.
AID654831Inhibition of trypsin using tosyl-Gly-Pro-Lys-pNA as substrate by spectrofluorometry2012Bioorganic & medicinal chemistry letters, Apr-01, Volume: 22, Issue:7
2-Amidino analogs of glycine-amiloride conjugates: inhibitors of urokinase-type plasminogen activator.
AID1733549Apparent half life in Balb/C mouse at 2.9 mg/kg, iv up to 24 hrs by LC-MS analysis2021Bioorganic & medicinal chemistry, 05-01, Volume: 37Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1797476Determination of Inhibition Constants from Article 10.1006/jmbi.2000.3966: \\Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.\\2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1346961Human Sodium/hydrogen exchanger 5 (SLC9 family of sodium/hydrogen exchangers)2003European journal of medicinal chemistry, Jun, Volume: 38, Issue:6
An overview of inhibitors of Na(+)/H(+) exchanger.
AID1346567Mouse TRPA1 (Transient Receptor Potential channels)2005The Journal of neuroscience : the official journal of the Society for Neuroscience, Apr-20, Volume: 25, Issue:16
Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing.
AID1346577Mouse TRPC6 (Transient Receptor Potential channels)2001Circulation research, Feb-16, Volume: 88, Issue:3
The transient receptor potential protein homologue TRP6 is the essential component of vascular alpha(1)-adrenoceptor-activated Ca(2+)-permeable cation channel.
AID1346973Rat Sodium/hydrogen exchanger 1 (SLC9 family of sodium/hydrogen exchangers)2003European journal of medicinal chemistry, Jun, Volume: 38, Issue:6
An overview of inhibitors of Na(+)/H(+) exchanger.
AID1346933Rat Sodium/hydrogen exchanger 3 (SLC9 family of sodium/hydrogen exchangers)2003European journal of medicinal chemistry, Jun, Volume: 38, Issue:6
An overview of inhibitors of Na(+)/H(+) exchanger.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID493017Wombat Data for BeliefDocking2000Journal of medicinal chemistry, Oct-19, Volume: 43, Issue:21
Identification of novel inhibitors of urokinase via NMR-based screening.
AID977610Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
AID1811Experimentally measured binding affinity data derived from PDB2000Journal of molecular biology, Aug-11, Volume: 301, Issue:2
Crystals of the urokinase type plasminogen activator variant beta(c)-uPAin complex with small molecule inhibitors open the way towards structure-based drug design.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7,396)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902340 (31.64)18.7374
1990's2734 (36.97)18.2507
2000's1420 (19.20)29.6817
2010's779 (10.53)24.3611
2020's123 (1.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 88.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index88.69 (24.57)
Research Supply Index8.98 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index165.11 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (88.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials339 (4.47%)5.53%
Reviews239 (3.15%)6.00%
Case Studies110 (1.45%)4.05%
Observational1 (0.01%)0.25%
Other6,895 (90.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (55)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Randomized Double-Blind Placebo-Controlled Study of Pyrazinoylguanidine Hydrochloride (Amiloride) in Subjects With Coronary Artery Disease [NCT01228214]Phase 2/Phase 3100 participants (Actual)Interventional2011-03-31Active, not recruiting
Increased Activity of ENaC in Proteinuric Kidney Transplant Recipients [NCT03036748]14 participants (Actual)Interventional2017-01-01Completed
Pharmacokinetics of Amiloride Nasal Spray in Healthy Volunteers [NCT04181008]Early Phase 115 participants (Actual)Interventional2020-09-28Completed
A Study to Evaluate the Safety and Efficacy of Chlorthalidone in Combination With Amiloride as a Treatment for Elderly Patients With Arterial Hypertension [NCT01191450]Phase 3280 participants (Anticipated)Interventional2011-08-31Recruiting
An Open-label, Randomized, Single-dose, Two-period Cross-over Study to Evaluate Bioequivalence of GSK3542503 Hydrochlorothiazide + Amiloride Hydrochloride 50 mg: 5 mg Fixed Dose Combination Tablets Versus Reference Product in Healthy Adult Participants Un [NCT03031496]Phase 142 participants (Actual)Interventional2017-03-17Completed
Randomized, Controlled Interventional Trial to Investigate the Efficacy of Amiloride for the Treatment of Edema in Human Nephrotic Syndrome [NCT05079789]Phase 320 participants (Actual)Interventional2020-06-08Terminated(stopped due to Low recruiting rate and decision to evaluate as pilot study)
The Effect and Safety of Amiloride in Decreasing Proteinuria for Patients With Chronic Kidney Disease in a Prospective , Crossover, Open-label Study. [NCT03170336]Phase 440 participants (Actual)Interventional2018-03-01Completed
Mechanisms of Diuretic Resistance in Heart Failure, Aim 2 [NCT05753059]Phase 150 participants (Anticipated)Interventional2023-08-10Recruiting
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium: a Randomized Controlled Trial [NCT05044611]Phase 4148 participants (Anticipated)Interventional2023-01-11Recruiting
Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride [NCT02122731]Phase 480 participants (Actual)Interventional2010-11-30Completed
Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease [NCT01231165]Phase 2/Phase 370 participants (Actual)Interventional2009-02-28Completed
Efficacy of Chlorthalidone and Hydrochlorothiazide in Combination With Amiloride in Multiple Doses on Blood Pressure in Patients With Primary Hypertension: a Factorial Randomized Controlled Trial. [NCT03928145]Phase 384 participants (Anticipated)Interventional2019-11-13Recruiting
A Crossover Pilot Study of the Effect of Amiloride on Proteinuria in Patients With Proteinuric Kidney Disease [NCT02522650]Phase 430 participants (Anticipated)Interventional2013-07-31Recruiting
The Effect of Amiloride and Spironolactone on Renovascular and Cardiovascular Variables in Patients With Essential Hypertension in a Doubleblinded, Randomized, Placebo-controlled, Crossover Study. [NCT01195805]25 participants (Anticipated)Interventional2010-08-31Completed
[NCT01308983]Phase 432 participants (Anticipated)Interventional2010-09-30Recruiting
Comparison of Optimal Hypertension Regimens (Part of the Ancestry Informative Markers in Hypertension (AIMHY) Programme - AIMHY-INFORM) [NCT02847338]Phase 41,320 participants (Anticipated)Interventional2016-11-30Recruiting
Treatment of Vascular Stiffness in Patients With Autosomal Dominant Polycystic Kidney Disease [NCT05228574]Phase 454 participants (Anticipated)Interventional2022-03-11Recruiting
Do Acid Sensing Ion Channels (ASICs) Contribute to Heartburn in Proton Pump Inhibitor (PPI)-Complete Responders or PPI-Partial Responders With Nonerosive Reflux Disease (NERD)? [NCT01095133]Phase 124 participants (Actual)Interventional2010-03-31Completed
Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use and COVID-19 Severity and Mortality Among US Veterans [NCT04467931]22,213 participants (Actual)Observational2020-01-19Completed
The Effect of Amiloride and Spironolactone Measured on Cardiovascular and Kidney Related Variables in Healthy Subjects in a Double-blinded, Randomised, Placebo-controlled, Cross-over Study [NCT00857909]Phase 130 participants (Actual)Interventional2009-01-31Completed
Estrogen Receptor Alpha Signaling in Endothelial Cells Exacerbates Arterial Stiffening Via Upregulation of ENaC in Insulin Resistant Females [NCT03837626]Phase 2/Phase 3157 participants (Anticipated)Interventional2019-07-15Recruiting
Phase 4 Study of Effects of ARB Compared With Diuretics in Hypertension Patients With High Cardiovascular Risks [NCT01011660]Phase 413,542 participants (Anticipated)Interventional2007-10-31Recruiting
Prevention of Hypertension in Patients With Pre-hypertension: PREVER-prevention Study [NCT00970931]Phase 3730 participants (Actual)Interventional2010-07-31Completed
A Comparison Between Diuretics and Angiotensin-receptor Blocker Agents in Patients With Stage I Hypertension: PREVER-treatment Study [NCT00971165]Phase 3655 participants (Actual)Interventional2010-07-31Completed
Randomized Trial of Spironolactone Versus Amiloride as an Add on Agent in Resistant Hypertension [NCT00709137]0 participants (Actual)Interventional2008-10-31Withdrawn(stopped due to lack of enrollment)
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease [NCT02875886]Phase 428 participants (Actual)Interventional2016-09-30Completed
A Randomized, Placebo-Controlled, Double-Blind, Phase IIa Study of Amiloride in the Treatment of Acute Autoimmune Optic Neuritis [NCT01879527]Phase 278 participants (Anticipated)Interventional2014-03-31Recruiting
A Multi-arm Phase IIB Randomised, Double Blind Placebo-controlled Clinical Trial Comparing the Efficacy of Three Neuroprotective Drugs in Secondary Progressive Multiple Sclerosis. [NCT01910259]Phase 2445 participants (Actual)Interventional2014-12-18Completed
Increased Activity of the Epithelial Sodium Channel (ENaC) in Diabetic Nephropathy [NCT01918488]80 participants (Anticipated)Interventional2013-10-31Enrolling by invitation
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura [NCT04063540]Phase 240 participants (Anticipated)Interventional2019-11-30Not yet recruiting
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease [NCT02497300]Phase 221 participants (Actual)Interventional2015-03-31Completed
Resistant Hypertension On Treatment - Sequential Nephron Blockade Compared to Dual Blockade of the Renin-angiotensin-aldosterone System Plus Bisoprolol in the Treatment of Resistant Arterial Hypertension: A Randomized Trial (ResHypOT) [NCT02832973]Phase 472 participants (Actual)Interventional2015-09-30Completed
Effect of Amiloride and Spironolactone on Renophysiological and Cardiovascular Variables in Patients With Essential Hypertension in a Doublle-blinded Randomised Placebo-controlled, Cross-over Study. [NCT01388088]Phase 423 participants (Actual)Interventional2010-09-30Completed
Double Blind Crossover Comparison od Diuretics in Young Patients With Low Renin Hypertension [NCT00429897]30 participants Interventional2006-08-31Recruiting
Effect of Antihypertensive Agents on Diastolic Function in Patients With Sleep Apnea: Protocol for a Randomized Controlled Trial [NCT02896621]Phase 369 participants (Actual)Interventional2014-12-07Completed
A Six Month Open Label Study of Amiloride Solution for Inhalation and Tobramycin Solution for Inhalation for the Eradication of Burkholderia Dolosa in Patients With Cystic Fibrosis [NCT00547053]Phase 125 participants (Anticipated)Interventional2006-12-31Completed
The Association Between Exposure to Spironolactone or Amiloride and Fracture Risk Among Subjects Treated With Thiazolidinediones [NCT01055223]98,483 participants (Actual)Observational2009-05-31Completed
Intensive Non-Sympathetic Activating Vasodilatory Treatment in Hypertensive Patients With Microvascular Angina Pectoris [NCT00424801]10 participants (Actual)Interventional2007-01-31Terminated(stopped due to Due to recent findings relating MRI contrast to nephrogenic systemic fibrosis)
The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride. A Double-blind Placebo Controlled Cross Over Study. [NCT00285805]13 participants (Actual)Interventional2006-02-28Completed
Clinical, Pharmacological and Biological Investigations of a Polymorphism of Nedd4 , a Regulatory Protein of the Epithelial Sodium Channel [NCT01706887]219 participants (Actual)Interventional2007-04-30Terminated(stopped due to end of recruitment period was reach)
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Amiloride vs Triamterene [NCT05125237]146,670 participants (Actual)Observational2021-10-01Active, not recruiting
Study of the Cutaneous Microcirculation: ASIC Involvement. [NCT01246180]20 participants (Actual)Interventional2010-10-31Completed
A Study to Investigate the Contribution of Extracellular Fluid Volume Expansion to Drug Resistant Hypertension [NCT00141596]32 participants (Anticipated)Interventional2003-07-31Terminated(stopped due to Insufficient accrual rate)
[NCT00004705]0 participants Interventional1996-09-30Completed
Hydrochlorothiazide and Amiloride vs Hydrochlorothiazide and Enalapril: a Randomized Clinical Trial of Antihypertensive Effectiveness. [NCT00394394]Phase 20 participants Interventional2005-02-28Completed
Efficacy of Amiloride and Hypertonic Saline in Cystic Fibrosis [NCT00274391]Phase 224 participants Interventional2001-07-31Completed
A Double Blind Randomised Control Trial on Neuroprotection of Amiloride in Optic Neuritis [NCT01802489]Phase 246 participants (Actual)Interventional2013-02-28Completed
ENaC as a Novel Mechanism for Hypertension and Volume Expansion in Type 2 Diabetes [NCT01804777]Early Phase 19 participants (Actual)Interventional2013-03-31Terminated(stopped due to Currently closed for data analysis.)
The Effect of Antihypertensive Agents Over Sleep Apnea: a Randomized Controlled Trial [NCT01896661]Phase 353 participants (Actual)Interventional2014-12-31Completed
Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism [NCT02525796]Phase 2/Phase 369 participants (Actual)Interventional2016-01-31Completed
Amiloride Hydrochloride as an Effective Treatment for ADHD [NCT01733680]Early Phase 13 participants (Actual)Interventional2012-09-30Terminated(stopped due to Study stopped due to lack of recruitment)
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus [NCT00478335]4 participants (Actual)Interventional2007-05-31Completed
SPironolactone Versus Amiloride for Treatment of REsistant Hypertension (SPARE Trial): A Comparison of Home Blood Pressure [NCT04331691]Phase 4118 participants (Anticipated)Interventional2020-11-16Recruiting
Comparison of Single and Combination Diuretics in Low-Renin Hypertension [NCT02351973]Phase 4423 participants (Actual)Interventional2009-11-30Active, not recruiting
Prospective Study Assessing Blood Pressure, Cardiovascular, Endothelial and Other Outcomes poSt-surgical and Medical Treatment in Patients With Primary Aldosteronism [NCT03174847]57 participants (Actual)Observational2017-02-20Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00478335 (1) [back to overview]24h Urine Volume
NCT01055223 (6) [back to overview]Number of Low Impact Fractures in Males and Females After 6 Months of Exposure to TZD
NCT01055223 (6) [back to overview]Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD
NCT01055223 (6) [back to overview]Number of Hip Fractures Combined in Males and Females After 6 Months of Exposure to TZD
NCT01055223 (6) [back to overview]Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD
NCT01055223 (6) [back to overview]Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 6 Months of Exposure to TZD
NCT01055223 (6) [back to overview]Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 12 Months of Exposure to TZD
NCT01733680 (3) [back to overview]The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)
NCT01733680 (3) [back to overview]Improvement in CGI
NCT01733680 (3) [back to overview]AISRS, Adult ADHD Investigator Rating Scale
NCT02497300 (5) [back to overview]Difference in 24 Hour Ambulatory Systolic Blood Pressure
NCT02497300 (5) [back to overview]Change in Albuminuria
NCT02497300 (5) [back to overview]Change in Oxidative Stress as Measured by Urine Levels of F2-isoprostanes
NCT02497300 (5) [back to overview]Change in Serum Creatinine (Baseline - Post-medication)
NCT02497300 (5) [back to overview]Change in Serum Potassium
NCT02525796 (2) [back to overview]Change in Calcium Levels
NCT02525796 (2) [back to overview]Change in Parathyroid Hormone Levels
NCT03031496 (16) [back to overview]Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Hydrochlorothiazide and Amiloride Hydrochloride
NCT03031496 (16) [back to overview]AUC From Time Zero to Infinity (AUC[0-inf]) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma
NCT03031496 (16) [back to overview]Blood Urea Nitrogen (BUN) Levels at Indicated Time Points
NCT03031496 (16) [back to overview]Body Temperature Values at Indicated Time Points
NCT03031496 (16) [back to overview]Calcium, Chloride, Glucose, Magnesium, Potassium and Sodium Levels at Indicated Time Points
NCT03031496 (16) [back to overview]Creatinine, Direct Bilirubin and Total Bilirubin Levels at Indicated Time Points
NCT03031496 (16) [back to overview]Total Protein Levels at Indicated Time Points
NCT03031496 (16) [back to overview]Time of Occurrence of Cmax (Tmax) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma
NCT03031496 (16) [back to overview]Terminal Phase Half-life (T1/2) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma
NCT03031496 (16) [back to overview]Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Indicated Time Points
NCT03031496 (16) [back to overview]Respiratory Rate Values at Indicated Time Points
NCT03031496 (16) [back to overview]Pulse Rate Values at Indicated Time Points
NCT03031496 (16) [back to overview]Percentage of AUC(0-inf) Obtained by Extrapolation (Percent AUCex) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma
NCT03031496 (16) [back to overview]Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment Period
NCT03031496 (16) [back to overview]Maximum Observed Concentration (Cmax) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma
NCT03031496 (16) [back to overview]Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.) and Aspartate Aminotransferase (AST) Levels at Indicated Time Points

24h Urine Volume

urine volume in mL/d (NCT00478335)
Timeframe: 4-days

,
Interventionurine volume in mL/d (Mean)
Period 1Period 2
Experimental First Then Standard64756652
Standard First Then Experimental41784188

[back to top]

Number of Low Impact Fractures in Males and Females After 6 Months of Exposure to TZD

ICD-9 codes (805-807.4x, 808-810.xx, 812-829.xx) were captured from Uniform Billing-92 records and Health Care Finance Administration records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for any low impact fracture occurring after the study period begin date (earliest date of the first TZD prescription). For each subject defined as case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched to cases on age (+ 5 years), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 and December 31, 2008

,,,
Interventionfractures (Number)
CaseControl
Other12
TZD Alone432517296
TZD+Amiloride1231
TZD+Spironolactone105292

[back to top]

Number of Low Impact Fractures in Males and Females After 12 Months of Exposure to TZD

ICD-9 codes (805-807.4x, 808-810.xx, 812-829.xx) were captured from Uniform Billing-92 records and Health Care Finance Administration records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for any low impact fracture occurring after the study period begin date (earliest date of the first TZD prescription). For each subject defined as case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched to cases on age (+ 5 years), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008

,,,
Interventionfractures (Number)
CaseControl
Other02
TZD Alone261910496
TZD+Amiloride820
TZD+Spironolactone64181

[back to top]

Number of Hip Fractures Combined in Males and Females After 6 Months of Exposure to TZD

ICD-9 codes (820.0x, 820.2x, 820.8x) were captured from UB-92 records and HCFA 1500 records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for hip fracture after the study period begin date (earliest date of the first TZD prescription). For each case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched on age (+ 5 yrs), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008

,
Interventionfractures (Number)
CaseControl
TZD Alone92387
TZD+Spironolactone64

[back to top]

Number of Hip Fractures Combined in Males and Females After 12 Months of Exposure to TZD

ICD-9 codes (820.0x, 820.2x, 820.8x) were captured from UB-92 records and HCFA 1500 records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for hip fracture after the study period begin date (earliest date of the first TZD prescription). For each case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched on age (+ 5 yrs), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008

,
Interventionfractures (Number)
CaseControl
TZD Alone44182
TZD+Spironolactone21

[back to top]

Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 6 Months of Exposure to TZD

ICD-9 codes (815.0x, 816.0x, 817.0x, 825.0x, 825.2x, 826.0x, 812.0x, 812.2x, 812.4x, 814.0x) were captured from UB-92 records and HCFA 1500 records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for hand, foot, upper arm, and wrist fracture after the study period begin date (earliest date of the first TZD prescription). For each case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched on age (+ 5 yrs), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008

,,,
Interventionfractures (Number)
CaseControl
Other12
TZD Alone21638615
TZD+Amiloride218
TZD+Spironolactone48148

[back to top]

Number of Fractures of the Hand, Foot, Upper Arm, and Wrist in Males and Females After 12 Months of Exposure to TZD

ICD-9 codes (815.0x, 816.0x, 817.0x, 825.0x, 825.2x, 826.0x, 812.0x, 812.2x, 812.4x, 814.0x) were captured from UB-92 records and HCFA 1500 records. Case is defined as incident cases of fracture with an ICD-9 diagnostic code for hand, foot, upper arm, and wrist fracture after the study period begin date (earliest date of the first TZD prescription). For each case, up to four controls were randomly selected from patients with type 2 diabetes exposed to TZD without a fracture diagnosis during follow-up and matched on age (+ 5 yrs), gender, and year of fracture diagnosis. (NCT01055223)
Timeframe: From the earliest date of first TZD prescription to the fracture diagnosis date (Cases) or the end of follow-up in the database (Controls) between January 1, 1997 to December 31, 2008

,,,
Interventionfractures (Number)
CaseControl
Other02
TZD Alone12855115
TZD+Amiloride012
TZD+Spironolactone2994

[back to top]

The Behavior Rating Inventory of Executive Function-Adult (BRIEF-A)

"BRIEF-A is a 75 item self report questionnaire that measures behavior and executive function. For each item the subject is asked during the past month, how often has each of the following behaviors been a problem?: The choices are N (never), S (sometimes), O (Often). Total score for the Global Executive Composite used. Raw data were transformed into t-scores, which are standardized scores that indicate the number of standard deviations away from the mean. A T-score of 50 is equal to the mean. Values less than 65 indicate executive function is not a problem and values greater than 65 indicate executive function is often a problem." (NCT01733680)
Timeframe: 8 weeks

,
InterventionGlobal Executive Composite T Score (Mean)
Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10
Arm 1-Amiloride66.570.56868.562.562.562.562
Arm 2-Placebo9592969696969696

[back to top]

Improvement in CGI

CGI Improvement scale: 1=very much improved; 2=Much improved; 3=Minimally improved; 4=No change; 5=Minimally worse; 6=Much worse; 7=Very much worse (NCT01733680)
Timeframe: 8 weeks

,
InterventionUnits on a scale (Mean)
CGI Week 3CGI Week 4CGI Week 5CGI Week 6CGI Week 7CGI Week 8CGI Week 9CGI Week 10
Amiloride4443.543.53.53.5
Placebo53555555

[back to top]

AISRS, Adult ADHD Investigator Rating Scale

An 18 item clinician administered questionnaire to evaluate ADHD in adults. Responses to questions were 0-None, 1-Mild, 2-Moderate, 3-Severe. A decrease of 30% in the total score would be considered improvement. Total score range is 0-54. A lower score indicates improvement in symptoms. A score of 24 or more indicates symptomatic ADHD. (NCT01733680)
Timeframe: 8 weeks

,
InterventionTotal score (Mean)
Week 3Week 4Week 5Week 6Week 7Week 8Week 9Week 10
Arm 1-Amiloride3938.532.53131342632.5
Arm 2-Placebo5451505050505050

[back to top]

Difference in 24 Hour Ambulatory Systolic Blood Pressure

"The study was not able to meet its recruitment goal, and participant numbers were too low to test the intended primary outcome of Difference in percent change of ultrasound-guided flow-mediated dilation between 6 weeks of spironolactone vs. 6 weeks of amiloride. The change in 24hr ABPM systolic BP (Baseline - 6 week) is reported here." (NCT02497300)
Timeframe: 6 weeks

Interventionmm Hg (Mean)
Spironolactone Exposure7.7
Amiloride Exposure12.5

[back to top]

Change in Albuminuria

Change of the urine albumin-to-creatinine ratio (baseline - post-study med) after 6 weeks of spironolactone vs. 6 weeks of amiloride. (NCT02497300)
Timeframe: 6 weeks

Interventionmg albumin/g creatinine (Mean)
Spironolactone129
Amiloride285

[back to top]

Change in Oxidative Stress as Measured by Urine Levels of F2-isoprostanes

Difference in level of urine 8-iso-prostaglandin-F2-alpha per mg of creatinine levels between 6 weeks of spironolactone vs. 6 weeks of amiloride. (NCT02497300)
Timeframe: 6 weeks

Interventionng F2 isoprostane/mg creatinine (Mean)
Spironolactone-2.77
Amiloride-0.17

[back to top]

Change in Serum Creatinine (Baseline - Post-medication)

Difference in serum creatinine (baseline - post-medication) after 6 weeks of spironolactone vs. 6 weeks of amiloride. (NCT02497300)
Timeframe: 6 weeks

Interventionmg/dL (Mean)
Spironolactone0.2
Amiloride-0.1

[back to top]

Change in Serum Potassium

Difference in serum potassium levels (baseline - post-medication) after 6 weeks of spironolactone vs. 6 weeks of amiloride. (NCT02497300)
Timeframe: 6 weeks

InterventionmEq/L (Mean)
Spironolactone0.4
Amiloride-0.5

[back to top]

Change in Calcium Levels

Change in serum calcium levels before and after intervention when compared to placebo (NCT02525796)
Timeframe: Change in serum calcium levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (calcium at 4 weeks minus calcium at baseline)

Interventionmg/dL (Median)
Eplerenone0.1
Amiloride0.0
Placebo0.1

[back to top]

Change in Parathyroid Hormone Levels

Change in circulating PTH levels before and after 4 weeks of double-blinded intervention when compared to placebo (NCT02525796)
Timeframe: Change in circulating PTH levels before and after 4 weeks of double-blinded monotherapy intervention when compared to placebo (PTH at 4 weeks minus PTH at baseline)

Interventionpg/mL (Median)
Eplerenone4.0
Amiloride-3.7
Placebo0.8

[back to top]

Area Under the Curve (AUC) From Time Zero to the Time of the Last Quantifiable Concentration (AUC [0-t]) of Hydrochlorothiazide and Amiloride Hydrochloride

Blood samples were collected at indicated time points under fasting conditions for pharmacokinetic (PK) analysis of hydrochlorothiazide and amiloride. Bioequivalence of test product and reference product was assessed based on the 90 percent confidence intervals (CIs) for estimates of the geometric mean ratios between the AUC (0-t) of the test and reference products in relation to the conventional bioequivalence range. An analysis of variance was used with sequence, subject (sequence), treatment and period as fixed effects. (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
InterventionHour x nanograms/milliliter (h*ng/mL) (Geometric Mean)
HydrochlorothiazideAmiloride
Treatment A216096.3
Treatment B236094.1

[back to top]

AUC From Time Zero to Infinity (AUC[0-inf]) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma

Blood samples were collected at indicated time points under fasting conditions for PK analysis of hydrochlorothiazide and amiloride. Bioequivalence of test product and reference product was assessed based on the 90 percent CIs for estimates of the geometric mean ratios between the AUC (0-inf) of the test and reference products in relation to the conventional bioequivalence range. An analysis of variance was used with sequence, subject (sequence), treatment and period as fixed effects. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
Interventionh*ng/mL (Geometric Mean)
Hydrochlorothiazide; n= 37, 38Amiloride; n= 22, 22
Treatment A2310117
Treatment B2490112

[back to top]

Blood Urea Nitrogen (BUN) Levels at Indicated Time Points

Serum BUN levels were assessed as a clinical chemistry laboratory parameter at Day -1 and Day 3 in each treatment period. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionMilligrams per deciliter (mg/dL) (Mean)
P1; Day-1; 24 hour pre-dose; n=21, 21P1; Day 3; 48 hour post-dose; n=21, 20P2; Day -1; 24 hour pre-dose; n=19, 19P2; Day 3; 48 hour post-dose; n=19, 19
Treatment A12.51914.97012.18516.372
Treatment B12.70215.59312.16415.208

[back to top]

Body Temperature Values at Indicated Time Points

Vital sign measurements including body temperature were taken in a supine position after at least 5 minutes of rest at Day -1, Day 1, Day 2 and Day 3 in each treatment period. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionDegree Celsius (Mean)
P1; Day-1; 12 hour pre-dose; n= 21, 21P1; Day1; 1 hour post-dose; n= 21, 21P1; Day1; 1.5 hour post-dose; n= 21, 21P1; Day1; 2 hour post-dose; n= 21, 21P1; Day1; 4 hour post-dose; n= 21, 21P1; Day1; 6 hour post-dose; n= 21, 21P1; Day1; 8 hour post-dose; n= 21, 21P1; Day2; 24 hour post-dose; n= 21, 21P1; Day3; 48 hour post-dose; n= 21, 20P2; Day-1; 12 hour pre-dose; n= 19, 19P2; Day1; 1 hour post-dose; n= 19, 19P2; Day1; 1.5 hour post-dose; n= 19, 19P2; Day1; 2 hour post-dose; n= 19, 19P2; Day1; 4 hour post-dose; n= 19, 19P2; Day1; 6 hour post-dose; n= 19, 19P2; Day1; 8 hour post-dose; n= 19, 19P2; Day2; 24 hour post-dose; n= 19, 19P2; Day3; 48 hour post-dose; n= 18, 19
Treatment A36.4236.4436.0636.4236.4536.5936.6436.2836.2636.4136.2836.0636.4136.5336.5936.6436.1536.08
Treatment B36.4336.4036.0536.3836.4636.6136.7536.3036.2836.3436.2436.1936.3836.4436.5736.6536.1736.28

[back to top]

Calcium, Chloride, Glucose, Magnesium, Potassium and Sodium Levels at Indicated Time Points

Serum calcium, chloride, glucose, magnesium, potassium and sodium levels were assessed as a clinical chemistry laboratory parameter at Day -1 and Day 3 in each treatment period. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionMillimoles per liter (Mmol/L) (Mean)
Calcium; P1; Day-1; 24 hour pre-dose; n= 21, 21Calcium; P1; Day 3; 48 hour post-dose; n= 21, 20Calcium; P2; Day-1; 24 hour pre-dose; n= 19, 19Calcium; P2; Day 3; 48 hour post-dose; n= 19, 19Chloride; P1; Day-1; 24 hour pre-dose; n= 21, 21Chloride; P1; Day 3; 48 hour post-dose; n= 21, 20Chloride; P2; Day-1; 24 hour pre-dose; n= 19, 19Chloride; P2; Day 3; 48 hour post-dose; n= 19, 19Glucose; P1; Day-1; 24 hour pre-dose; n= 21, 20Glucose; P1; Day 3; 48 hour post-dose; n= 21, 20Glucose; P2; Day-1; 24 hour pre-dose; n= 19, 19Glucose; P2; Day 3; 48 hour post-dose; n= 19, 19Magnesium; P1; Day-1; 24 hour pre-dose; n= 21, 21Magnesium; P1; Day 3; 48 hour post-dose; n= 21, 20Magnesium; P2; Day-1; 24 hour pre-dose; n= 19, 19Magnesium; P2; Day 3; 48 hour post-dose; n= 19, 19Potassium; P1; Day-1; 24 hour pre-dose; n= 21, 21Potassium; P1; Day 3; 48 hour post-dose; n= 21, 20Potassium; P2; Day-1; 24 hour pre-dose; n= 19, 19Potassium; P2; Day 3; 48 hour post-dose; n= 19, 19Sodium; P1; Day-1; 24 hour pre-dose; n= 21, 21Sodium; P1; Day 3; 48 hour post-dose; n= 21, 20Sodium; P2; Day-1; 24 hour pre-dose; n= 19, 19Sodium; P2; Day 3; 48 hour post-dose; n= 19, 19
Treatment A2.4002.3962.3742.415104.80103.27104.36102.624.7465.0064.7544.6520.7820.7810.8260.8214.2874.3034.3004.364140.86138.90140.11139.11
Treatment B2.4182.3932.3352.379103.62102.63104.85103.494.6434.8274.7654.7320.8010.8040.8050.7834.2944.2224.2254.336140.67139.25139.68139.11

[back to top]

Creatinine, Direct Bilirubin and Total Bilirubin Levels at Indicated Time Points

Serum creatinine, direct bilirubin and total bilirubin levels were assessed as a clinical chemistry laboratory parameter at Day -1 and Day 3 in each treatment period. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionMicromoles per liter (µmol/L) (Mean)
Creatinine; P1; Day-1; 24 hour pre-dose; n= 21, 21Creatinine; P1; Day3; 48 hour post-dose; n= 21, 20Creatinine; P2; Day-1; 24 hour pre-dose; n= 19, 19Creatinine; P2; Day3; 48 hour post-dose; n= 19, 19Direct bilirubin;P1;Day-1;24 hour pre-dose;n=21,21Direct bilirubin;P1;Day3;48 hour post-dose;n=21,20Direct bilirubin;P2;Day-1;24 hour pre-dose;n=19,19Direct bilirubin;P2;Day3;48 hour post-dose;n=19,19Total bilirubin;P1;Day-1;24 hour pre-dose;n=21,21Total bilirubin;P1;Day3;48 hour post-dose;n=21,20Total bilirubin;P2;Day-1;24 hour pre-dose;n=19,19Total bilirubin;P2;Day3;48 hour post-dose;n=19,19
Treatment A85.287.082.185.64.253.203.943.7712.109.4010.6110.83
Treatment B85.087.382.588.74.523.723.643.1413.4810.8010.088.67

[back to top]

Total Protein Levels at Indicated Time Points

Serum total protein levels were assessed as a clinical chemistry laboratory parameter at Day -1 and Day 3 in each treatment period. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionGrams per liter (g/L) (Mean)
P1; Day-1; 24 hours pre-dose; n= 21, 21P1; Day 3; 48 hours post-dose; n= 21, 20P2; Day-1; 24 hours pre-dose; n= 19, 19P2; Day 3; 48 hours post-dose; n= 19, 19
Treatment A74.0874.5371.2973.56
Treatment B76.0674.9970.0672.33

[back to top]

Time of Occurrence of Cmax (Tmax) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma

Blood samples were collected at indicated time points under fasting conditions for PK analysis of hydrochlorothiazide and amiloride. Median and full range has been presented. (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
InterventionHour (Median)
HydrochlorothiazideAmiloride
Treatment A2.5052.507
Treatment B1.5092.508

[back to top]

Terminal Phase Half-life (T1/2) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma

Blood samples were collected at indicated time points under fasting conditions for PK analysis of hydrochlorothiazide and amiloride. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
InterventionHour (Median)
Hydrochlorothiazide; n= 37, 38Amiloride; n= 22, 22
Treatment A12.415.2
Treatment B11.316.6

[back to top]

Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) Values at Indicated Time Points

Vital sign measurements including SBP and DBP were taken in a supine position after at least 5 minutes of rest at Day -1, Day 1, Day 2 and Day 3 in each treatment period. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionMillimeters of mercury (mmHg) (Mean)
SBP; P1; Day-1; 12 hour pre-dose; n=21,21SBP; P1; Day1; 1 hour post-dose; n= 21, 21SBP; P1; Day1; 1.5 hour pre-dose; n= 21, 21SBP; P1; Day1; 2 hour post-dose; n= 21, 21SBP: P1; Day1; 4 hour post-dose; n= 21, 21SBP; P1; Day1; 6 hour post-dose; n= 21, 21SBP; P1; Day1; 8 hour post-dose; n= 21, 21SBP; P1; Day2; 24 hour post-dose; n= 21, 21SBP; P1; Day3; 48 hour post-dose; n= 21, 20SBP; P2; Day-1; 12 hour pre-dose; n= 19, 19SBP; P2; Day1; 1 hour post-dose; n= 19, 19SBP; P2; Day1; 1.5 hour post-dose; n= 19, 19SBP; P2; Day1; 2 hour post-dose; n= 19, 19SBP: P2; Day1; 4 hour post-dose; n= 19, 19SBP: P2; Day1; 6 hour post-dose; n= 19, 19SBP: P2; Day1; 8 hour post-dose; n= 19, 19SBP: P2; Day2; 24 hour post-dose; n= 19, 19SBP; P2; Day3; 48 hour post-dose; n= 18, 19DBP; P1; Day-1; 12 hour pre-dose; n= 21, 21DBP; P1; Day1; 1 hour post-dose; n= 21, 21DBP: P1; Day1; 1.5 hour post-dose; n= 21, 21DBP; P1; Day1; 2 hour post-dose; n= 21, 21DBP: P1; Day1; 4 hour post-dose; n= 21, 21DBP; P1; Day1; 6 hour post-dose; n= 21, 21DBP; P1; Day1; 8 hour post-dose; n= 21, 21DBP: P1; Day2; 24 hour post-dose; n= 21, 21DBP: P1; Day3; 48 hour post-dose; n= 21, 20DBP; P2; Day-1; 12 hour post-dose; n= 19, 19DBP; P2; Day1; 1 hour post-dose; n= 19, 19DBP; P2; Day1; 1.5 hour post-dose; n= 19, 19DBP; P2; Day1; 2 hour post-dose; n= 19, 19DBP; P2; Day1; 4 hour post-dose; n= 19, 19DBP: P2; Day1; 6 hour post-dose; n= 19, 19DBP; P2; Day1; 8 hour post-dose; n= 19, 19DBP: P2; Day2; 24 hour post-dose; n= 19, 19DBP: P2; Day3; 48 hour post-dose; n= 18, 19
Treatment A115.9112.8111.5113.3112.5110.9113.0111.4114.5113.8110.0108.9109.6109.5108.5109.8109.1112.965.463.764.063.464.861.463.064.967.363.163.961.162.562.859.461.162.965.9
Treatment B115.8111.6110.8112.6114.0113.0111.8110.5113.8116.2113.7112.2113.8113.5112.4111.5110.6116.564.963.563.965.764.462.763.764.266.065.864.163.465.365.361.562.964.467.2

[back to top]

Respiratory Rate Values at Indicated Time Points

Vital sign measurements including respiratory rate were taken in a supine position after at least 5 minutes of rest at Day -1, Day 1, Day 2 and Day 3 in each treatment period. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionBreaths per minute (Mean)
P1; Day-1; 12 hour pre-dose; n= 21, 21P1; Day1; 1 hour post-dose; n= 21, 21P1; Day1; 1.5 hour post-dose; n= 21, 21P1; Day1; 2 hour post-dose; n= 21, 21P1; Day1; 4 hour post-dose; n= 21, 21P1; Day1; 6 hour post-dose; n= 21, 21P1; Day1; 8 hour post-dose; n= 21, 21P1; Day2; 24 hour post-dose; n= 21, 21P1; Day3; 48 hour post-dose; n= 21, 20P2; Day-1; 12 hour pre-dose; n= 19, 19P2; Day1; 1 hour post-dose; n= 19, 19P2; Day1; 1.5 hour post-dose; n= 19, 19P2; Day1; 2 hour post-dose; n= 19, 19P2; Day1; 4 hour post-dose; n= 19, 19P2; Day1; 6 hour post-dose; n= 19, 19P2; Day1; 8 hour post-dose; n= 19, 19P2; Day2; 24 hour post-dose; n= 19, 19P2; Day3; 48 hour post-dose; n= 18, 19
Treatment A16.516.316.717.016.917.216.918.217.117.917.715.818.017.917.218.717.518.4
Treatment B17.017.017.917.517.018.418.218.017.717.217.916.317.317.418.318.217.617.2

[back to top]

Pulse Rate Values at Indicated Time Points

Vital sign measurements including pulse rate were taken in a supine position after at least 5 minutes of rest at Day -1, Day 1, Day 2 and Day 3 in each treatment period. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionBeats per minute (bpm) (Mean)
P1; Day-1; 12 hour pre-dose; n= 21, 21P1; Day1; 1 hour post-dose; n= 21, 21P1; Day1; 1.5 hour post-dose; n= 21, 21P1; Day1; 2 hour post-dose; n= 21, 21P1; Day1; 4 hour post-dose; n= 21, 21P1; Day1; 6 hour post-dose; n= 21, 21P1; Day1; 8 hour post-dose; n= 21, 21P1; Day2; 24 hour post-dose; n= 21, 21P1; Day3; 48 hour post-dose; n= 21, 20P2; Day-1; 12 hour pre-dose; n= 19, 19P2; Day1; 1 hour post-dose; n= 19, 19P2; Day1; 1.5 hour post-dose; n= 19, 19P2; Day1; 2 hour post-dose; n= 19, 19P2; Day1; 4 hour post-dose; n= 19, 19P2; Day1; 6 hour post-dose; n= 19, 19P2; Day1; 8 hour post-dose; n= 19, 19P2; Day2; 24 hour post-dose; n= 19, 19P2; Day3; 48 hour post-dose; n= 18, 19
Treatment A66.961.862.561.764.171.566.069.071.465.262.561.560.762.472.968.269.070.3
Treatment B64.762.060.960.762.570.867.868.673.065.260.162.859.262.771.466.268.873.4

[back to top]

Percentage of AUC(0-inf) Obtained by Extrapolation (Percent AUCex) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma

Blood samples were collected at indicated time points under fasting conditions for PK analysis of hydrochlorothiazide and amiloride. Bioequivalence of test product and reference product was assessed based on the 90 percent CIs for estimates of the geometric mean ratios between percent AUCex of the test and reference products in relation to the conventional bioequivalence range. Only those participants with data available at the specified data points were analyzed (represented by n= X in the category titles). (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
InterventionPercent of area (Geometric Mean)
Hydrochlorothiazide; n= 37, 38Amiloride; n= 22, 22
Treatment A5.249.68
Treatment B4.6310.7

[back to top]

Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment Period

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is defined as any untoward medical occurrence that, at any dose results in death, is life threatening requires hospitalization or prolongation of existing hospitalization, results in disability, is a congenital anomaly/ birth effect, other situations and is associated with liver injury or impaired liver function. Only those participants with data available at the specified time points were analyzed (NCT03031496)
Timeframe: Up to 25 days

,
InterventionParticipants (Number)
AEsSAEs
Treatment A50
Treatment B80

[back to top]

Maximum Observed Concentration (Cmax) of Hydrochlorothiazide and Amiloride Hydrochloride in Plasma

Blood samples were collected at indicated time points under fasting conditions for pharmacokinetic (PK) analysis of hydrochlorothiazide and amiloride. Bioequivalence of test product and reference product was assessed based on the 90 percent CIs for estimates of the geometric mean ratios between the Cmax of the test and reference products in relation to the conventional bioequivalence range. An analysis of variance was used with sequence, subject (sequence), treatment and period as fixed effects. (NCT03031496)
Timeframe: Pre-dose, 0.33, 0.67, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12,14, 16 hours post-dose on Day 1, 24 and 36 hours post dose on Day 2 and 48 hours post-dose on Day 3

,
Interventionng/mL (Geometric Mean)
HydrochlorothiazideAmiloride
Treatment A3129.27
Treatment B3778.92

[back to top]

Alanine Aminotransferase (ALT), Alkaline Phosphatase (Alk.Phosph.) and Aspartate Aminotransferase (AST) Levels at Indicated Time Points

Serum ALT, alk. phosph. and AST levels were assessed as a clinical chemistry laboratory parameter at Day -1 and Day 3 in each treatment period. Only those participants available at the specified time points were analyzed (represented by n=X in the category titles). (NCT03031496)
Timeframe: Day -1 and Day 3 of each treatment period

,
InterventionUnit per liter (U/L) (Mean)
ALT;Period 1 (P1);Day -1;24 hour pre-dose;n=21,21ALT; P1; Day 3; 48 hour post-dose; n= 21,20ALT; P2; Day -1; 24 hour pre-dose; n= 19,19ALT; P2; Day 3; 48 hour post-dose; n= 19, 19Alk.phosph.; P1; Day -1; 24 hour pre-dose; n=21,21Alk.phosph.; P1; Day 3; 48 hour post-dose; n=21,20Alk.phosph.; P2; Day -1; 24 hour pre-dose; n=19,19Alk.phosph.; P2; Day 3; 48 hour post-dose; n=19,19AST; P1; Day -1; 24 hour pre-dose; n=21, 21AST; P1; Day 3; 48 hour post-dose; n=21, 20AST; P2; Day -1; 24 hour pre-dose; n=19, 19AST; P2; Day 3; 48 hour post-dose; n=19, 19
Treatment A19.815.915.815.867.567.165.166.821.917.521.619.9
Treatment B16.614.117.616.971.169.963.665.220.117.821.118.4

[back to top]